EP2922832A1 - Glutamase inhibitors and method of use - Google Patents

Glutamase inhibitors and method of use

Info

Publication number
EP2922832A1
EP2922832A1 EP13808311.8A EP13808311A EP2922832A1 EP 2922832 A1 EP2922832 A1 EP 2922832A1 EP 13808311 A EP13808311 A EP 13808311A EP 2922832 A1 EP2922832 A1 EP 2922832A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
phenyl
nhc
diyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13808311.8A
Other languages
German (de)
French (fr)
Other versions
EP2922832B1 (en
Inventor
Rene M. Lemieux
Janeta Popovici-Muller
Francesco G. Salituro
Jeffrey O. Saunders
Jeremy Travins
Shunqi Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of EP2922832A1 publication Critical patent/EP2922832A1/en
Application granted granted Critical
Publication of EP2922832B1 publication Critical patent/EP2922832B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • Cancer cells rely primarily on glycolysis to generate cellular energy and biochemical intermediates for biosynthesis of lipids and nucleotides, while the majority of "normal" cells in adult tissues utilize aerobic respiration. This fundamental difference in cellular metabolism between cancer cells and normal cells is termed the Warburg Effect. As a result of this difference, pyruvate generated via the glycolytic pathway is converted to lactic acid, rather than being used to acetyl-CoA and eventually, the citrate utilized in a normal citric acid cycle. To compensate for these energetic changes and to maintain a citric acid cycle, cancer cells rely on glutamine metabolism which is achieved through an elevation of glutaminase activity. Exploitation of this phenomenon can be achieved by inhibition of this elevated glutaminase activity.
  • heterocyclic containing, pharmaceutically acceptable salts, solvates, and hydrates thereof are heterocyclic containing, pharmaceutically acceptable salts, solvates, and hydrates thereof.
  • the compounds can be used to treat a disorder described herein, for example, by inhibiting glutaminase in a patient. Also provided are
  • compositions comprising a compound provided herewith and the use of such compositions in methods of treating diseases and conditions, for example, that are associated with the aberrant function of glutaminase or elevated activity of glutaminase, including, e.g., cancer.
  • each R 1 and R 2 is independently C 1-6 alkylene-R 4 , -N(R 3 )-R 4 , -N(R 3 )-C(0)-R 4 , - C(0)-N(R 3 )-R 4 , -N(R 3 )-C(0)-0-R 4 , -N(R 3 )-C(0)-N(R 3 )-R 4 , -0-C(0)-N(R 3 )-R 4 , -N(R 3 )- C(0)-Ci_6 alkylene-C(0)-R 4 , -N(R 3 )-C(0)-Ci_ 6 alkylene-N(R 3 )-C(0)-R 4 or -N(R 3a )-C(0)- CH 2 -N(R 3 )-C(0)-R 4 ;
  • each R is independently hydrogen, Ci_6 alkyl or aryl
  • each R 4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R 5 , or two adjacent R 5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
  • each R 6 is independently hydrogen, fluoro, OH or Q-6 alkyl
  • each R is independently hydrogen, Ci_6 alkyl, -OH, -SH, cyano, halo, -CF 3 , - OCF 3 , -S0 2 -C 1-6 alkyl, -N0 2 , -N(R 7 )-C(0)-C 1-6 alkyl, -N(R 6 ) 2 or C 1-6 alkoxy; m is 1, 2 or 3;
  • p 1, 2 or 3;
  • R 1 and R 2 are not both -NHC(0)-R 4 , wherein R 4 is C 1-6 alkyl, a monocyclic ring, monocyclic aralkyl, monocyclic heterocyclylalkyl, monocyclic heteroaralkyl and each member of R 4 is substituted with 0-3 occurrences of R 5 ; and (ii) R 1 and R 2 are not both - NHC(0)0-methyl, -NHC(0)0-ethyl, -NHC(0)-6-pyrimidine-2,4(lH,3H)-dionyl, - N(ethyl)C(0)-benzyl, or -NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH- phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
  • R 1 and R 2 are not both -NHC(0)-furanyl, -NHC(0)-phenyl, -NHC(0)-o-methoxy-phenyl, -NHC(0)-Ci_6 alkyl, -NH-benzyl, -NHC(0)-NH-phenyl, -NHC(0)-NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R 5 ;
  • R 1 and R 2 are not both -NHC(0)-C 1 _6 alkyl, -NHC(0)-cyclohexyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is optionally substituted with methyl;
  • composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the composition is a pharmaceutical composition.
  • provided herein is a method for treating or preventing a disease, condition or disorder as described (e.g., treating) herein comprising
  • provided herein is a method of inhibiting glutaminase, e.g, in a patient in need thereof.
  • a method of inhibiting glutaminase e.g, in a patient in need thereof.
  • reducing the level of the product of glutaminase in a subject e.g., a patient in need thereof.
  • the methods include administering an effective amount of a compound described herein or a pharaiacetucally acceptable salt thereof to a subject in need thereof, thereby inhibiting the level of glutaminase in the subject.
  • provided herein is a method of treating a subject suffering from or susceptible to a disease or disorder associated with the aberrant function of glutaminase or elevated activity of glutaminase in a subject in need thereof.
  • the method comprises the step of administering an effective amount of a compound described herein to the subject in need thereof, thereby treating, preventing or
  • the compound is provided in a pharmaceutical composition.
  • the method includes identifying or selecting a subject who would benefit from inhibiting glutaminase or decreasing the level of glutaminase.
  • the subject can be identified on the basis of the level of glutaminase activity in a cell or tissue sample of the subject for treatment of cancer associated with aberrant glutaminase function or activity.
  • the selected subject is a patient suffering from or susceptible to a disorder or disease identified herein, e.g., a disorder characterized by unwanted cell growth or proliferation, e.g., cancer or other neoplastic disorders.
  • a method for treating cancer in a subject comprising: optionally, acquiring a subject sample; acquiring an evaluation of or evaluating the subject sample, wherein the subject sample is
  • the subject sample is characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, or iii) a low or decreased level of pyruvate carboxylase expression; and administering to the subject in need thereof a therapeutically effective amount of a compound described here.
  • the subject sample is characterized by i) a low level of E-cadherin expression compared to a reference standard and ii) a high level of vimentin expression compared to a reference standard.
  • the subject sample is characterized or further characterized by low or decreased levels of pyruvate carboxylase expression compared to a reference standard.
  • a method for treating cancer in a subject characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, or iii) a low or decreased level of pyruvate carboxylase expression; comprising administering to the subject in need thereof a therapeutically effective amount of a compound described here.
  • the subject is characterized by i) a low level of E-cadherin expression compared to a reference standard and ii) a high level of vimentin expression compared to a reference standard.
  • the subject is characterized or further characterized by low or decreased levels of pyruvate carboxylase expression compared to a reference standard.
  • Compounds that inhibit glutaminase can be used to treat disorders such as neoplastic disorders (e.g., cancer).
  • disorders such as neoplastic disorders (e.g., cancer).
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • each R 1 and R 2 is independently C 1-6 alkylene-R 4 , -N(R 3 )-R 4 , -N(R 3 )-C(0)-R 4 , - C(0)-N(R 3 )-R 4 , -N(R 3 )-C(0)-0-R 4 , -N(R 3 )-C(0)-N(R 3 )-R 4 , -0-C(0)-N(R 3 )-R 4 , -N(R 3 )- C(0)-Ci_6 alkylene-C(0)-R 4 , -N(R 3 )-C(0)-Ci_ 6 alkylene-N(R 3 )-C(0)-R 4 or -N(R 3a )-C(0)- CH 2 -N(R 3 )-C(0)-R 4 ;
  • each R is independently hydrogen, Ci_6 alkyl or aryl
  • each R 4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R 5 , or two adjacent R 5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
  • each R is independently hydrogen, C 1-6 alkyl, -OH, -SH, cyano, halo, -CF 3 , - OCF 3 , -S0 2 -Ci_6 alkyl, -N0 2 , -N(R 7 )-C(0)-Ci_ 6 alkyl, -N(R 6 ) 2 or Ci_ 6 alkoxy;
  • n 1, 2 or 3;
  • p 1, 2 or 3;
  • R 1 and R 2 are not both -NHC(0)-R 4 , wherein R 4 is C 1-6 alkyl, a monocyclic ring, monocyclic aralkyl, monocyclic heterocyclylalkyl, monocyclic heteroaralkyl and each member of R 4 is substituted with 0-3 occurrences of R 5 ; and (ii) R 1 and R 2 are not both - NHC(0)0-methyl, -NHC(0)0-ethyl, -NHC(0)-6-pyrimidine-2,4(lH,3H)-dionyl, - N(ethyl)C(0)-benzyl, or -NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH- phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
  • R 1 and R 2 are not both -NHC(0)-furanyl, -NHC(0)-phenyl, -NHC(0)-o-methoxy-phenyl, -NHC(0)-Ci_6 alkyl, -NH-benzyl, -NHC(0)-NH-phenyl, -NHC(0)-NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R 5 ;
  • R 1 and R 2 are not both -NHC(0)C(R*) 2 -phenyl wherein the phenyl is unsubstituted or substituted with 0-3 occurrences of R 5 and R* is H, -OH, -C 1-2 alkyl-OH, -Ci-2 alkyl-OCH 3 , or -CH 3 ;
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • each R 1 and R 2 is independently -N(R 3 )-R 4 , -C(0)-N(R 3 )-R 4 , -N(R 3 )-C(0)-0-R 4 , or -N(R 3 )-C(0)-N(R 3 )-R 4 ;
  • each R is independently hydrogen, C 1-6 alkyl or aryl
  • each R 4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R 5 , or two adjacent R 5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
  • each R 6 is independently hydrogen, fluoro, OH or C 1-6 alkyl
  • each R is independently hydrogen, C 1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF 3 , -S0 2 -Ci_6 alkyl, -N0 2 , -N(R 7 )-C(0)-Ci_ 6 alkyl, -N(R 6 ) 2 or Ci_ 6 alkoxy;
  • p 1, 2 or 3;
  • R 1 and R 2 are not both -NHC(0)0-methyl, -NHC(0)0-ethyl or -NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH-phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
  • R 1 and R 2 are not both -NH-benzyl, -NHC(0)-NH-phenyl, -NHC(0)NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R 5 ;
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • each R 1 and R 2 is independently C 1-6 alkylene-R 4 , -N(R 3 )-R 4 , -N(R 3 )-C(0)-R 4 , - C(0)-N(R 3 )-R 4 , -N(R 3 )-C(0)-0-R 4 , -N(R 3 )-C(0)-N(R 3 )-R 4 , -0-C(0)-N(R 3 )-R 4 , -N(R 3 )- C(0)-Ci-6 alkylene-C(0)-R 4 , -N(R 3 )-C(0)-C 1-6 alkylene-N(R 3 )-C(0)-R 4 or -N(R 3a )-C(0)- CH 2 -N(R 3 )-C(0)-R 4 ;
  • each R is independently hydrogen, C 1-6 alkyl or aryl
  • each R 4 is independently C 1-6 alkyl, C 1-6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R 5 , or two adjacent R 5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
  • each R 6 is independently hydrogen, fluoro, OH or C 1-6 alkyl
  • each R is independently hydrogen, C 1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF 3 , -SO2-C1-6 alkyl, -N0 2 , -N(R 7 )-C(0)-C 1-6 alkyl, -N(R 6 ) 2 or C 1-6 alkoxy;
  • n 1, 2 or 3;
  • p 1, 2 or 3;
  • R 1 and R 2 are not both -NHC(0)-R 4 , wherein R 4 is C 1-6 alkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic aralkyl, monocyclic heteroaralkyl and each member of R 4 is substituted with 0-3 occurrences of R 5 ; and (ii) R 1 and R 2 are not both - NHC(0)0-methyl, -NHC(0)0-ethyl, -NHC(0)-6-pyrimidine-2,4(lH,3H)-dionyl, or - NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH-phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
  • R 1 and R 2 are not both -NHC(0)-furanyl, -NHC(0)-phenyl, -NHC(0)-o-methoxy-phenyl, -NHC(0)-Ci_6 alkyl, -NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R 5 ;
  • R 1 and R 2 are not both -NHC(0)-C 1 _6 alkyl, -NHC(0)-cyclohexyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is optionally substituted with methyl;
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • each R 1 and R 2 is independently C 1-6 alkylene-R 4 , -N(R 3 )-R 4 , -N(R 3 )-C(0)-R 4 , - C(0)-N(R 3 )-R 4 , -N(R 3 )-C(0)-0-R 4 , -N(R 3 )-C(0)-N(R 3 )-R 4 , -0-C(0)-N(R 3 )-R 4 , -N(R 3 )- C(0)-Ci-6 alkylene-C(0)-R 4 , -N(R 3 )-C(0)-C 1-6 alkylene-N(R 3 )-C(0)-R 4 or -N(R 3a )-C(0)- CH 2 -N(R 3 )-C(0)-R 4 ;
  • each R is independently hydrogen, C 1-6 alkyl or aryl
  • each R 4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R 5 , or two adjacent R 5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
  • each R 6 is independently hydrogen, fluoro, OH or C 1-6 alkyl
  • each R is independently hydrogen, C 1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF 3 , -S0 2 -Ci_6 alkyl, -N0 2 , -N(R 7 )-C(0)-Ci_ 6 alkyl, -N(R 6 ) 2 or Ci_ 6 alkoxy;
  • n 1, 2 or 3;
  • n 1, 2 or 3; provided that the sum of m and n is from 2 to 4;
  • o 1, 2 or 3;
  • p 1, 2 or 3;
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • each R is independently hydrogen, Ci_6 alkyl or aryl
  • each R 4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R 5 , or two adjacent R 5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
  • each R 6 is independently hydrogen, fluoro, OH or Ci_6 alkyl
  • each R is independently hydrogen, Ci_6 alkyl, -OH, -SH, cyano, halo, -CF 3 , - OCF 3 , -S0 2 -C 1-6 alkyl, -N0 2 , -N(R 7 )-C(0)-C 1-6 alkyl, -N(R 6 ) 2 or C 1-6 alkoxy;
  • n 1, 2 or 3;
  • n 1, 2 or 3; provided that the sum of m and n is from 2 to 4;
  • o 1, 2 or 3;
  • p 1, 2 or 3.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • each R 1 and R 2 is independently C 1-6 alkylene-R 4 , -N(R 3 )-R 4 , -N(R 3 )-C(0)-R 4 , - C(0)-N(R 3 )-R 4 , -N(R 3 )-C(0)-0-R 4 , -N(R 3 )-C(0)-N(R 3 )-R 4 , -0-C(0)-N(R 3 )-R 4 , -N(R 3 )- C(0)-Ci-6 alkylene-C(0)-R 4 , -N(R 3 )-C(0)-C 1-6 alkylene-N(R 3 )-C(0)-R 4 or -N(R 3a )-C(0)- CH 2 -N(R 3 )-C(0)-R 4 ;
  • each R is independently hydrogen, C 1-6 alkyl or aryl
  • each R 4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R 5 , or two adjacent R 5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
  • each R 6 is independently hydrogen, fluoro, OH or C 1-6 alkyl
  • each R is independently hydrogen, C 1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF 3 , -S0 2 -Ci_6 alkyl, -N0 2 , -N(R 7 )-C(0)-Ci_ 6 alkyl, -N(R 6 ) 2 or Ci_ 6 alkoxy;
  • n 1, 2 or 3;
  • n 1, 2 or 3; provided that the sum of m and n is from 2 to 4;
  • o 1, 2 or 3;
  • p 1, 2 or 3;
  • o is 1. In some embodiments, p is 1. In some
  • o is 1 and p is 1.
  • m is 1. In some embodiments, n is 1. In some embodiments, n is i and m is 1. In some aspects of these embodiments, each R 6 is hydrogen. In some aspects of these embodiments, each R 6 is -OH. In some embodiments, R 1 and R2 are the same. In some embodiments, R 1 and R2 are different.
  • n is 1. In some embodiments,
  • n is i and m is 1.
  • each R 6 is hydrogen.
  • R 1 and R2 are the same.
  • R 1 and R2 are the same.
  • n is 1. In some embodiments, n is 2. In some
  • n is 2 and m is 1.
  • each R 6 is hydrogen. In some aspects of these embodiments, each R 6 is -OH. In some
  • R 1 and R2 are the same. In some embodiments, R 1 and R2 are different.
  • n is 1. In some embodiments, n is 2. In some
  • n is 2 and m is 1.
  • each R 6 is hydrogen.
  • R 1 and R2 are the same.
  • R 1 and R2 are the same.
  • n is 1. In some embodiments,
  • n is 1 and m is 2.
  • each R 6 is hydrogen.
  • X is -S-.
  • R 1 and R 2 are the same.
  • R 1 and R2 are different.
  • m is 2, n is 1, X is -S-, and R 1 and R 2 are the same.
  • n is 1. In some embodiments,
  • n is 1 and m is 2.
  • each R 6 is hydrogen.
  • R 1 and R2 are the same.
  • R 1 and R2 are the same.
  • n is 1. In some embodiments,
  • n is 3 and m is 1.
  • each R 6 is hydrogen.
  • two R 6 on the same carbon are C 1-6 alkyl (e.g., methyl) and the remaining R 6 are each hydrogen.
  • R 1 and R 2 are the same.
  • R 1 and R 2 are different. In some aspects of these embodiments, m is 3, n is 1, X is -S-, and R 1 and R 2 are the same. In some embodiments, m is 2. In some embodiments, n is 2. In some embodiments, n is 2 and m is 2. In some aspects of these embodiments, each R 6 is hydrogen. In some aspects of these embodiments, each R 6 is -
  • X is -S-.
  • R 1 and R 2 are the same. In some embodiments, R 1 and R 2 are different.
  • n is 2. In some embodiments,
  • n is 2 and m is 2.
  • each R 6 is hydrogen.
  • R 1 and R2 are the same.
  • R 1 and R2 are the same.
  • n is 2. In some embodiments, n is 3. In some
  • n is 3 and m is 2.
  • each R 6 is hydrogen.
  • two R 6 on the same carbon are C 1-6 alkyl (e.g., methyl) and the remaining R 6 are each hydrogen.
  • R 1 and R 2 are the same.
  • R 1 and R 2 are different.
  • n is 2. In some embodiments,
  • n is 3 and m is 2.
  • each R 6 is hydrogen.
  • two R 6 on the same carbon are C 1-6 alkyl (e.g., methyl) and the remaining R 6 are each hydrogen.
  • R 1 and R 2 are the same.
  • R 1 and R 2 are different.
  • n is 3. In some embodiments,
  • n is 3 and m is 3.
  • each R 6 is hydrogen.
  • R 1 and R2 are the same.
  • R 1 and R2 are the same.
  • R 1 and R 2 are each -N(R 3 )-C(0)-0-R 4 , wherein R 3 is hydrogen.
  • each R 4 is C 1-6 alkyl (e.g., isopropyl, isobutyl or tert-butyl) substituted with 0-3 occurrences of R 5 .
  • each R 4 is Ci_6 alkyl (e.g., isopropyl, isobutyl or tert-butyl) substituted with 0 occurrences of R 5 .
  • each R 4 is aryl (e.g., phenyl) substituted with 0-3 occurrences of R 5 .
  • each R 4 is aryl (e.g., phenyl) substituted with 0 occurrences of R 5 .
  • each R 4 is C 3 _ 7 cycloalkyl substituted with 0-3 occurrences of R 5 .
  • each R 4 is C 3 _ 7 cycloalkyl substituted with 0 occurrences of R 5 (e.g., cyclohexyl).
  • each R 4 is aralkyl substituted with 0-3 occurrences of R 5 .
  • each R 4 is aralkyl substituted with 0 occurrences of R 5 (e.g., benzyl).
  • R 1 and R2 are the same. In other aspects of these embodiments, R 1 and R2 are different.
  • R 1 and R 2 are each -N(R 3 )-C(0)-R 4 , wherein each R 3 is hydrogen. In some embodiments, R 1 and R 2 are each -N(R 3 C(0)-R 4", wherein each R 3 J is Ci g., methyl). In some aspects of these embodiments, R 1 and R 2
  • R 1 and R 2 are different.
  • each R 4 is aralkyl substituted with 0-3 occurrences of R 5 . In other aspects of these embodiments, each R 4 is aralkyl substituted with 0 occurrences of R 5 (e.g., benzyl, 2-phenylethyl, 1-phenylethyl, 2-phenylpropyl, 3- phenylpropyl or naphthylmethyl). In other aspects of these embodiments, each R 4 is aralkyl (e.g., benzyl, 2-phenethyl, 1-phenethyl or phenpropyl) substituted with one occurrence of R 5 . In further aspects of these embodiments, each R 5 is heterocyclyl (e.g., isoindo represented by the following structure: . In further aspects of these embodiments, each R 5 is Ci_6 alkoxy
  • each R 5 is -OH. In other further aspects of these embodiments, each R 5 is Ci_6 alkyl (e.g., methyl). In other further aspects of these embodiments, each R 5 is -N(Me) 2 . In other further aspects of these embodiments, each R 5 is halo (e.g., chloro). In other further aspects of these
  • each R 5 is Ci_6 alkoxy (e.g., methoxy) substituted with one R 6 wherein R 6 is aryl (e.g., phenyl).
  • each R 4 is aralkyl (e.g., benzyl) substituted with two occurrences of R 5 .
  • each R 5 is C 1-6 alkoxy (e.g., methoxy).
  • two R 5 are halo (e.g., fluoro) and the other two R 5 are haloalkyl (e.g., trifluoromethyl).
  • two R 5 are C 1-6 alkyl (e.g., methyl) and two R 5 are -O- C(0)-Ci- 6 alkyl (e.g., -OC(0)-CH 3 ), each of which is further substituted with 0 occurrences of R 7.
  • two adjacent R 5 moieties are taken together with the atoms to which they are attached to form a heterocyclyl ring resulting in a moiety of the following structure: .
  • each R 5 is halo (e.g., fluoro).
  • each R 4 is aralkyl (e.g., 2- phenylethyl) substituted with 3 occurrences of R 5 .
  • each R 5 is C 1-6 alkoxy (e.g., methoxy).
  • one R 4 is aralkyl (e.g., benzyl) substituted with 0 occurrences of R 5 and the other R 4 is aralkyl (e.g., benzyl) substituted with 1 occurrence of R 5 .
  • R 5 is C 1-6 alkoxy (e.g., ethoxy) which is further substituted with one R 6 , wherein R 6 is -NH 2 .
  • one R 4 is aralkyl (e.g., benzyl) substituted with 0 occurrences of R 5 and the other R 4 is C 1-6 alkyl (e.g., methyl) substituted with 0 occurrences of R 5 .
  • one R 4 is C 1-6 alkyl (e.g., methyl) substituted with 0 occurrences of R 5 and the other R 4 is aralkyl (e.g., benzyl) substituted with 2 occurrences of R 5 , wherein each R 5 is Ci_6 alkoxy (e.g., methoxy).
  • each R 4 is cycloalkylalkyl substituted with 0-3 occurrences of R 5 . In still other aspects of these embodiments, each R 4 is
  • each R 4 is heteroaralkyl substituted with 0-3 occurrences of R 5 .
  • each R 4 is cycloalkylalkyl (e.g., cyclopentylalkyl) substituted with 3 occurrences of R 5 wherein two occurrences are oxo and each other occurrence is taken together with the atoms to which they are attached to form an aryl ring substituted with one R 7 , wherein each R 7 is Ci_6 alkoxy (e.g., methoxy).
  • each R 4 is represented by the following structure:
  • each R 4 is heteroaralkyl substituted with 0 occurrences of R 5 (e.g., 2-pyridinylmethyl, 3-pyridinylmethyl, 3-pyridinylethyl, 3- benzoisoxazolylmethyl, 3-indolylmethyl, 5-tetrazolylmethyl 2-thiophenylmethyl or 2- thiophenylethyl).
  • each R 4 is heteroaralkyl (e.g., 3-pyridinylmethyl, 3-indolylmethyl or 5-isoxazolylmethyl) substituted with one occurrence of R 5 .
  • each R 5 is C 1-6 alkyl (e.g., methyl). In other further aspects of these embodiments, each R 5 is Ci_6 alkoxy (e.g., methoxy). In other further aspects of these embodiments, each R 5 is halo (e.g., chloro). In other aspects of these embodiments, each R 4 is heteroaralkyl substituted with 2 occurrences of R 5 . In some further aspects of these embodiments, each R 5 is Ci_6 alkyl (e.g., methyl) and the heteroaralkyl has the following structure:
  • each R 4 is C 1-6 alkyl (e.g., methyl, isobutyl or tert-pentyl) substituted with 0 occurrences of R 5 .
  • each R 4 is C 1-6 alkyl (e.g., methyl, isobutyl or tert-pentyl) substituted with 0 occurrences of R 5 .
  • each R 4 is Ci_6 alkyl (e.g., isopropyl or n-propyl) substituted with one occurrence of R 5 , wherein R 5 is aryl (e.g., phenyl) substituted with 0 occurrences of R 7.
  • each R 4 is C 1-6 alkyl (e.g., isopropyl) substituted with one occurrence of R 5 , wherein R 5 is aryloxy (e.g., phenoxy) substituted with one occurrence of R 7 wherein R 7 is halo (e.g., chloro).
  • each R 4 is C 3 _ 7 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) substituted with 0 occurrences of R 5 .
  • each R 4 is C 1-6 alkyl (e.g., methyl or ethyl) substituted with 1 occurrence of R 5 .
  • each R 5 is aryloxy (e.g., phenoxy) substituted with 0 occurrences of R .
  • each R 5 is aryloxy (e.g., phenoxy) substituted with one occurrence of
  • each R 7 is C 1-6 alkyl (e.g., methyl or isopropyl).
  • each R 5 is aryloxy (e.g., phenoxy) substituted with one occurrence of
  • each R 7 is C 1-6 alkoxy (e.g., methoxy).
  • each R 5 is aryloxy (e.g., phenoxy) substituted with two occurrences of R 6 , wherein each R is C 1-6 alkyl (e.g., methyl).
  • one R 4 is Ci-6 alkyl (e.g., methyl) and the other R 4 is aralkyl (e.g., benzyl), each of which is substituted with 0 occurrences of R 5 .
  • each R 4 is heterocyclylalkyl (e.g., 2- tetrahydropyranylmethyl, N-piperidinylethyl or 5-benzo[l,3]dioxolylmethyl) substituted with 0 occurrences of R 5 .
  • each R is heterocyclylalkyl substituted with 0 occurrences of R 5 and is represented by the following structure:
  • each R 4 is
  • each R 4 is represented by the following structure:
  • each R 4 is cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) substituted with 0-3 occurrences of R 5 . In other aspects of these embodiments, each R 4 is cycloalkyl (e.g., cyclobutyl, cyclopentyl or cyclohexyl) substituted with 0 occurrences of R 5 . In other aspects of these embodiments, each R 4 is cycloalkyl (e.g., cyclopropyl) substituted with one occurrence of R 5 . In some further aspects of these embodiments, each R 5 is aryl (e.g., phenyl) further substituted with 0 occurrences of R .
  • each R 4 is C3-7 cycloalkenyl (e.g., cyclopentenyl) substituted with 0-3 occurrences of R 5 . In other aspects of these embodiments, each R 4 is C 3 _ 7 cycloalkenyl (e.g., cyclopentenyl) substituted with 0 occurrences of R 5 .
  • each R 4 is aryl (e.g., phenyl or naphthyl) substituted with 0-3 occurrences of R 5 . In other aspects of these embodiments, each R 4 is aryl (e.g., phenyl or naphthyl) substituted with 0 occurrences of R 5 .
  • each R 4 is heteroaryl (e.g., 6- benzimidazolyl) substituted with 0-3 occurrences of R 5 . In other aspects of these embodiments, each R 4 is heteroaryl (e.g., 6-benzimidazolyl) substituted with one occurrence of R 5 . In some further aspects of these embodiments, each R 5 is C 1-6 alkyl (e.g., methyl).
  • each R 4 is C 2 -6 alkenyl (e.g., propenyl) substituted with 0-3 occurrences of R 5 . In other aspects of these embodiments, each R 4 is C 2 -6 alkenyl (e.g., propenyl) substituted with one occurrence of R 5 . In some further aspects of these embodiments, each R 5 is aryl (e.g., phenyl) substituted with 0
  • R 1 and R 2 are each -N(R 3a )-C(0)-N(R 3 )-R 4 , wherein each R 3a and R 3 are hydrogen.
  • each R 4 is aryl substituted with 0-3 occurrences of R 5 .
  • each R 4 is aryl substituted with 0 occurrences of R 5 (e.g., phenyl).
  • each R 4 is aryl substituted with one occurrence of R 5 (e.g., 3-tolyl or 4- tolyl).
  • each R 5 is C 1-6 alkyl (e.g., methyl).
  • R and R are the same. In other aspects of these embodiments, R and R are the same.
  • R and R are different.
  • R 1 and R 2 are each -N(R 3a )-C(0)-N(R 3 )-R 4 , wherein each R 3a is hydrogen and each R 3 is C 1-6 alkyl (e.g., methyl).
  • each R 4 is aryl substituted with 0-3 occurrences of R 5 .
  • each R 4 is aryl substituted with 0 occurrences of R 5 (e.g., phenyl).
  • R 1 and R 2 are each -N(R 3a )-C(0)-Ci-6 alkylene-N(R 3 )- C(0)-R 4 , wherein each R 3a is hydrogen and each R 3 is C 1-6 alkyl (e.g., methyl).
  • R 4 is C 1-6 alkoxy (e.g., tert-butoxy).
  • R and R are the same. In other aspects of these embodiments, R and R are different.
  • R 1 and R 2 are each -N(R 3a )-C(0)-Ci-6 alkylene-N(R 3 )- C(0)-R 4 , wherein each R 3a is hydrogen and each R 3 is hydrogen.
  • each R 4 is C 1-6 alkyl (e.g., methyl).
  • each R 4 is aryl (e.g., phenyl) substituted with 0 occurrences of R 5 .
  • R and R are the same. In other aspects of these embodiments, R and R are the same.
  • R and R are different.
  • R 1 and R 2 are each -N(R 3 )-C(0)-C 1 _ 6 alkylene-C(0)-R 4 ,
  • each R is hydrogen.
  • R and R are each -N(H)-C(0)-CH 2 CH(CH 3 )-C(0)-R 4 or -N(H)-C(0)-CH 2 CH 2 CH 2 -C(0)-R 4 .
  • each R 4 is C 1-6 alkoxy (e.g., ethoxy).
  • R 1 and R 2 are each -N(H)-C(0)-CH2CH 2 CH 2 CH2-C(0)-R 4 .
  • each R 4 is C 1-6 alkyl (e.g., methyl).
  • R 1 and R 2 are each -N(H)-C(0)-CH 2 CH 2 -C(0)-R 4 or -N(H)-C(0)- CH(CH 3 )CH 2 -C(0)-R 4 .
  • each R 4 is aryl (e.g., phenyl) substituted with 0 occurrences of R 5 .
  • R 1 and R 2 are the same. In other aspects of these embodiments, R 1 and R2 are different.
  • R 1 and R 2 are each -N(R 3 )-C(0)0-R 4 , wherein each R 3 is hydrogen.
  • each R 4 is aryl (e.g., phenyl) substituted with 0 occurrences of R 5 .
  • each R 4 is cycloalkyl (e.g., cyclohexyl) substituted with 0 occurrences of R 5 .
  • each R 4 is C 1-6 alkyl (e.g., isopropyl, isobutyl or tert-butyl) substituted with 0 occurrences of R 5 .
  • each R 4 is aralkyl (e.g., benzyl) substituted with 0 occurrences of R 5 .
  • R 1 and R2 are the same. In other aspects of these embodiments, R 1 and R2 are different.
  • R 1 is -N(R 3 )-C(0)-R 4 , wherein R 3 is hydrogen and R 4 is aralkyl (e.g., phenethyl) substituted with one occurrence of R 5 and R 2 is -N(R 3 )R 4 , wherein R 3 and R 4 are both hydrogen.
  • R 5 is -OH.
  • a compound of Formula (I) is represented by a compound of Formula (II):
  • a compound of Formula (I) is represented by a compound of Formula (Ila):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , o, p, m, n and X are as defined in Formula (I).
  • a compound of Formula (I) is represented by a compound of Formula (lib):
  • a compound of Formula (I) is represented by a compound of Formula (III):
  • R 4 , R 6 , m, n and X are as defined in Formula (I).
  • each R 4 is the same. In other aspects of these embodiments, each R 4 is different.
  • a compound of Formula (I) is represented by a compound of Formula (Ilia):
  • R 4 , R 6 , m, n and X are as defined in Formula (I).
  • each R 4 is the same. In other aspects of these embodiments, each R 4 is different.
  • a compound of Formula (I) is represented by a compound of Formula (Illb):
  • exemplary compounds of Formula I include the compounds described in Table 1 and in the Examples.
  • a compound described herein may be tested for its ability to inhibit glutaminase, e.g., by an assay as described in the Examples.
  • the inhibition activity of these compounds is represented as an IC 50 tested in an assay of Example A or Example B in Table 1.
  • Exemplary compounds are shown in Table 1 below. As shown, "A” refers to an inhibitor of glutaminase with an IC 50 ⁇ 100 nM.
  • B refers to inhibitor of glutaminase with an IC 50 between 100 nM and 500 nM.
  • C refers to inhibitor of glutaminase with an IC 50 between 500 nM and 1000 nM.
  • D refers to inhibitor of glutaminase with an IC 50 between 1 ⁇ and 10 ⁇ .
  • ⁇ ' refers to data that is not available.
  • the compounds described herein can be made using a variety of synthetic techniques such as those described in the examples provided herein. As can be appreciated by the skilled artisan, methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L.
  • the compounds provided herein may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual
  • the compounds provided herein may also comprise one or more isotopic substitutions.
  • H may be in any isotopic form, including l H,
  • C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 0 and 18 0; and the like.
  • the compounds provided herein may also be represented in multiple tautomeric forms, in such instances, expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented (e.g., alkylation of a ring system may result in alkylation at multiple sites; all such reaction products are expressly included). All such isomeric forms of such compounds are expressly included. All crystal forms of the compounds described herein are expressly included.
  • a salt for example, can be formed between an anion and a positively charged substituent (e.g., amino) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate. Likewise, a salt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein.
  • a positively charged substituent e.g., amino
  • Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate.
  • a salt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein.
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
  • Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active compounds.
  • the compounds provided herein may be modified by appending appropriate functionalities to enhance selected biological properties, e.g., targeting to a particular tissue.
  • modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • the compounds described herein may be used as platforms or scaffolds that may be utilized in combinatorial chemistry techniques for preparation of derivatives and/or chemical libraries of compounds.
  • Such derivatives and libraries of compounds have biological activity and are useful for identifying and designing compounds possessing a particular activity.
  • Combinatorial techniques suitable for utilizing the compounds described herein are known in the art as exemplified by Obrecht, D.
  • one embodiment relates to a method of using the compounds described herein for generating derivatives or chemical libraries comprising: 1) providing a body comprising a plurality of wells; 2) providing one or more compounds identified by methods described herein in each well; 3) providing an additional one or more chemicals in each well; 4) isolating the resulting one or more products from each well.
  • An alternate embodiment relates to a method of using the compounds described herein for generating derivatives or chemical libraries comprising: 1) providing one or more compounds described herein attached to a solid support; 2) treating the one or more compounds identified by methods described herein attached to a solid support with one or more additional chemicals; 3) isolating the resulting one or more products from the solid support.
  • tags or identifier or labeling moieties may be attached to and/or detached from the compounds described herein or their derivatives, to facilitate tracking, identification or isolation of the desired products or their intermediates.
  • moieties are known in the art.
  • the chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like. Examples of such chemicals are those that appear in the various synthetic and protecting group chemistry texts and treatises referenced herein.
  • halo or halogen refers to any radical of fluorine, chlorine, bromine or iodine.
  • alkyl refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms.
  • CrC 12 alkyl indicates that the group may have from 1 to 12 (inclusive) carbon atoms in it.
  • alkyl includes alkenyl, which contains unsaturation in the hydrocarbon chain.
  • haloalkyl refers to an alkyl in which one or more hydrogen atoms are replaced by halo, and includes alkyl moieties in which all hydrogens have been replaced by halo (e.g., perfluoroalkyl).
  • arylalkyl or “aralkyl” refer to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group.
  • Aralkyl includes groups in which more than one hydrogen atom has been replaced by an aryl group. Examples of “arylalkyl” or “aralkyl” include benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, and trityl groups.
  • alkylene or "cycloalkylene” refers to a divalent alkyl or cycloalkyl, e.g., -CH 2 -, -CH 2 CH 2 -, and -CH 2 CH 2 CH 2 -.
  • alkoxy refers to an -O-alkyl radical.
  • haloalkoxy refers to an alkoxy in which one or more hydrogen atoms are replaced by halo, and includes alkoxy moieties in which all hydrogens have been replaced by halo (e.g.,
  • aryl refers to a monocyclic, bicyclic, or tricyclic aromatic
  • any ring atom capable of substitution can be substituted (e.g., by one or more substituents).
  • aryl moieties include, but are not limited to, phenyl, naphthyl, and anthracenyl. Unless otherwise specified, any ring atom in an aryl can be substituted by one or more substituents.
  • cycloalkyl as employed herein includes cyclic, bicyclic, tricyclic,or polycyclic non-aromatic hydrocarbon groups having 3 to 12 carbons. Any substitutable ring atom can be substituted (e.g., by one or more substituents).
  • cycloalkyl includes cycloalkenyl, which contains unsaturation in the ring.
  • the cycloalkyl groups can contain fused or spiro rings. Fused rings are rings that share a common carbon atom. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclohexyl, methylcyclohexyl, adamantyl, and norbornyl.
  • cycloalkylalkyl refers to an alkyl group substituted with a cycloalkyl group.
  • heterocyclyl or “heterocyclic group” refer to 3- to 14-membered non- aromatic ring structures (e.g., 3- to 14-membered rings, more preferably 3- to 7- membered rings), whose ring structures include one to four heteroatoms independently selected from O, N and S.
  • the heterocyclyl or heterocyclic groups can contain fused or spiro rings. Heterocycles can also be polycycles, with each group having, e.g., 5-7 ring members.
  • heterocyclyl or “heterocyclic group” includes saturated and partially saturated heterocyclyl structures. The heteroatom may optionally be the point of attachment of the heterocyclyl substituent.
  • heteroaryl refers to a 5-14 membered (i.e., a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic) aromatic ring system having 1-3 ring heteroatoms if monocyclic, 1-6 ring heteroatoms if bicyclic, or 1-9 ring heteroatoms if tricyclic, said ring heteroatoms independently selected from O, N, and S (e.g., 1-3, 1-6, or 1-9 ring heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively). Any substitutable ring atom can be substituted (e.g., by one or more substituents).
  • Bicyclic and tricyclic ring systems containing one or more heteroatoms and both aromatic and non-aromatic rings wherein the point of attachment from the ring system to the rest of the molecule is through a non-aromatic ring are considered to be heterocyclyl groups.
  • Bicyclic or tricyclic ring systems where an aryl or a heteroaryl is fused to a cycloalkyl or heterocyclyl and the point of attachment from the ring system to the rest of the molecule is through an aromatic ring are considered to be aryl or heteroaryl groups.
  • heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
  • heteroaryl refers to an alkyl group substituted with a heteroaryl group.
  • the ring heteroatoms of the compounds provided herein include N-O, S(O), and S(0) 2 .
  • each R b is independently selected from hydrogen, and -CrC 4 alkyl; or two R b s are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered heterocyclyl optionally comprising one additional heteroatom selected from N, S, and O; and
  • each R b is independently selected from C3-C7 carbocylyl, phenyl, heteroaryl, and heterocyclyl, wherein one or more substitutable positions on said phenyl, cycloalkyl, heteroaryl or heterocycle substituent is optionally further substituted with one or more of -(C C 4 alkyl), -(C C 4 fluoroalkyl), -OH, -0-(Ci-C 4 alkyl), -0-(Ci-C 4 fluoroalkyl), halo, -NH 2 , -NH(C C 4 alkyl), or -N(C C 4 alkyl) 2 .
  • substituted refers to the replacement of a hydrogen atom by another group.
  • selective is meant at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, or 10- fold greater inhibition of glutaminase than other targets.
  • inhibitor means an agent that measurably slows, stops, decreases or inactivates the enzymatic activity of glutaminase to decrease to a level that is less than the glutaminase normal levels of activity.
  • Inhibitors of glutaminase may be peptides or nucleic acids (e.g., glutamate).
  • An agent can be evaluated to determine if it is an inhibitor by measuring either directly or indirectly the activity of glutaminase when subjected to the agent. The activity of the agent can be measured, for example, against a control substance. In some instances, the activity measured of the agent is for inhibition of glutaminase.
  • Directly acquiring means performing a process (e.g., performing a synthetic or analytical method) to obtain the physical entity or value.
  • Indirectly acquiring refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value).
  • Directly acquiring a physical entity includes performing a process that includes a physical change in a physical substance, e.g., a starting material.
  • Exemplary changes include making a physical entity from two or more starting materials, shearing or fragmenting a substance, separating or purifying a substance, combining two or more separate entities into a mixture, performing a chemical reaction that includes breaking or forming a covalent or non-covalent bond.
  • Directly acquiring a value includes performing a process that includes a physical change in a sample or another substance, e.g., performing an analytical process which includes a physical change in a substance, e.g., a sample, analyte, or reagent (sometimes referred to herein as "physical analysis"), performing an analytical method, e.g., a method which includes one or more of the following: separating or purifying a substance, e.g., an analyte, or a fragment or other derivative thereof, from another substance; combining an analyte, or fragment or other derivative thereof, with another substance, e.g., a buffer, solvent, or reactant; or changing the structure of an analyte, or a fragment or other derivative thereof, e.g., by breaking or forming a covalent or non-covalent bond, between a first and a second atom of the analyte; or by changing the structure of a reagent, or a fragment or other derivative
  • a sample refers to obtaining possession of a sample, e.g., a tissue sample or nucleic acid sample, by "directly acquiring” or
  • Directly acquiring a sample means performing a process (e.g., performing a physical method such as a surgery or extraction) to obtain the sample.
  • Indirectly acquiring a sample refers to receiving the sample from another party or source (e.g., a third party laboratory that directly acquired the sample).
  • Directly acquiring a sample includes performing a process that includes a physical change in a physical substance, e.g., a starting material, such as a tissue, e.g., a tissue in a human patient or a tissue that has was previously isolated from a patient. Exemplary changes include making a physical entity from a starting material, dissecting or scraping a tissue; separating or purifying a substance (e.g., a sample tissue or a nucleic acid sample);
  • Directly acquiring a sample includes performing a process that includes a physical change in a sample or another substance, e.g., as described above.
  • a "low" of E-cadherin expression compared to a reference standard refers a low, decreased, or absent level of E-cadherin expression compared to the level of E-cadherin expression in an epithelial cell as characterized by methods known in the art, e.g., on any one of the following references: (Yauch et ah , (2005) Clin Cancer Res 11 :24; Savagner et ah , (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et ah , (2002) Nature Reviews Cancer 2(6):442).
  • a "high" level of vimentin compared to a reference standard refers to a high or increased level of vimentin expression compared to the level of expression of vimentin in an epithelial cell as characterized by methods known in the art, e.g., on any one of the following references: (Yauch et ah , (2005) Clin Cancer Res 11 :24; Savagner et ah , (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et ah , (2002) Nature Reviews Cancer 2(6):442).
  • a "low” or “decreased”, level of pyruvate carboxylase expression compared to a reference standard refers to a low, decreased, or absent level of E-cadherin expression compared to the level of E-cadherin expression in an epithelial cell as characterized by methods known in the art, e.g., on any one of the following references: (Yauch et al , (2005) Clin Cancer Res 11 :24; Savagner et al , (2010) Ann Oncol.
  • cancer and “tumor” are synonymous terms.
  • the term “cancer” or “tumor” refer to the presence of cells possessing characteristics typical of cancer- causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features.
  • Cancer cells are often in the form of a tumor, but such cells may exist alone within an animal, or may be a non-tumorigenic cancer cell, such as a leukemia cell.
  • the cells can possess characteristics typical of a mesenchymal cell, such as characterized on any one of the following references: (Yauch et al , (2005) Clin Cancer Res 11 :24; Savagner et al. , (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al , (2002) Nature Reviews Cancer 2(6):442).
  • Me, Et, Ph, Tf, Nf, Ts, Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, p-toluenesulfonyl and
  • Glutaminase activity can be monitored by detecting production of either of the products of the reaction, glutamate or ammonia. In some embodiments, glutamate production is measured because ammonia is a product of any of a number of biological reactions.
  • Glutamate production can be measured by any of a number of standard methods known in the art, e.g., chemical and chromatographic detection methods and coupled enzyme assays that utilize NADH and glutamate dehydrogenase. Extracellular glutamate concentrations can also be measured in vivo, using microdialysis methods known in the art.
  • One suitable method for measuring glutamate is a microtiter-based two-step assay in which glutamate formed in the initial step is quantitatively deaminated by glutamate dehydrogenase to yield an equivalent amount of NADH (Godfrey et al., 1977; Kvamme et al., 1985), which can then be detected spectrophotometrically.
  • a method for treating or preventing a disease, condition or disorder as described herein comprising administering a compound, a pharmaceutically acceptable salt of a compound or pharmaceutical composition comprising a compound described herein (e.g., a compound of formula (I) or in Table 1).
  • the compounds and compositions described herein can be administered to cells in culture, e.g. in vitro or ex vivo, or to a subject, e.g., in vivo, to treat, prevent, and/or diagnose a variety of disorders, including those described herein below.
  • the term "treat” or “treatment” is defined as the application or administration of a compound, alone or in combination with, a second compound to a subject, e.g., a patient, or application or administration of the compound to an isolated tissue or cell, e.g., cell line, from a subject, e.g., a patient, who has a disorder (e.g., a disorder as described herein), a symptom of a disorder, or a predisposition toward a disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder, one or more symptoms of the disorder or the
  • predisposition toward the disorder e.g., to prevent at least one symptom of the disorder or to delay onset of at least one symptom of the disorder.
  • an amount of a compound effective to treat a disorder refers to an amount of the compound which is effective, upon single or multiple dose administration to a subject, in treating a cell, or in curing, alleviating, relieving or improving a subject with a disorder beyond that expected in the absence of such treatment.
  • an amount of a compound effective to prevent a disorder, or a "a prophylactically effective amount” of the compound refers to an amount effective, upon single- or multiple-dose administration to the subject, in preventing or delaying the occurrence of the onset or recurrence of a disorder or a symptom of the disorder.
  • patient and “subject” are synonymous, and as used herein, refer to an animal, typically a human (i.e., a male or female of any age group, e.g., a pediatric patient or adult patient or other mammal, such as primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys, that will be or has been the object of treatment, observation, and/or experiment.
  • a human i.e., a male or female of any age group, e.g., a pediatric patient or adult patient or other mammal, such as primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or
  • a cancer can be evaluated to determine whether it is using a method described herein.
  • Exemplary cancers can include but are not limited to, lung cancer, e.g. , non-small cell lung cancer; breast cancer, e.g., triple negative breast cancer; or hepatocellular carcninoma, osteosarcoma, lipomas, chondrosarcoma, or mesothelioma.
  • the cancer is selected from colon cancer, renal cell carcinoma, acute myeloid leukemia (AML), melanoma, and multiple myeloma.
  • the cancer can be a primary tumor, i.e., located at the anatomical site of tumor growth initiation.
  • the cancer can also be metastatic, i.e., appearing at least a second anatomical site other than the anatomical site of tumor growth initiation.
  • the cancer can be a recurrent cancer, i.e., cancer that returns following treatment, and after a period of time in which the cancer was undetectable.
  • the recurrent cancer can be anatomically located locally to the original tumor, e.g. , anatomically near the original tumor; regionally to the original tumor, e.g. , in a lymph node located near the original tumor; or distantly to the original tumor, e.g., anatomically in a region remote from the original tumor.
  • a compound described herein is administered together with one or more additional cancer treatments.
  • exemplary cancer treatments include, for example: chemotherapy, targeted therapies such as antibody therapies, immunotherapy, and hormonal therapy. Examples of each of these treatments are provided below.
  • a compound described herein is administered with one or morechemo therapies.
  • Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. "Chemotherapy” usually refers to cytotoxic drugs which affect rapidly dividing cells in general, in contrast with targeted therapy. Chemotherapy drugs interfere with cell division in various possible ways, e.g., with the duplication of DNA or the separation of newly formed chromosomes. Most forms of chemotherapy target all rapidly dividing cells and are not specific for cancer cells, although some degree of specificity may come from the inability of many cancer cells to repair DNA damage, while normal cells generally can.
  • chemotherapeutic agents used in cancer therapy include, for example, antimetabolites (e.g., folic acid, purine, and pyrimidine derivatives) and alkylating agents (e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poison, cytotoxic agents, toposimerase inhibitors and others).
  • antimetabolites e.g., folic acid, purine, and pyrimidine derivatives
  • alkylating agents e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poison, cytotoxic agents, toposimerase inhibitors and others.
  • alkylating agents e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, tria
  • Carboquone Carmofur, Carmustine, Celecoxib, Chlorambucil, Chlormethine, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Demecolcine, Docetaxel, Doxorubicin, Efaproxiral, Elesclomol, Elsamitrucin, Enocitabine, Epirubicin, Estramustine, Etoglucid, Etoposide, Floxuridine, Fludarabine, Fluorouracil (5FU), Fotemustine, Gemcitabine, Gliadel implants, Hydroxycarbamide, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Irofulven, Ixabepilone, Larotaxel, Leucovorin, Liposomal doxorubicin, Liposomal
  • Mitobronitol Mitoguazone, Mitotane, Mitomycin, Mitoxantrone, Nedaplatin, Nimustine, Oblimersen, Omacetaxine, Ortataxel, Oxaliplatin, Paclitaxel, Pegaspargase, Pemetrexed, Pentostatin, Pirarubicin, Pixantrone, Plicamycin, Porfimer sodium, Prednimustine, Procarbazine, Raltitrexed, Ranimustine, Rubitecan, Sapacitabine, Semustine, Sitimagene ceradenovec, Satraplatin, Streptozocin, Talaporfin, Tegafur-uracil, Temoporfin,
  • Temozolomide Teniposide, Tesetaxel, Testolactone, Tetranitrate, Thiotepa, Tiazofurin, Tioguanine, Tipifarnib, Topotecan, Trabectedin, Triaziquone, Triethylenemelamine, Triplatin, Tretinoin, Treosulfan, Trofosfamide, Uramustine, Valrubicin, Verteporfin, Vinblastine, Vincristine, Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zorubicin, and other cytostatic or cytotoxic agents described herein.
  • the chemotherapy agents can be used in combination with a compound described herein.
  • a compound described herein is administered with one or more targeted therapies.
  • Targeted therapy constitutes the use of agents specific for the deregulated proteins of cancer cells.
  • Small molecule targeted therapy drugs are generally inhibitors of enzymatic domains on mutated, overexpressed, or otherwise critical proteins within the cancer cell.
  • Prominent examples are the tyrosine kinase inhibitors such as Axitinib, Bosutinib, Cediranib, dasatinib, erlotinib, imatinib, gefitinib, lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, and Vandetanib, and also cyclin-dependent kinase inhibitors such as Alvocidib and Seliciclib.
  • Monoclonal antibody therapy is another strategy in which the therapeutic agent is an antibody which specifically binds to a protein on the surface of the cancer cells.
  • Examples include the anti-HER2/neu antibody trastuzumab (HERCEPTIN®) typically used in breast cancer, and the anti-CD20 antibody rituximab and Tositumomab typically used in a variety of B- cell malignancies.
  • Other exemplary anbibodies include Cetuximab, Panitumumab, Trastuzumab, Alemtuzumab, Bevacizumab, Edrecolomab, and Gemtuzumab.
  • Exemplary fusion proteins include Aflibercept and Denileukin diftitox.
  • the targeted therapy can be used in combination with a compound described herein.
  • Exemplary additional therapeutic agents can also include epidermal growth factor receptor (EGFR) inhibitors, e.g., cetuximab, panitumumab, gefitinib, erlotinib, nimotuzamab, matuzamab, zalutumumab, or lapatinib.
  • EGFR epidermal growth factor receptor
  • Resistance to EGFR inhibitors can occur as a result of the transition of a cell to a mesenchymal phenotype or a mesenchymal phenotype, and tumors with EGFR mutations and mesenchymal phenotype can be less sensitive to EGFR inhibitors (see for example, Sequist et al., (2011) Sci Transl Med. 3:75. Buck et al, (2007) Mol Cancer Ther. 6: 532; Thomson et al, (2008) Clin Exp Metastasis 25: 843).
  • EGFR epidermal growth factor receptor
  • Exemplary additional therapeutic agents can also include glutathione depleting agents, e.g., L-buthionine-(S,R)-sulfoximine (BSO).
  • glutathione depleting agents e.g., L-buthionine-(S,R)-sulfoximine (BSO).
  • Exemplary additional therapeutic agents can also include Phosphoinositide 3- kinase (PI3K) inhibitors, e.g., Perifosine, Idelalisib, BKM120, PX-866, IPI- 145, NVP- BEZ235, GDC0941, and BAY 80-6946.
  • PI3K Phosphoinositide 3- kinase
  • Exemplary additional therapeutic agents can also include Heat Shock Protein 90 (HSP90) inhibitors, e.g., geldanamycin, radicicol, 17-N-Allylamino-17- demethoxygeldanamycin (17AAG). ganetespib, 4-(4-(2,3-Dihydro-l,4-benzodioxin-6- yl)-5-methyl-lH-pyrazol-3-yl)-6-ethylresorcinol, AUY922 (NVP-AUY922), BIIB021, STA9090, AT13387, NVP-BEP800, and SNX-2112 (PF-04928473).
  • HSP90 Heat Shock Protein 90
  • Targeted therapy can also involve small peptides as "homing devices” which can bind to cell surface receptors or affected extracellular matrix surrounding the tumor. Radionuclides which are attached to these peptides (e.g., RGDs) eventually kill the cancer cell if the nuclide decays in the vicinity of the cell.
  • RGDs Radionuclides which are attached to these peptides
  • An example of such therapy includes BEXXAR®.
  • a compound described herein is administered with one or more immunotherapies.
  • Cancer immunotherapy refers to a diverse set of therapeutic strategies designed to induce the patient's own immune system to fight the tumor.
  • Contemporary methods for generating an immune response against tumors include intravesicular BCG immunotherapy for superficial bladder cancer, and use of interferons and other cytokines to induce an immune response in renal cell carcinoma and melanoma patients.
  • Allogeneic hematopoietic stem cell transplantation can be considered a form of immunotherapy, since the donor's immune cells will often attack the tumor in a graft- versus-tumor effect.
  • the immunotherapy agents can be used in combination with a compound described herein.
  • a compound described herein is administered with one or more hormonal therapies.
  • the growth of some cancers can be inhibited by providing or blocking certain hormones.
  • hormone-sensitive tumors include certain types of breast and prostate cancers. Removing or blocking estrogen or testosterone is often an important additional treatment.
  • administration of hormone agonists, such as progestogens may be therapeutically beneficial.
  • the hormonal therapy agents can be used in combination with a compound described herein.
  • Nutrient restricted diets In some embodiments, a compound described herein is administered in conjunction with one or more nutrient restricted diets. Since cancer cells rely on glucose to generate cellular energy, lowering glucose blood levels through carbohydrate and protein restriction may inhibit the growth of some cancers. In certain cancers, nutrient restricted diets such as caloric restriction, fasting, and ketogenic diets may be used.
  • such nutrient restricted diets can be used in combination with a compound described herein.
  • a compound or composition described herein can be used to treat or prevent neuronal cell death as a result of an injury to neuronal tissue, e.g., nervous tissue exposed to an ischemic or hypoxic event, to trauma or to a chronic neurodegenerative disorder.
  • a "neuronal disorder” is a neurological disease or disorder that is associated with glutamate excitotoxicity, e.g., cerebral ischemia or hypoxia resulting from an neurological event such as a stroke or ischemic event.
  • Treatment with the compound may be in an amount effective to provide a neuroprotective effect, e.g., to prevent neuronal cell death.
  • compositions and routes of administration are provided.
  • compositions delineated herein include the compounds delineated herein (e.g., a compound described herein), as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein.
  • pharmaceutically acceptable carrier or adjuvant refers to a carrier or adjuvant that may be administered to a subject, together with a compound provided herewith, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions provided herewith include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-cc-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene
  • Cyclodextrins such as ⁇ -, ⁇ -, and ⁇ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
  • compositions provided herewith may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection.
  • the pharmaceutical compositions provided herewith may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3- butanediol.
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or
  • carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions.
  • Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions provided herewith may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
  • compositions provided herewith may also be administered in the form of suppositories for rectal administration.
  • These compositions can be prepared by mixing a compound provided herewith with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
  • suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • Topical administration of the pharmaceutical compositions provided herewith is useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds provided herewith include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions provided herewith may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included.
  • compositions provided herewith may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • the compositions provided herewith comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents
  • both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
  • the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds provided herewith. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds provided herewith in a single composition.
  • the compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug.
  • the methods herein contemplate administration of an effective amount of compound or compound
  • compositions provided herewith will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a typical preparation will contain from about 5% to about 95% active compound (w/w).
  • such preparations contain from about 20% to about 80% active compound.
  • a maintenance dose of a compound, composition or combination provided herewith may be administered, if necessary.
  • the dosage or frequency of administration, or both may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level.
  • Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • the compounds described herein can inhibit glutaminase. Accordingly, a patient and/or subject can be selected for treatment using a compound described herein by first evaluating the patient and/or subject to determine whether the subject is in need of inhibition of glutaminase, and if the subject is determined to be in need of glutaminase inhibition, then administering to the subject a compound described herein.
  • a subject can be evaluated as being in need of glutaminase inhibition using methods known in the art, e.g., by measuring the presence and/or activity of glutaminase in the patient. In some embodiments, the activity and/or level of glutaminase is evaluated in the cancer.
  • a patient receiving a compound described herein can be monitored, for example, for improvement in the condition and/or adverse effects. Improvement of a patient's condition can be evaluated, for example, by monitoring the growth, absence of growth, or regression of the cancer (e.g., a tumor). In some embodiments, the patient is evaluated using a radiological assay or evaluation of hemolytic parameters.
  • a patient and/or subject can be selected for treatment using a compound described hereby by optionally, acquiring a patient sample; evaluating the sample to determine whether the sample is characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, and/or iii) a low or decreased level of pyruvate carboxylase expression compared to a reference standard; and if the patient is determined to have a low level of E-cadherin expression compared to a reference standard, or a high level of vimentin expression compared to a reference standard, then the patient is administered a compound described herein.
  • the level of E-cadherin expression is compared to a reference standard, wherein the reference standard is the level of E-cadherin expression in an epithelial cell as characterized on any one of the following references: (Yauch et al., (2005) Clin Cancer Res 11:24; Savagner et al, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442).
  • the level of E-cadherin expression is low, decreased, or absent compared to the reference standard.
  • the level of E-cadherin expression is measured by the evaluation of the level of RNA that encodes E-cadherin.
  • the level of E- cadherin expression is evaluated by the level of E-cadherin protein expression. In some embodiments the level of E-cadherin expression is at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90% less than the reference standard. In some embodiments the level of E- cadherin expression is at least a 1.5, 2, 5, 10, 15, 20, 25, 50, 75, 100 fold decrease in expression compared to the reference standard.
  • the level of vimentin expression is compared to a reference standard, wherein the reference standard is the level of vimentin expression in an epithelial cell as characterized on any one of the following references: (Yauch et al, (2005) Clin Cancer Res 11:24; Savagner et al, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442).
  • the level of vimentin expression is measured by the evaluation of the level of RNA that encodes vimentin.
  • the level of vimentin expression is evaluated by the level of vimentin protein expression.
  • the level of vimentin expression is at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90% greater than the reference standard. In some embodiments the level of vimentin expression is at least a 1.5, 2, 5, 10, 15, 20, 25, 50, 75, 100 fold increase in expression compared to the reference standard.
  • the level of pyruvate carboxylase expression is low or decreased compared to a reference standard, wherein the reference standard is the level of pyruvate carboxylase expression in an epithelial cell as characterized on any one of the following references: (Yauch et ah, (2005) Clin Cancer Res 11:24; Savagner et ah, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442).
  • the level of pyruvate carboxylase expression is high or increased compared to the reference standard.
  • the level of pyruvate carboxylase expression is measured by the evaluation of the level of RNA that encodes pyruvate carboxylase. In some embodiments, the level of vimentin expression is evaluated by the level of pyruvate carboxylase protein expression. In some embodiments the level of pyruvate carboxylase expression is at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90% greater than the reference standard. In some embodiments the level of pyruvate carboxylase expression is at least a 1.5, 2, 5, 10, 15, 20, 25, 50, 75, 100 fold increase in expression compared to the reference standard.
  • the patient sample can be a tissue, or bodily fluid, or bodily product.
  • Tissue samples can include fixed, paraffin embedded, fresh, or frozen samples.
  • the tissue sample can include a biopsy, cheek swab.
  • Exemplary tissues include lung, breast, brain, nervous tissue, kidney, ovary, thyroid, pancreas, colon, prostate, lymph node, skin, hair follicles and nails.
  • Exemplary samples include samples derived from solid tumors.
  • Exemplary bodily fluids include blood, plasma, urine, lymph, tears, sweat, saliva, semen, and cerebrospinal fluid.
  • Exemplary bodily products include exhaled breath.
  • the tissue, fluid or product can be removed from the patient and analyzed.
  • the evaluation can include one or more of: performing the analysis of the tissue, fluid or product; requesting analysis of the tissue fluid or product; requesting results from analysis of the tissue, fluid or product; or receiving the results from analysis of the tissue, fluid or product.
  • the sample tissue, fluid, or product can be analyzed for the expression level of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase.
  • the sample tissue, fluid, or product can be analyzed for the expression level of a protein described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase.
  • the sample tissue, fluid or product can further be analyzed for the level of gene expression of a gene or plurality of genes of a preselected signaling pathway or phenotypic pathway, e.g., the epithelial to mesenchymal transition pathway, E-cadherin pathway, vimentin pathway, or the pyruvate carboxylase pathway.
  • sample tissue, fluid or product can further be analyzed for the level of protein expression of a protein or plurality of proteins of a preselected signaling pathway or phenotypic pathway, e.g., the epithelial to mesenchymal transition pathway, E-cadherin pathway, vimentin pathway, or the pyruvate carboxylase pathway.
  • a preselected signaling pathway or phenotypic pathway e.g., the epithelial to mesenchymal transition pathway, E-cadherin pathway, vimentin pathway, or the pyruvate carboxylase pathway.
  • the expression level of a gene described herein can be assessed using any of a wide variety of well known methods for detecting expression of a transcribed molecule, gene, protein, mRNA, genomic DNA, or cDNA.
  • Gene expression can be measured or monitored by measure of a gene transcript, e.g., mRNA, by a measure of the quantity of a translated protein, or by a measure of gene product activity; any of which can be measured using standard techniques known to one of skill in the art.
  • Non-limiting examples of such methods include nucleic acid hybridization methods, nucleic acid reverse transcription methods, nucleic acid amplification methods, immunological methods for detection of proteins, protein purification methods, protein function or activity assays.
  • E-cadherin gene is located on human chromosome 16.
  • E-cadherin is a classical cadherin of the cadherin superfamily.
  • the encoded E-cadherin protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail.
  • E-cadherin Loss of function of E-cadherin is contemplated to contribute to cancer progression by increasing proliferation, invasion, and/or metastasis.
  • the ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization.
  • Identified E-cadherin transcript variants arise from mutation at consensus splice sites.
  • the vimentin gene is located on human chromosome 10 and encodes a member of the intermediate filament family of proteins. Intermediate filaments, along with microtubules and actin microfilaments, make up the cellular cytoskeleton, which helps maintain cell shape and integrity of the cytoplasm, as well as stabilizing cyto skeletal interactions. Vimentin also functions in mediating immune responses, control of the transport of low-density lipoprotein derived cholesterol from lysosomes to the sites of esterification, and as an organizer of a number of critical proteins involved in attachment, migration, and cell signaling.
  • the PC gene is located on human chromosomes 11 and encodes the protein pyruvate carboxylase, which catalyzes the carboxylation of pyruvate to oxaloacetate.
  • the active enzyme is a homotetramer arranged in a tetrahedron which is located exclusively in the mitochondrial matrix.
  • Pyruvate carboxylase is involved in multiple cellular processes including gluconeogenesis, lipogenesis, insulin secretion and synthesis of the neurotransmitter glutamate. Mutations in this gene have been associated with pyruvate carboxylase deficiency. Alternatively spliced transcript variants with different 5' UTRs, but encoding the same protein, have been identified.
  • the methods described herein can pertain to the evaluation of a sample for the expression of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase; based on isolated nucleic acids which correspond to the gene described herein, e.g., the mRNA level of E-cadherin; the mRNA level of vimentin; the mRNA level of pyruvate carboxylase.
  • nucleic acid or "nucleic acid molecule” is intended to include DNA molecules ⁇ e.g., cDNA or genomic DNA) and RNA molecules ⁇ e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
  • the nucleic acid molecule can be single- stranded or double- stranded.
  • An “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule.
  • An “isolated” nucleic acid molecule can be free of sequences (such as protein-encoding sequences) which naturally flank the nucleic acid ⁇ i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
  • An “isolated” nucleic acid molecule, such mRNA can be substantially free of other cellular material cellular material or other contaminating proteins from the cell or tissue source from which the nucleic acid is derived.
  • nucleic acid molecule described herein can be isolated using standard molecular biology techniques and the sequence information available in database records known to those of skill in the art. Using all or a portion of such nucleic acid sequences, nucleic acid molecules described herein can be isolated using standard hybridization and cloning techniques ⁇ e.g., as described in Sambrook et ah, ed., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • a nucleic acid molecule described herein can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.
  • the nucleic acid molecules so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
  • oligonucleotides corresponding to all or a portion of a nucleic acid molecule can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
  • An isolated nucleic acid molecule can comprise a nucleic acid molecule which has a nucleotide sequence complementary to the nucleotide sequence of a nucleic acid corresponding to gene described herein, or to the nucleotide sequence of a nucleic acid encoding a protein which corresponds to the gene described herein.
  • a nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.
  • a nucleic acid molecule described herein can comprise only a portion of a nucleic acid sequence. Such nucleic acid molecules can be used, for example, as a probe or primer.
  • the probe/primer can be one or more substantially purified oligonucleotides.
  • Probes based on the sequence of a nucleic acid molecules described herein can be used to detect transcripts or genomic sequences corresponding to the genes described herein.
  • the probe can contain comprise a label group, e.g. , a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
  • Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a patient, e.g., detecting mRNA levels.
  • Methods of detecting and/or quantifying a gene transcript, e.g., mRNA or cDNA made therefrom can include but are not limited to Southern Blot analysis, Northern Blot analysis, polymerase chain reaction (PCR) analyses and probe arrays.
  • Methods of detecting and/or quantifying a gene transcript, e.g. , mRNA or cDNA made therefrom can include but are not limited to hybridization based methods, e.g., hybridization with a probe that is specific for the gene transcript, e.g., mRNA or cDNA made therefrom.
  • the level of a gene transcript e.g., mRNA or cDNA made therefrom, can be assayed by applying the sample, or the mRNA or cDNA made therefrom, or amplified from; to a nucleic acid microarray, or chip array.
  • the level of a gene transcript e.g., mRNA or cDNA made therefrom, can be assayed by a polymerase chain reaction (PCR) based method, e.g., quantitative PCR, quantitative real time PCR, real time PCR, reverse transcription PCR, real time reverse transcription PCR.
  • PCR polymerase chain reaction
  • the level of a gene transcript, e.g., mRNA or cDNA made therefrom can be assayed by a sequencing based method, e.g., quantitative RNA sequencing.
  • the level of a gene transcript e.g., mRNA
  • a gene transcript e.g., mRNA
  • in situ or by in vitro methods known in the art any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from a sample, e.g., from cells of a sample (see, e.g., Ausubel et ah, ed., Current
  • tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155).
  • a cell or tissue sample can be prepared/processed using known histological methods. The sample can then be immobilized on a support, and then contacted with a probe that can hybridize to mRNA that encodes the gene transcript of interest.
  • Determinations can be based on absolute expression level; normalized expression level, or relative expression level; of a gene transcript, e.g., mRNA.
  • Expression levels can be normalized by correcting the absolute expression level of a gene transcript by comparing its expression level to the expression level of another gene which is stably expressed, e.g., a housekeeping gene that is constitutively expressed.
  • Suitable genes for normalization include housekeeping genes such as histone H3 gene or the actin gene.
  • This normalization allows the comparison of the expression level in one sample to another sample, e.g., a first sample taken from a patient to a second sample taken from the same patient, e.g., from another tissue or at a different time point; or between samples from different sources, e.g., a patient sample from one patient to a patient sample from another patient.
  • the expression level can be provided as a relative expression level.
  • the relative expression level can be determined by comparing the absolute level of expression of the gene transcript, e.g., mRNA, to a reference standard.
  • the reference standard can include the level of expression of the gene transcript of interest in a genotypically or
  • the reference standard can be the level of expression of the gene transcript of interest, e.g., E-cadherin, vimentin, pyruvate carboxylase, in a cell genotypically or phenotypically characterized as an epithelial cell.
  • An epithelial cell can be characterized as in any one of the following references: (Yauch et ah, (2005) Clin Cancer Res 11:24; Savagner et ah, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et ah, (2002) Nature Reviews Cancer 2(6):442).
  • the expression level of a gene transcript described herein can be measured at least at two time-points to determine if a change in the level of expression has occurred.
  • the level of expression can be measured pre- and post-treatment with a compound described herein, or at one or more time-points while treatment with a compound described herein is ongoing. If the expression level is found to be decreased, e.g., decreased expression of E-cadherin compared to a reference standard and/or increased expression of vimentin compared to a reference standard; the subject may be administered treatment with a compound described herein.
  • the reference standard can be the level of expression of the gene transcript of interest in an epithelial cell characterized.
  • An epithelial cell can be characterized by methods known in the art, e.g., as in any one of the following references: (Yauch et ah, (2005) Clin Cancer Res 11:24; Savagner et ah, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442).
  • the methods described herein can pertain to the evaluation of a sample for the expression of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase; based on isolated proteins which correspond to the gene described herein, e.g., the protein level of E-cadherin; the protein level of vimentin; the protein level of pyruvate carboxylase.
  • This can also include the evaluation of biologically active portions, variants, isoforms, or splice variants thereof.
  • the native polypeptide corresponding to the protein of interest can be isolated from the sample by an appropriate purification scheme using standard protein purification techniques known to those of skill in the art.
  • an “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived.
  • the language “substantially free of cellular material” includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated.
  • Biologically active portions of a polypeptide can include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein, which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein.
  • biologically active portions comprise a domain or motif with at least one activity of the corresponding protein.
  • the level of expression of a protein or polypeptide can be detected and quantified by any of a number of means well known to those of skill in the art.
  • Methods of detecting and/or quantifying a protein or polypeptide described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase; can include but are not limited to biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, or various immunoassays such as fluid or gel precipitin reactions, immunodiffusion (single or double), Immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, Western blotting, immunohistochemistry, in situ hybridization, fluorescence-activated cell sorting (FACS) and the like.
  • a skilled artisan can readily adapt known protein
  • a protein or polypeptide can be detected using an immunoassay.
  • immunoassays include assays that utilize an antibody to specifically bind to a protein or polypeptide.
  • An immunoassay can be characterized by the detection of specific binding of a protein or polypeptide to an antibody as opposed to the use of other physical or chemical properties to isolate, target, and quantify the polypeptide.
  • the polypeptide can be detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and
  • an antibody capable of binding to a protein or polypeptide e.g., an antibody with a detectable label (either directly or indirectly labeled), corresponding to a protein or polypeptide described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase, can be used to detect the protein or polypeptide.
  • Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof, e.g., Fab or F(ab') 2 can be used.
  • labeled with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling, i.e., physically linking a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
  • indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
  • the antibody can also be labeled, e.g., a radio-labeled, chromophore- labeled, fluorophore-labeled, or enzyme-labeled antibody.
  • An antibody derivative e.g., an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair, e.g., biotin-streptavidin, or an antibody fragment, e.g., a single-chain antibody, an isolated antibody hypervariable domain, etc, which binds specifically with a protein described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase, such as the protein encoded by the open reading frame corresponding to the gene transcript of a protein or polypeptide described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase, or such a protein or polypeptide which has undergone all or a portion of its normal post- translational modification, is used.
  • a protein described herein e.g., E-cadherin, vimentin, pyruvate carboxylase, such as the protein encoded by the open reading frame corresponding to the gene transcript
  • Proteins from cells can be isolated using techniques that are well known to those of skill in the art.
  • the protein isolation methods employed can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).
  • the expression level can be provided as a relative expression level.
  • the relative expression level can be determined by comparing the absolute level of expression of the protein, to a reference standard.
  • the reference standard can include the level of expression of the protein of interest in a genotypically or phenotypically defined sample.
  • the reference standard can be the level of expression of the protein of interest, e.g., E- cadherin, vimentin, pyruvate carboxylase, in a cell genotypically or phenotypically characterized as an epithelial cell.
  • An epithelial cell can be characterized by methods known in the art, e.g., as described in on any one of the following references: (Yauch et al, (2005) Clin Cancer Res 11:24; Savagner et al, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442).
  • the expression level of a protein or polypeptide described herein can be measured at least at two time-points to determine if a change in the level of expression has occurred.
  • the level of expression can be measured pre- and post-treatment with a compound described herein, or at one or more time-points while treatment with a compound described herein is ongoing. If the expression level is found to be decreased, e.g., decreased expression of E- cadherin compared to a reference standard and/or increased expression of vimentin compared to a reference standard; the subject may be administered treatment with a compound described herein.
  • kits comprising a means to assay the level of gene expression of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase.
  • the kit can include an agent capable of interacting with a gene expression product of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase.
  • the kit can include a plurality of agents capable of interacting with gene expression products of a plurality of genes described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase.
  • the agent can include, but is not limited to, an antibody, a plurality of antibodies, an oligonucleotide, or a plurality of oligonucleotides.
  • the gene expression product can include, but is not limited to, a transcribed molecule, a RNA molecule, a polypeptide, a protein, genomic DNA, or cDNA.
  • the kit can further optionally include reagents for performing the assays described herein.
  • the kit can include buffers, solvents, stabilizers, preservatives, purification columns, detection reagents, and enzymes, which may be necessary for isolating nucleic acids from a patient sample, amplifying the samples, e.g., by qRT-PCR, and applying the samples to the agent described above; or for isolating proteins from a subject sample, and applying the samples to the agent described above; or reagents for directly applying the subject sample to the agent described above.
  • a kit can also include positive and negative control samples, e.g., control nucleic acid samples (e.g., nucleic acid sample from a non-cancer subject, or a non-tumor tissue sample, or a subject who has not received treatment for cancer, or other test samples for testing at the same time as subject samples.
  • a kit can also include instructional material, which may provide guidance for collecting and processing patient samples, applying the samples to the level of gene expression assay, and for interpreting assay results.
  • the components of the kit can be provided in any form, e.g., liquid, dried, semi- dried, or in lyophilized form, or in a form for storage in a frozen condition. Typically, the components of the kit are provided in a form that is sterile.
  • the liquid solution generally is an aqueous solution, e.g., a sterile aqueous solution.
  • a suitable solvent e.g., sterile buffer, can optionally be provided in the kit.
  • the kit can include one or more containers for the kit components in a concentration suitable for use in the level of gene expression assays or with instructions for dilution for use in the assay.
  • the kit can contain separate containers, dividers or compartments for the assay components, and the informational material.
  • the positive and negative control samples can be contained in a bottle or vial
  • the clinically compatible classifier can be sealed in a sterile plastic wrapping
  • the informational material can be contained in a plastic sleeve or packet.
  • the kit can include a plurality (e.g., a pack) of individual containers, each containing one or more unit forms (e.g., for use with one assay) of an agent.
  • the containers of the kits can be air tight and/or waterproof.
  • the container can be labeled for use.
  • the kit can include informational material for performing and interpreting the assay.
  • the kit can also provide guidance as to where to report the results of the assay, e.g., to a treatment center or healthcare provider.
  • the kit can include forms for reporting the results of a gene activity assay described herein, and address and contact information regarding where to send such forms or other related information; or a URL (Uniform Resource Locator) address for reporting the results in an online database or an online application (e.g. , an app).
  • the informational material can include guidance regarding whether a patient should receive treatment with an anti-cancer stem cell agent, depending on the results of the assay.
  • the informational material of the kits is not limited in its form.
  • the informational material e.g., instructions
  • the informational material is provided in printed matter, e.g., a printed text, drawing, and/or photograph, e.g., a label or printed sheet.
  • the informational material can also be provided in other formats, such as computer readable material, video recording, or audio recording.
  • the informational material of the kit can be contact information, e.g., a physical address, email address, website, or telephone number, where a user of the kit can obtain substantive information about the gene activity assay and/or its use in the methods described herein.
  • the informational material can also be provided in any combination of formats.
  • a subject sample can be provided to an assay provider, e.g., a service provider (such as a third party facility) or a healthcare provider that evaluates the sample in an assay and provides a read out.
  • an assay provider can receive a sample from a subject, such as a tissue sample, or a plasma, blood or serum sample, and evaluate the sample using an assay described herein, and determines that the subject is a candidate to receive treatment with an inhibitor as described herein.
  • the assay provider can inform a healthcare provider that the subject is a candidate for treatment with an inhibitor as described herein, and the candidate is administered the inhibitor as described herein.
  • the assay provider can provide the results of the evaluation, and optionally, conclusions regarding one or more of diagnosis, prognosis, or appropriate therapy options to, for example, a healthcare provider, or patient, or an insurance company, in any suitable format, such as by mail or electronically, or through an online database.
  • the information collected and provided by the assay provider can be stored in a database.
  • the enzymatic activity of glutaminase is measured through a coupled endpoint assay.
  • Glutamine and phosphate are supplied to GAC at a
  • Resorufin in measured after the assay is stopped with SDS by Ex544/Em590. A reduction in the signal indicates inhibition of some component of the coupled enzyme system.
  • Prospective hits are counterscreened against GDH/diaphorase alone to remove hits to the coupling enzyme system in a second assay.
  • 2X Buffer 300 mM NaCl, 100 mM HEPES pH 8.5, 0.1% BSA, 0.5 mM EDTA, 100 mM sodium phosphate pH 8.5
  • the potential for a compound to inhibit the coupled enzyme assay system of the glutaminase HTS method is tested through a coupled endpoint assay.
  • Glutamate is supplied at Km to GDH, which then performs a reductive deamidation to produce 20G.
  • NAD is supplied at 2X Km to the system, and its conversion to NADH is monitored by the activity of diaphorase.
  • Diaphorase supplied in large kinetic excess to GDH, converts NADH back to NAD to keep NAD levels constant in the reaction while at the same time reducing rezasurin to the highly fluorescent resorufin.
  • Resorufin in measured after the assay is stopped with SDS by Ex544/Em590. A reduction in the signal indicates inhibition of some component of the coupled enzyme system.
  • 2X Buffer 300 mM NaCl, 100 mM HEPES pH 8.5, 0.1% BSA, 0.5 mM EDTA, 100 mM phosphate pH 8.5
  • reaction mixture was quenched with aq. NaHC0 3 solution and solvent was evaporated to dryness. Water was added to the residue, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by standard methods to afford the desired products (1-13).
  • the following compounds were synthesized by following the general procedure as described for 1-13:
  • the title compound was synthesized from octanedioic acid 1-59 and
  • the title compound was synthesized from 5-(3-(((5-amino-l,3,4-thiadiazol-2- yl)methyl) thio)propyl)-l,3,4-thiadiazol-2-amine 1-82 by following the general procedure as described for 1-3.
  • Method B The mixture of Diamine 1-97 (1 equivalent), RCOOR' (4 equivalent), CH30Na (4 equivalent) in DMF in the sealed vial which was irradiated in the micromave reactor on a Biotage Smith Synthesis at 100 ° C for lh. The reaction was monitored by LCMS. After completion of the reaction, the crude product was purified by standard methods to afford the desired products (1-98).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

Description

GLUTAMASE INHIBITORS AND METHOD OF USE
CLAIM OF PRIORITY
This application claims priority from U.S. S.N. 61/729,321, filed November 21, 2012, which is incorporated herein by reference in its entirety.
BACKGROUND OF INVENTION
Cancer cells rely primarily on glycolysis to generate cellular energy and biochemical intermediates for biosynthesis of lipids and nucleotides, while the majority of "normal" cells in adult tissues utilize aerobic respiration. This fundamental difference in cellular metabolism between cancer cells and normal cells is termed the Warburg Effect. As a result of this difference, pyruvate generated via the glycolytic pathway is converted to lactic acid, rather than being used to acetyl-CoA and eventually, the citrate utilized in a normal citric acid cycle. To compensate for these energetic changes and to maintain a citric acid cycle, cancer cells rely on glutamine metabolism which is achieved through an elevation of glutaminase activity. Exploitation of this phenomenon can be achieved by inhibition of this elevated glutaminase activity.
SUMMARY OF INVENTION
Described herein are heterocyclic containing, pharmaceutically acceptable salts, solvates, and hydrates thereof. The compounds can be used to treat a disorder described herein, for example, by inhibiting glutaminase in a patient. Also provided are
compositions (e.g., pharmaceutical compositions) comprising a compound provided herewith and the use of such compositions in methods of treating diseases and conditions, for example, that are associated with the aberrant function of glutaminase or elevated activity of glutaminase, including, e.g., cancer.
In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein
X is a bond, -S-, -S(O)-, -S02-, -CH=CH-, -NH-, or -C(O)-;
each W, Y and Z is independently -S-, -CH=, -CH=CH-, -CH^R1-, -CR^CR1-, -0-, -N=, or -NH-, provided that (1) for each ring at least one of W, Y and Z is not -CH= and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH=;
each R1 and R2 is independently C1-6 alkylene-R4, -N(R3)-R4, -N(R3)-C(0)-R4, - C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, -N(R3)-C(0)-N(R3)-R4, -0-C(0)-N(R3)-R4, -N(R3)- C(0)-Ci_6 alkylene-C(0)-R4, -N(R3)-C(0)-Ci_6 alkylene-N(R3)-C(0)-R4 or -N(R3a)-C(0)- CH2-N(R3)-C(0)-R4;
each R is independently hydrogen, Ci_6 alkyl or aryl;
each R4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), Ci_6 alkyl, Ci_6 haloalkyl, Q-6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2, -O-C(O)- Ci-6 alkyl, C3_7 cycloalkyl, (C3_7 cycloalkyl)alkyl, aryl, aryloxy, -C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R ;
each R6 is independently hydrogen, fluoro, OH or Q-6 alkyl;
each R is independently hydrogen, Ci_6 alkyl, -OH, -SH, cyano, halo, -CF3, - OCF3, -S02-C1-6 alkyl, -N02, -N(R7)-C(0)-C1-6 alkyl, -N(R6)2 or C1-6 alkoxy; m is 1, 2 or 3;
n is 1, 2 or 3; provided that when X is bond, the sum of m and n is from 3 to 6 and when X is -S-, -S(O)-, -S02-, -CH=CH-, or -C(O)-, the sum of m and n is from 2 to 4; o is 1, 2 or 3; and
p is 1, 2 or 3;
with the proviso that: (1) when X is -S-, m and n are both 2, each R6 is H, then (i) R1 and R2 are not both -NHC(0)-R4, wherein R4 is C1-6 alkyl, a monocyclic ring, monocyclic aralkyl, monocyclic heterocyclylalkyl, monocyclic heteroaralkyl and each member of R4 is substituted with 0-3 occurrences of R5; and (ii) R1 and R2 are not both - NHC(0)0-methyl, -NHC(0)0-ethyl, -NHC(0)-6-pyrimidine-2,4(lH,3H)-dionyl, - N(ethyl)C(0)-benzyl, or -NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH- phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
(2) when X is -S-, m and n are both 1, each R6 is H, then (i) R1 and R2 are not both -NH-phenyl or -NH-4-methoxy-phenyl or -NHC(0)-benzyl;
(3) when X is a bond, the sum of m and n is 3, each R6 is H, then R1 and R2 are not both-NHC(0)-R4, wherein R4 is monocyclic aryl or monocyclic aralkyl or methyl, and each member of R4 is optionally substituted with 0-3 occurrences of R5;
(4) when X is a bond, m and n are both 2, each R6 is H, then R1 and R2 are not both -NHC(0)-furanyl, -NHC(0)-phenyl, -NHC(0)-o-methoxy-phenyl, -NHC(0)-Ci_6 alkyl, -NH-benzyl, -NHC(0)-NH-phenyl, -NHC(0)-NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R5;
(5) when X is a bond, the sum of m and n is 5, each R6 is H, then R1 and R2 are not both -NHC(0)-C1_6 alkyl, -NHC(0)-cyclohexyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is optionally substituted with methyl; and
(6) when X is a bond, m and n are both 3, each R6 is H, then R1 and R2 are not both NH-phenyl; (7) when X is a bond, m and n are both 2, and one of W, Y or Z is -CH=CH- or - CH=CR1 -, then R1 and R2 are not both -NHC(0)C(R*)2-phenyl wherein the phenyl is unsubstituted or substituted with 0-3 occurrences of R5 and R* is H, -OH, -C1-2 alkyl-OH, -Ci-2 alkyl-OCH3, or -CH3;
(8) when X is a bond, m and n are both 2, one of W, Y or Z is -CH=CH- or - CH^R1 -, and one of R1 and R2 is -NHC(0)CH2-RA, wherein RA is hydrogen, -NH2, heteroaryl, or a fused ring, wherein the heteroaryl is unsubstituted or substituted with 0-3 occurrences of R5; -NHC(0)NH-benzyl; or -NHC02-benzyl; then the other of R1 and R2 is not -NHC(0)C(R*)2-phenyl, wherein the phenyl is unsubstituted or substituted with 0- 3 occurrences of R5, and R* is H, -OH, -C1-2 alkyl-OH, -C1-2 alkyl-OCH3, or methyl;
the compound of formula (I) is not:
in another embodiment, provided is a composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the composition is a pharmaceutical composition.
In another embodiment, provided herein is a method for treating or preventing a disease, condition or disorder as described (e.g., treating) herein comprising
administering a compound described herein, a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a
pharmaceutically acceptable salt thereof. In another embodiment, provided herein is a method of inhibiting glutaminase, e.g, in a patient in need thereof. In some embodiments, provided here is reducing the level of the product of glutaminase in a subject, e.g., a patient in need thereof. The methods include administering an effective amount of a compound described herein or a pharaiacetucally acceptable salt thereof to a subject in need thereof, thereby inhibiting the level of glutaminase in the subject.
In another embodiment, provided herein is a method of treating a subject suffering from or susceptible to a disease or disorder associated with the aberrant function of glutaminase or elevated activity of glutaminase in a subject in need thereof. The method comprises the step of administering an effective amount of a compound described herein to the subject in need thereof, thereby treating, preventing or
ameliorating the disease or disorder in the subject. In certain embodiments, the compound is provided in a pharmaceutical composition. In certain embodiments, the method includes identifying or selecting a subject who would benefit from inhibiting glutaminase or decreasing the level of glutaminase. E.g., the subject can be identified on the basis of the level of glutaminase activity in a cell or tissue sample of the subject for treatment of cancer associated with aberrant glutaminase function or activity. In another embodiment, the selected subject is a patient suffering from or susceptible to a disorder or disease identified herein, e.g., a disorder characterized by unwanted cell growth or proliferation, e.g., cancer or other neoplastic disorders.
In another embodiment, provided herein is a method for treating cancer in a subject, the method comprising: optionally, acquiring a subject sample; acquiring an evaluation of or evaluating the subject sample, wherein the subject sample is
characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, or iii) a low or decreased level of pyruvate carboxylase expression; and administering to the subject in need thereof a therapeutically effective amount of a compound described here. In some embodiments, the subject sample is characterized by i) a low level of E-cadherin expression compared to a reference standard and ii) a high level of vimentin expression compared to a reference standard. In some embodiments, the subject sample is characterized or further characterized by low or decreased levels of pyruvate carboxylase expression compared to a reference standard.
In another embodiment, provided herein is a method for treating cancer in a subject characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, or iii) a low or decreased level of pyruvate carboxylase expression; comprising administering to the subject in need thereof a therapeutically effective amount of a compound described here. In some embodiments, the subject is characterized by i) a low level of E-cadherin expression compared to a reference standard and ii) a high level of vimentin expression compared to a reference standard. In some embodiments, the subject is characterized or further characterized by low or decreased levels of pyruvate carboxylase expression compared to a reference standard.
DETAILED DESCRIPTION
The details of construction and the arrangement of components set forth in the following description or illustrated in the drawings are not meant to be limiting.
Embodiments can be practiced or carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having," "containing", "involving", and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.
Compounds
Described herein are compounds and compositions that inhibit glutaminase. Compounds that inhibit glutaminase, can be used to treat disorders such as neoplastic disorders (e.g., cancer). In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
Formula (I), wherein
X is a bond, -S-, -S(O)-, -S02-, -CH=CH-, -NH-, or -C(O)-;
each W, Y and Z is independently -S-, -CH=, -CH=CH-, -CH^R1-, -CR^CR1-, -0-, -N=, or -NH-, provided that (1) for each ring at least one of W, Y and Z is not -CH= and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH=;
each R1 and R2 is independently C1-6 alkylene-R4, -N(R3)-R4, -N(R3)-C(0)-R4, - C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, -N(R3)-C(0)-N(R3)-R4, -0-C(0)-N(R3)-R4, -N(R3)- C(0)-Ci_6 alkylene-C(0)-R4, -N(R3)-C(0)-Ci_6 alkylene-N(R3)-C(0)-R4 or -N(R3a)-C(0)- CH2-N(R3)-C(0)-R4;
each R is independently hydrogen, Ci_6 alkyl or aryl;
each R4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), Ci_6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2, -O-C(O)- Ci_6 alkyl, C3_7 cycloalkyl, (C3_7 cycloalkyl)alkyl, aryl, aryloxy, -C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R ; each R6 is independently hydrogen, fluoro, OH or C1-6 alkyl;
each R is independently hydrogen, C1-6 alkyl, -OH, -SH, cyano, halo, -CF3, - OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2 or Ci_6 alkoxy;
m is 1, 2 or 3;
n is 1, 2 or 3; provided that when X is bond, the sum of m and n is from 3 to 6 and when X is -S-, -S(O)-, -S02-, -CH=CH-, or -C(O)-, the sum of m and n is from 2 to 4; o is 1, 2 or 3; and
p is 1, 2 or 3;
with the proviso that: (1) when X is -S-, m and n are both 2, each R6 is H, then (i) R1 and R2 are not both -NHC(0)-R4, wherein R4 is C1-6 alkyl, a monocyclic ring, monocyclic aralkyl, monocyclic heterocyclylalkyl, monocyclic heteroaralkyl and each member of R4 is substituted with 0-3 occurrences of R5; and (ii) R1 and R2 are not both - NHC(0)0-methyl, -NHC(0)0-ethyl, -NHC(0)-6-pyrimidine-2,4(lH,3H)-dionyl, - N(ethyl)C(0)-benzyl, or -NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH- phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
(2) when X is -S-, m and n are both 1, each R6 is H, then (i) R1 and R2 are not both -NH-phenyl or -NH-4-methoxy-phenyl or -NHC(0)-benzyl;
(3) when X is a bond, the sum of m and n is 3, each R6 is H, then R1 and R2 are not both-NHC(0)-R4, wherein R4 is monocyclic aryl or monocyclic aralkyl or methyl, and each member of R4 is optionally substituted with 0-3 occurrences of R5;
(4) when X is a bond, m and n are both 2, each R6 is H, then R1 and R2 are not both -NHC(0)-furanyl, -NHC(0)-phenyl, -NHC(0)-o-methoxy-phenyl, -NHC(0)-Ci_6 alkyl, -NH-benzyl, -NHC(0)-NH-phenyl, -NHC(0)-NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R5;
(5) when X is a bond, the sum of m and n is 5, each R6 is H, then R1 and R2 are not both -NHC(0)-C1_6 alkyl, -NHC(0)-cyclohexyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is optionally substituted with methyl; and (6) when X is a bond, m and n are both 3, each R6 is H, then R1 and R2 are not both NH-phenyl;
(7) when X is a bond, m and n are both 2, and one of W, Y or Z is -CH=CH- or - CH=CR1 -, then R1 and R2 are not both -NHC(0)C(R*)2-phenyl wherein the phenyl is unsubstituted or substituted with 0-3 occurrences of R5 and R* is H, -OH, -C1-2 alkyl-OH, -Ci-2 alkyl-OCH3, or -CH3;
(8) when X is a bond, m and n are both 2, one of W, Y or Z is -CH=CH- or - CH^R1 -, and one of R1 and R2 is -NHC(0)CH2-RA, wherein RA is hydrogen, -NH2, heteroaryl, or a fused ring, wherein the heteroaryl is unsubstituted or substituted with 0-3 occurrences of R5; -NHC(0)NH-benzyl; or -NHC02-benzyl; then the other of R1 and R2 is not -NHC(0)C(R*)2-phenyl, wherein the phenyl is unsubstituted or substituted with 0- 3 occurrences of R5, and R* is H, -OH, -C1-2 alkyl-OH, -C1-2 alkyl-OCH3, or methyl;
the compound of formula (I) is not:
in one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein
X is a bond, -S-, -S(O)-, -S02-, -CH=CH-, -NH-, or -C(O)-;
each W, Y and Z is independently -S-, -CH=, -CH=CH-, -CT^CR1-, -CR^CR1-, -0-, -N=, or -NH-, provided that (1) for each ring at least one of W, Y and Z is not -CH= and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH=;
each R1 and R2 is independently -N(R3)-R4, -C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, or -N(R3)-C(0)-N(R3)-R4;
each R is independently hydrogen, C1-6 alkyl or aryl;
each R4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), Ci_6 alkyl, Ci_6 haloalkyl, C1-6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2, -O-C(O)- Ci_6 alkyl, C3_7 cycloalkyl, (C3_7 cycloalkyl)alkyl, aryl, aryloxy, -C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R ;
each R6 is independently hydrogen, fluoro, OH or C1-6 alkyl;
each R is independently hydrogen, C1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2 or Ci_6 alkoxy;
m is 1, 2 or 3; n is 1, 2 or 3; provided that when X is bond, the sum of m and n is from 3 to 6 and when X is -S-, -S(O)-, -S02-, -CH=CH-, or -C(O)-, the sum of m and n is from 2 to 4; o is 1, 2 or 3; and
p is 1, 2 or 3;
with the proviso that: (1) when X is -S-, m and n are both 2, each R6 is H, then (ii) R1 and R2 are not both -NHC(0)0-methyl, -NHC(0)0-ethyl or -NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH-phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
(2) when X is -S- or -S(0)2-, m and n are both 1, each R6 is H, then R1 and R2 are not both -NH-phenyl or -NH-4-methoxy-phenyl;
(3) when X is a bond, m and n are both 2, each R6 is H, then R1 and R2 are not both -NH-benzyl, -NHC(0)-NH-phenyl, -NHC(0)NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R5;
(4) when X is a bond, the sum of m and n is 5, each R6 is H, then R1 and R2 are not both -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is optionally substituted with methyl;
(5) when X is a bond, m and n are both 3, each R6 is H, then R1 and R2 are not both NH-phenyl.
In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein
X is a bond, -S-, -S(O)-, -S02-, -CH=CH-, or -C(O)-; each W, Y and Z is independently -S-, -CH=, -0-, -N=, or -NH-, provided that (1) at least one of W, Y and Z is not -CH= and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH=;
each R1 and R2 is independently C1-6 alkylene-R4, -N(R3)-R4, -N(R3)-C(0)-R4, - C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, -N(R3)-C(0)-N(R3)-R4, -0-C(0)-N(R3)-R4, -N(R3)- C(0)-Ci-6 alkylene-C(0)-R4, -N(R3)-C(0)-C1-6 alkylene-N(R3)-C(0)-R4 or -N(R3a)-C(0)- CH2-N(R3)-C(0)-R4;
each R is independently hydrogen, C1-6 alkyl or aryl;
each R4 is independently C1-6 alkyl, C1-6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2, -O-C(O)- Ci_6 alkyl, C3_7 cycloalkyl, (C3_7 cycloalkyl)alkyl, aryl, aryloxy, -C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R ;
each R6 is independently hydrogen, fluoro, OH or C1-6 alkyl;
each R is independently hydrogen, C1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF3, -SO2-C1-6 alkyl, -N02, -N(R7)-C(0)-C1-6 alkyl, -N(R6)2 or C1-6 alkoxy;
m is 1, 2 or 3;
n is 1, 2 or 3; provided that when X is bond, the sum of m and n is from 3 to 6 and when X is -S-, -S(O)-, -S02-, -CH=CH-, or -C(O)-, the sum of m and n is from 2 to 4; o is 1, 2 or 3; and
p is 1, 2 or 3;
with the proviso that: (1) when X is -S-, m and n are both 2, each R6 is H, then (i) R1 and R2 are not both -NHC(0)-R4, wherein R4 is C1-6 alkyl, monocyclic aryl, monocyclic heteroaryl, monocyclic aralkyl, monocyclic heteroaralkyl and each member of R4 is substituted with 0-3 occurrences of R5; and (ii) R1 and R2 are not both - NHC(0)0-methyl, -NHC(0)0-ethyl, -NHC(0)-6-pyrimidine-2,4(lH,3H)-dionyl, or - NHC(0)NH-phenyl wherein said phenyl of the -NHC(0)NH-phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
(2) when X is -S-, m and n are both 1, each R6 is H, then (i) R1 and R2 are not both -NH-phenyl or -NH-4-methoxy-phenyl;
(3) when X is a bond, the sum of m and n is 3, each R6 is H, then R1 and R2 are not both NHC(0)-phenyl;
(4) when X is a bond, m and n are both 2, each R6 is H, then R1 and R2 are not both -NHC(0)-furanyl, -NHC(0)-phenyl, -NHC(0)-o-methoxy-phenyl, -NHC(0)-Ci_6 alkyl, -NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R5;
(5) when X is a bond, the sum of m and n is 5, each R6 is H, then R1 and R2 are not both -NHC(0)-C1_6 alkyl, -NHC(0)-cyclohexyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is optionally substituted with methyl; and
(6) when X is a bond, m and n are both 3, each R6 is H, then R1 and R2 are not both NH-phenyl. In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
(I), wherein
X is -S(O)-, -SO2-, -CH=CH-, or -C(O)-;
each W, Y and Z is independently -S-, -CH=, -CH=CH-, -CT^CR1-, -CR^CR1- N=, or -NH-, provided that (1) for each ring at least one of W, Y and Z is not -CH and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH=;
each R1 and R2 is independently C1-6 alkylene-R4, -N(R3)-R4, -N(R3)-C(0)-R4, - C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, -N(R3)-C(0)-N(R3)-R4, -0-C(0)-N(R3)-R4, -N(R3)- C(0)-Ci-6 alkylene-C(0)-R4, -N(R3)-C(0)-C1-6 alkylene-N(R3)-C(0)-R4 or -N(R3a)-C(0)- CH2-N(R3)-C(0)-R4;
each R is independently hydrogen, C1-6 alkyl or aryl;
each R4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-C1-6 alkyl, -N02, -N(R7)-C(0)-C1-6 alkyl, -N(R6)2, -O-C(O)- Ci_6 alkyl, C3_7 cycloalkyl, (C3_7 cycloalkyl)alkyl, aryl, aryloxy, -C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R ;
each R6 is independently hydrogen, fluoro, OH or C1-6 alkyl;
each R is independently hydrogen, C1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2 or Ci_6 alkoxy;
m is 1, 2 or 3;
n is 1, 2 or 3; provided that the sum of m and n is from 2 to 4;
o is 1, 2 or 3; and
p is 1, 2 or 3;
ith the proviso that the compound of formula (I) is not:
in one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
(I), wherein
X is -S-, -S(O)-, -SO2-, -CH=CH-, -NH-, or -C(O)-;
each W, Y and Z is independently -S-, -CH=, -CH=CH-, -CH^R1-, -CR^CR1-, -0-, -N=, or -NH-, provided that (1) for each ring at least one of W, Y and Z is not -CH= and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH= and (3) at least one of W, Y and Z is -CH=CH-, -CH^R1-, -CR^CR1-; each R1 and R2 is independently C1-6 alkylene-R4, -N(R3)-R4, -N(R3)-C(0)-R4, - C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, -N(R3)-C(0)-N(R3)-R4, -0-C(0)-N(R3)-R4, -N(R3)- C(0)-Ci_6 alkylene-C(0)-R4, -N(R3)-C(0)-Ci_6 alkylene-N(R3)-C(0)-R4 or -N(R3a)-C(0)- CH2-N(R3)-C(0)-R4;
each R is independently hydrogen, Ci_6 alkyl or aryl;
each R4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2, -O-C(O)- Ci-6 alkyl, C3_7 cycloalkyl, (C3_7 cycloalkyl)alkyl, aryl, aryloxy, -C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R ;
each R6 is independently hydrogen, fluoro, OH or Ci_6 alkyl;
each R is independently hydrogen, Ci_6 alkyl, -OH, -SH, cyano, halo, -CF3, - OCF3, -S02-C1-6 alkyl, -N02, -N(R7)-C(0)-C1-6 alkyl, -N(R6)2 or C1-6 alkoxy;
m is 1, 2 or 3;
n is 1, 2 or 3; provided that the sum of m and n is from 2 to 4;
o is 1, 2 or 3; and
p is 1, 2 or 3.
In one embodiment, provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:
(I), wherein
X is -S(O)-, -S02-, -CH=CH-, or -C(O)-;
each W, Y and Z is independently -S-, -CH=, -0-, -N=, or -NH-, provided that (1) for each ring at least one of W, Y and Z is not -CH= and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH=;
each R1 and R2 is independently C1-6 alkylene-R4, -N(R3)-R4, -N(R3)-C(0)-R4, - C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, -N(R3)-C(0)-N(R3)-R4, -0-C(0)-N(R3)-R4, -N(R3)- C(0)-Ci-6 alkylene-C(0)-R4, -N(R3)-C(0)-C1-6 alkylene-N(R3)-C(0)-R4 or -N(R3a)-C(0)- CH2-N(R3)-C(0)-R4;
each R is independently hydrogen, C1-6 alkyl or aryl;
each R4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-C1-6 alkyl, -N02, -N(R7)-C(0)-C1-6 alkyl, -N(R6)2, -O-C(O)- Ci_6 alkyl, C3_7 cycloalkyl, (C3_7 cycloalkyl)alkyl, aryl, aryloxy, -C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R ;
each R6 is independently hydrogen, fluoro, OH or C1-6 alkyl;
each R is independently hydrogen, C1-6 alkyl, -OH, -SH, cyano, halo, -CF , - OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2 or Ci_6 alkoxy;
m is 1, 2 or 3;
n is 1, 2 or 3; provided that the sum of m and n is from 2 to 4;
o is 1, 2 or 3; and
p is 1, 2 or 3;
ith the proviso that the compound of formula (I) is not:
In some embodiments, X is -S-. In some embodiments, X is -S(O)-. In some embodiments, X is -S02-. In some embodiments, X is a bond. In some embodiments, X is -CH=CH-. In some embodiments, X is -NH-.
In some embodiments, each Y is -N=. In some embodiments, each Z is -N=. In some embodiments, each Z is -0-. In some embodiments, each W is -S-. In some embodiments, each W is -CH=. In some aspects of these embodiments, each W is -S-, each Y is -N= and each Z is -N=. In other aspects of these embodiments, each W is - CH=, each Z is -O- and each Y is -N=. In some embodiments, at least one of W, Y and Z is -CH=CH-, -CI^CR1-, or -CR^CR1-. In some embodiments, each W is -CH=CH-. In some embodiments, one W is -CH=CH-. In some aspects of these embodiments, each W is -CH=CH-, each Y is -N= and each Z is -N=. In some aspects of these
embodiments, one W is -CH=CH-, and Y in the same ring is -N= and Z in the same ring is -N=, and the other W is -S-, Y in the same ring is -N= and Z in the same ring is -N=.
In some embodiments, each Y is -N=. In some embodiments, each Z is -N=. In some embodiments, each Z is -0-. In some embodiments, each W is -S-. In some embodiments, each W is -CH=. In some aspects of these embodiments, each W is -S-, each Y is -N= and each Z is -N=. In other aspects of these embodiments, each W is - CH=, each Z is -O- and each Y is -N=.
In some embodiments, o is 1. In some embodiments, p is 1. In some
embodiments, o is 1 and p is 1.
In some embodiments, m is 1. In some embodiments, n is 1. In some embodiments, n is i and m is 1. In some aspects of these embodiments, each R6 is hydrogen. In some aspects of these embodiments, each R6 is -OH. In some embodiments, R 1 and R2 are the same. In some embodiments, R 1 and R2 are different.
In some embodiments, m is 1. In some embodiments, n is 1. In some
embodiments, n is i and m is 1. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, R 1 and R2 are the same. In some embodiments, R 1 and
R are different.
In some embodiments, m is 1. In some embodiments, n is 2. In some
embodiments, n is 2 and m is 1. In some aspects of these embodiments, each R6 is hydrogen. In some aspects of these embodiments, each R6 is -OH. In some
embodiments, R 1 and R2 are the same. In some embodiments, R 1 and R2 are different.
In some embodiments, m is 1. In some embodiments, n is 2. In some
embodiments, n is 2 and m is 1. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, R 1 and R2 are the same. In some embodiments, R 1 and
R are different.
In some embodiments, m is 2. In some embodiments, n is 1. In some
embodiments, n is 1 and m is 2. In some aspects of these embodiments, each R6 is hydrogen. In some aspects of these embodiments, X is -S-. In some embodiments, R1 and R 2 are the same. In some embodiments, R 1 and R2 are different. In some aspects of these embodiments, m is 2, n is 1, X is -S-, and R 1 and R 2 are the same.
In some embodiments, m is 2. In some embodiments, n is 1. In some
embodiments, n is 1 and m is 2. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, R 1 and R2 are the same. In some embodiments, R 1 and
R are different.
In some embodiments, m is 3. In some embodiments, n is 1. In some
embodiments, n is 3 and m is 1. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, two R6 on the same carbon are C1-6 alkyl (e.g., methyl) and the remaining R6 are each hydrogen. In some embodiments, R1 and R2 are the same.
In some embodiments, R 1 and R 2 are different. In some aspects of these embodiments, m is 3, n is 1, X is -S-, and R 1 and R 2 are the same. In some embodiments, m is 2. In some embodiments, n is 2. In some embodiments, n is 2 and m is 2. In some aspects of these embodiments, each R6 is hydrogen. In some aspects of these embodiments, each R6 is -
OH. In some aspects of these embodiments, X is -S-. In some embodiments, R 1 and R 2 are the same. In some embodiments, R 1 and R 2 are different.
In some embodiments, m is 2. In some embodiments, n is 2. In some
embodiments, n is 2 and m is 2. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, R 1 and R2 are the same. In some embodiments, R 1 and
R are different.
In some embodiments, m is 2. In some embodiments, n is 3. In some
embodiments, n is 3 and m is 2. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, two R6 on the same carbon are C1-6 alkyl (e.g., methyl) and the remaining R6 are each hydrogen. In some embodiments, R1 and R2 are the same.
In some embodiments, R 1 and R 2 are different.
In some embodiments, m is 3. In some embodiments, n is 2. In some
embodiments, n is 3 and m is 2. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, two R6 on the same carbon are C1-6 alkyl (e.g., methyl) and the remaining R6 are each hydrogen. In some embodiments, R1 and R2 are the same.
In some embodiments, R 1 and R 2 are different.
In some embodiments, m is 3. In some embodiments, n is 3. In some
embodiments, n is 3 and m is 3. In some aspects of these embodiments, each R6 is hydrogen. In some embodiments, R 1 and R2 are the same. In some embodiments, R 1 and
R are different.
In some embodiments, R 1 and R 2 are each -N(R 3 )-C(0)-0-R 4 , wherein R 3 is hydrogen. In some aspects of these embodiments, each R4 is C1-6 alkyl (e.g., isopropyl, isobutyl or tert-butyl) substituted with 0-3 occurrences of R5. In some aspects of these embodiments, each R4 is Ci_6 alkyl (e.g., isopropyl, isobutyl or tert-butyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, each R4 is aryl (e.g., phenyl) substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is aryl (e.g., phenyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, each R4 is C3_7 cycloalkyl substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is C3_7 cycloalkyl substituted with 0 occurrences of R5 (e.g., cyclohexyl). In other aspects of these embodiments, each R4 is aralkyl substituted with 0-3 occurrences of R5. In still other aspects of these embodiments, each R4 is aralkyl substituted with 0 occurrences of R5 (e.g., benzyl). In some aspects of these embodiments, R 1 and R2 are the same. In other aspects of these embodiments, R 1 and R2 are different.
In some embodiments, R 1 and R 2 are each -N(R 3 )-C(0)-R 4 , wherein each R 3 is hydrogen. In some embodiments, R 1 and R 2 are each -N(R 3 C(0)-R 4", wherein each R 3J is Ci g., methyl). In some aspects of these embodiments, R 1 and R 2
_6 alkyl (e. are the same. In other aspects of these embodiments, R 1 and R 2 are different.
In some aspects of these embodiments, each R4 is aralkyl substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is aralkyl substituted with 0 occurrences of R5 (e.g., benzyl, 2-phenylethyl, 1-phenylethyl, 2-phenylpropyl, 3- phenylpropyl or naphthylmethyl). In other aspects of these embodiments, each R4 is aralkyl (e.g., benzyl, 2-phenethyl, 1-phenethyl or phenpropyl) substituted with one occurrence of R5. In further aspects of these embodiments, each R5 is heterocyclyl (e.g., isoindo represented by the following structure: . In further aspects of these embodiments, each R5 is Ci_6 alkoxy
(e.g., methoxy). In other further aspects of these embodiments, each R5 is -OH. In other further aspects of these embodiments, each R5 is Ci_6 alkyl (e.g., methyl). In other further aspects of these embodiments, each R5 is -N(Me)2. In other further aspects of these embodiments, each R5 is halo (e.g., chloro). In other further aspects of these
embodiments, each R5 is Ci_6 alkoxy (e.g., methoxy) substituted with one R6 wherein R6 is aryl (e.g., phenyl). In other aspects of these embodiments, each R4 is aralkyl (e.g., benzyl) substituted with two occurrences of R5. In further aspects of these embodiments, each R5 is C1-6 alkoxy (e.g., methoxy). In other further aspects of these embodiments, two R5 are halo (e.g., fluoro) and the other two R5 are haloalkyl (e.g., trifluoromethyl). In other further aspects of these embodiments, two R5 are C1-6 alkyl (e.g., methyl) and two R5 are -O- C(0)-Ci-6 alkyl (e.g., -OC(0)-CH3), each of which is further substituted with 0 occurrences of R 7. In other further aspects, of these embodiments, two adjacent R 5 moieties are taken together with the atoms to which they are attached to form a heterocyclyl ring resulting in a moiety of the following structure: . In other further aspects of these embodiments, each R5 is halo (e.g., fluoro). In other aspects of these embodiments, each R4 is aralkyl (e.g., 2- phenylethyl) substituted with 3 occurrences of R5. In further aspects of these
embodiments, each R5 is C1-6 alkoxy (e.g., methoxy).
In other aspects of these embodiments, one R4 is aralkyl (e.g., benzyl) substituted with 0 occurrences of R5 and the other R4 is aralkyl (e.g., benzyl) substituted with 1 occurrence of R5. In a further aspect of this embodiment, R5 is C1-6 alkoxy (e.g., ethoxy) which is further substituted with one R6, wherein R6 is -NH2. In other aspects of these embodiments, one R4 is aralkyl (e.g., benzyl) substituted with 0 occurrences of R5 and the other R4 is C1-6 alkyl (e.g., methyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, one R4 is C1-6 alkyl (e.g., methyl) substituted with 0 occurrences of R5 and the other R4 is aralkyl (e.g., benzyl) substituted with 2 occurrences of R5, wherein each R5 is Ci_6 alkoxy (e.g., methoxy).
In other aspects of these embodiments, each R4 is cycloalkylalkyl substituted with 0-3 occurrences of R5. In still other aspects of these embodiments, each R4 is
cycloalkylalkyl substituted with 0 occurrences of R5 (e.g., cyclohexylmethyl or 3- cyclohexylpropyl). In still other aspects of these embodiments, each R4 is heteroaralkyl substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is cycloalkylalkyl (e.g., cyclopentylalkyl) substituted with 3 occurrences of R5 wherein two occurrences are oxo and each other occurrence is taken together with the atoms to which they are attached to form an aryl ring substituted with one R 7 , wherein each R 7 is Ci_6 alkoxy (e.g., methoxy). In further aspects of these embodiments each R4 is represented by the following structure:
In other aspect of these embodiments, each R4 is heteroaralkyl substituted with 0 occurrences of R5 (e.g., 2-pyridinylmethyl, 3-pyridinylmethyl, 3-pyridinylethyl, 3- benzoisoxazolylmethyl, 3-indolylmethyl, 5-tetrazolylmethyl 2-thiophenylmethyl or 2- thiophenylethyl). In other aspects of these embodiments, each R4 is heteroaralkyl (e.g., 3-pyridinylmethyl, 3-indolylmethyl or 5-isoxazolylmethyl) substituted with one occurrence of R5. In some further aspects of these embodiments, each R5 is C1-6 alkyl (e.g., methyl). In other further aspects of these embodiments, each R5 is Ci_6 alkoxy (e.g., methoxy). In other further aspects of these embodiments, each R5 is halo (e.g., chloro). In other aspects of these embodiments, each R4 is heteroaralkyl substituted with 2 occurrences of R5. In some further aspects of these embodiments, each R5 is Ci_6 alkyl (e.g., methyl) and the heteroaralkyl has the following structure:
In other aspects of these embodiments, each R4 is C1-6 alkyl (e.g., methyl, isobutyl or tert-pentyl) substituted with 0 occurrences of R5. In other aspects of these
embodiments, each R4 is Ci_6 alkyl (e.g., isopropyl or n-propyl) substituted with one occurrence of R 5 , wherein R 5 is aryl (e.g., phenyl) substituted with 0 occurrences of R 7. In other aspects of these embodiments, each R4 is C1-6 alkyl (e.g., isopropyl) substituted with one occurrence of R5, wherein R5 is aryloxy (e.g., phenoxy) substituted with one occurrence of R 7 wherein R 7 is halo (e.g., chloro).
In other aspects of these embodiments, each R4 is C3_7 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, each R4 is C1-6 alkyl (e.g., methyl or ethyl) substituted with 1 occurrence of R5. In further aspects of these embodiments, each R5 is aryloxy (e.g., phenoxy) substituted with 0 occurrences of R . In other further aspects of these embodiments, each R5 is aryloxy (e.g., phenoxy) substituted with one occurrence of
R 7 wherein each R 7 is C1-6 alkyl (e.g., methyl or isopropyl). In other further aspects of these embodiments, each R5 is aryloxy (e.g., phenoxy) substituted with one occurrence of
R 7 wherein each R 7 is C1-6 alkoxy (e.g., methoxy). In other further aspects of these embodiments, each R5 is aryloxy (e.g., phenoxy) substituted with two occurrences of R6, wherein each R is C1-6 alkyl (e.g., methyl). In other aspects of these embodiments, one R4 is Ci-6 alkyl (e.g., methyl) and the other R4 is aralkyl (e.g., benzyl), each of which is substituted with 0 occurrences of R5.
In other aspects of these embodiments, each R4 is heterocyclylalkyl (e.g., 2- tetrahydropyranylmethyl, N-piperidinylethyl or 5-benzo[l,3]dioxolylmethyl) substituted with 0 occurrences of R5. In some further aspects of these embodiments, each R is heterocyclylalkyl substituted with 0 occurrences of R5 and is represented by the following structure:
. In some further aspects of these embodiments, each R4 is
heterocyclylalkyl (e.g., 2-tetrahydrofuranyl) substituted with 3 occurrences of R5 wherein two occurrences of R5 are oxo and the remaining taken together with the atoms to which they are attached form an aryl moiety (e.g., phenyl). In some further aspects of these embodiments, each R4 is represented by the following structure:
In other aspects of these embodiments, each R4 is cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is cycloalkyl (e.g., cyclobutyl, cyclopentyl or cyclohexyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, each R4 is cycloalkyl (e.g., cyclopropyl) substituted with one occurrence of R5. In some further aspects of these embodiments, each R5 is aryl (e.g., phenyl) further substituted with 0 occurrences of R .
In other aspects of these embodiments, each R4 is C3-7 cycloalkenyl (e.g., cyclopentenyl) substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is C3_7 cycloalkenyl (e.g., cyclopentenyl) substituted with 0 occurrences of R5.
In other aspects of these embodiments, each R4 is aryl (e.g., phenyl or naphthyl) substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is aryl (e.g., phenyl or naphthyl) substituted with 0 occurrences of R5.
In other aspects of these embodiments, each R4 is heteroaryl (e.g., 6- benzimidazolyl) substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is heteroaryl (e.g., 6-benzimidazolyl) substituted with one occurrence of R5. In some further aspects of these embodiments, each R5 is C1-6 alkyl (e.g., methyl).
In other aspects of these embodiments, each R4 is C2-6 alkenyl (e.g., propenyl) substituted with 0-3 occurrences of R5. In other aspects of these embodiments, each R4 is C2-6 alkenyl (e.g., propenyl) substituted with one occurrence of R5. In some further aspects of these embodiments, each R5 is aryl (e.g., phenyl) substituted with 0
occurrences of R7. In some embodiments, R1 and R2 are each -N(R3a)-C(0)-N(R3)-R4, wherein each R3a and R3 are hydrogen. In some aspects of these embodiments, each R4 is aryl substituted with 0-3 occurrences of R5. In some aspects of these embodiments, each R4 is aryl substituted with 0 occurrences of R5 (e.g., phenyl). In some aspect of these embodiments, each R4 is aryl substituted with one occurrence of R5 (e.g., 3-tolyl or 4- tolyl). In some further aspects of these embodiments, each R5 is C1-6 alkyl (e.g., methyl).
1 2
In some aspects of these embodiments, R and R are the same. In other aspects of these
1 2
embodiments, R and R are different.
In some embodiments, R1 and R2 are each -N(R3a)-C(0)-N(R3)-R4, wherein each R3a is hydrogen and each R3 is C1-6 alkyl (e.g., methyl). In some aspects of these embodiments, each R4 is aryl substituted with 0-3 occurrences of R5. In some aspects of these embodiments, each R4 is aryl substituted with 0 occurrences of R5 (e.g., phenyl).
In some embodiments, R1 and R2 are each -N(R3a)-C(0)-Ci-6 alkylene-N(R3)- C(0)-R4, wherein each R3a is hydrogen and each R3 is C1-6 alkyl (e.g., methyl). In some aspects of these embodiments, R4 is C1-6 alkoxy (e.g., tert-butoxy). In some aspects of
1 2 1 these embodiments, R and R are the same. In other aspects of these embodiments, R and R are different.
In some embodiments, R1 and R2 are each -N(R3a)-C(0)-Ci-6 alkylene-N(R3)- C(0)-R4, wherein each R3a is hydrogen and each R3 is hydrogen. In some aspects of these embodiments, each R4 is C1-6 alkyl (e.g., methyl). In some aspects of these embodiments, each R4 is aryl (e.g., phenyl) substituted with 0 occurrences of R5. In some
1 2
aspects of these embodiments, R and R are the same. In other aspects of these
1 2
embodiments, R and R are different.
In some embodiments, R1 and R2 are each -N(R3)-C(0)-C1_6 alkylene-C(0)-R4,
3 1 2 wherein each R is hydrogen. In some aspects of these embodiments, R and R are each -N(H)-C(0)-CH2CH(CH3)-C(0)-R4 or -N(H)-C(0)-CH2CH2CH2-C(0)-R4. In some aspects of these embodiments, each R4 is C1-6 alkoxy (e.g., ethoxy). In some aspects of these embodiments, R1 and R2 are each -N(H)-C(0)-CH2CH2CH2CH2-C(0)-R4. In some aspects of these embodiments, each R4 is C1-6 alkyl (e.g., methyl). In some aspects of these embodiments, R1 and R2 are each -N(H)-C(0)-CH2CH2-C(0)-R4 or -N(H)-C(0)- CH(CH3)CH2-C(0)-R4. In some aspects of these embodiments, each R4 is aryl (e.g., phenyl) substituted with 0 occurrences of R5. In some aspects of these embodiments, R1 and R 2 are the same. In other aspects of these embodiments, R 1 and R2 are different.
In some embodiments, R 1 and R 2 are each -N(R 3 )-C(0)0-R 4 , wherein each R 3 is hydrogen. In some aspects of these embodiments, each R4 is aryl (e.g., phenyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, each R4 is cycloalkyl (e.g., cyclohexyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, each R4 is C1-6 alkyl (e.g., isopropyl, isobutyl or tert-butyl) substituted with 0 occurrences of R5. In other aspects of these embodiments, each R4 is aralkyl (e.g., benzyl) substituted with 0 occurrences of R5. In some aspects of these embodiments, R 1 and R2 are the same. In other aspects of these embodiments, R 1 and R2 are different.
In some embodiments, R1 is -N(R3)-C(0)-R4, wherein R3 is hydrogen and R4 is aralkyl (e.g., phenethyl) substituted with one occurrence of R5 and R2 is -N(R3)R4, wherein R3 and R4 are both hydrogen. In some aspects of these embodiments, R5 is -OH.
In some embodiments, a compound of Formula (I) is represented by a compound of Formula (II):
In some embodiments, a compound of Formula (I) is represented by a compound of Formula (Ila):
wherein R1, R2, R3, R4, R5, R6, o, p, m, n and X are as defined in Formula (I).
In some embodiments, a compound of Formula (I) is represented by a compound of Formula (lib):
wherein R1, R2, R3, R4, R5, R6, o, p, m, n and X are as defined in Formula (I). In some embodiments, a compound of Formula (I) is represented by a compound of Formula (III):
wherein R4, R6, m, n and X are as defined in Formula (I). In some aspects of these embodiments, each R4 is the same. In other aspects of these embodiments, each R4 is different.
In some embodiments, a compound of Formula (I) is represented by a compound of Formula (Ilia):
wherein R4, R6, m, n and X are as defined in Formula (I). In some aspects of these embodiments, each R4 is the same. In other aspects of these embodiments, each R4 is different.
In some embodiments, a compound of Formula (I) is represented by a compound of Formula (Illb):
(nib), wherein R4, R6, m, n and X are as defined in Formula (I). In some aspects of these embodiments, each R4 is the same. In other aspects of these embodiments, each R4 is different. In certain embodiments, exemplary compounds of Formula I include the compounds described in Table 1 and in the Examples. A compound described herein may be tested for its ability to inhibit glutaminase, e.g., by an assay as described in the Examples. For simplicity, the inhibition activity of these compounds is represented as an IC50 tested in an assay of Example A or Example B in Table 1. Exemplary compounds are shown in Table 1 below. As shown, "A" refers to an inhibitor of glutaminase with an IC50 < 100 nM. "B" refers to inhibitor of glutaminase with an IC50 between 100 nM and 500 nM. "C" refers to inhibitor of glutaminase with an IC50 between 500 nM and 1000 nM. "D" refers to inhibitor of glutaminase with an IC50 between 1 μΜ and 10 μΜ. "Ε' refers to data that is not available.
Table 1
The compounds described herein can be made using a variety of synthetic techniques such as those described in the examples provided herein. As can be appreciated by the skilled artisan, methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents or Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
The compounds provided herein may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual
diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included within the scope. Unless otherwise indicated when a compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound. The compounds provided herewith may also contain linkages (e.g., carbon- carbon bonds) or substituents that can restrict bond rotation, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers are expressly included.
The compounds provided herein (e.g. of Formula I) may also comprise one or more isotopic substitutions. For example, H may be in any isotopic form, including lH,
2 H (D or deuterium), and 3 H (T or tritium); C may be in any isotopic form, including 12 C, 13C, and 14C; O may be in any isotopic form, including 160 and 180; and the like. The compounds provided herein may also be represented in multiple tautomeric forms, in such instances, expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented (e.g., alkylation of a ring system may result in alkylation at multiple sites; all such reaction products are expressly included). All such isomeric forms of such compounds are expressly included. All crystal forms of the compounds described herein are expressly included.
The compounds provided herein include the compounds themselves, as well as their salts and their prodrugs, if applicable. A salt, for example, can be formed between an anion and a positively charged substituent (e.g., amino) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate. Likewise, a salt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active compounds.
The compounds provided herein may be modified by appending appropriate functionalities to enhance selected biological properties, e.g., targeting to a particular tissue. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
In an alternate embodiment, the compounds described herein may be used as platforms or scaffolds that may be utilized in combinatorial chemistry techniques for preparation of derivatives and/or chemical libraries of compounds. Such derivatives and libraries of compounds have biological activity and are useful for identifying and designing compounds possessing a particular activity. Combinatorial techniques suitable for utilizing the compounds described herein are known in the art as exemplified by Obrecht, D. and Villalgrodo, J.M., Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries, Pergamon-Elsevier Science Limited (1998), and include those such as the "split and pool" or "parallel" synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, A.W., Curr. Opin. Chem. Bio., (1997) 1, 60. Thus, one embodiment relates to a method of using the compounds described herein for generating derivatives or chemical libraries comprising: 1) providing a body comprising a plurality of wells; 2) providing one or more compounds identified by methods described herein in each well; 3) providing an additional one or more chemicals in each well; 4) isolating the resulting one or more products from each well. An alternate embodiment relates to a method of using the compounds described herein for generating derivatives or chemical libraries comprising: 1) providing one or more compounds described herein attached to a solid support; 2) treating the one or more compounds identified by methods described herein attached to a solid support with one or more additional chemicals; 3) isolating the resulting one or more products from the solid support. In the methods described above, "tags" or identifier or labeling moieties may be attached to and/or detached from the compounds described herein or their derivatives, to facilitate tracking, identification or isolation of the desired products or their intermediates. Such moieties are known in the art. The chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like. Examples of such chemicals are those that appear in the various synthetic and protecting group chemistry texts and treatises referenced herein.
Definitions
The term "halo" or "halogen" refers to any radical of fluorine, chlorine, bromine or iodine.
The term "alkyl" refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, CrC12 alkyl indicates that the group may have from 1 to 12 (inclusive) carbon atoms in it. The term "alkyl" includes alkenyl, which contains unsaturation in the hydrocarbon chain. The term "haloalkyl" refers to an alkyl in which one or more hydrogen atoms are replaced by halo, and includes alkyl moieties in which all hydrogens have been replaced by halo (e.g., perfluoroalkyl). The terms "arylalkyl" or "aralkyl" refer to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. Aralkyl includes groups in which more than one hydrogen atom has been replaced by an aryl group. Examples of "arylalkyl" or "aralkyl" include benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, and trityl groups.
The term "alkylene" or "cycloalkylene" refers to a divalent alkyl or cycloalkyl, e.g., -CH2-, -CH2CH2-, and -CH2CH2CH2-.
The term "alkoxy" refers to an -O-alkyl radical. The term "haloalkoxy" refers to an alkoxy in which one or more hydrogen atoms are replaced by halo, and includes alkoxy moieties in which all hydrogens have been replaced by halo (e.g.,
perfluoroalkoxy) .
The term "aryl" refers to a monocyclic, bicyclic, or tricyclic aromatic
hydrocarbon ring system, wherein any ring atom capable of substitution can be substituted (e.g., by one or more substituents). Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, and anthracenyl. Unless otherwise specified, any ring atom in an aryl can be substituted by one or more substituents.
The term "cycloalkyl" as employed herein includes cyclic, bicyclic, tricyclic,or polycyclic non-aromatic hydrocarbon groups having 3 to 12 carbons. Any substitutable ring atom can be substituted (e.g., by one or more substituents). The term "cycloalkyl" includes cycloalkenyl, which contains unsaturation in the ring. The cycloalkyl groups can contain fused or spiro rings. Fused rings are rings that share a common carbon atom. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclohexyl, methylcyclohexyl, adamantyl, and norbornyl.
The term "cycloalkylalkyl" as employed herein refers to an alkyl group substituted with a cycloalkyl group.
The terms "heterocyclyl" or "heterocyclic group" refer to 3- to 14-membered non- aromatic ring structures (e.g., 3- to 14-membered rings, more preferably 3- to 7- membered rings), whose ring structures include one to four heteroatoms independently selected from O, N and S. The heterocyclyl or heterocyclic groups can contain fused or spiro rings. Heterocycles can also be polycycles, with each group having, e.g., 5-7 ring members. The term "heterocyclyl" or "heterocyclic group" includes saturated and partially saturated heterocyclyl structures. The heteroatom may optionally be the point of attachment of the heterocyclyl substituent.
The term "heteroaryl" refers to a 5-14 membered (i.e., a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic) aromatic ring system having 1-3 ring heteroatoms if monocyclic, 1-6 ring heteroatoms if bicyclic, or 1-9 ring heteroatoms if tricyclic, said ring heteroatoms independently selected from O, N, and S (e.g., 1-3, 1-6, or 1-9 ring heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively). Any substitutable ring atom can be substituted (e.g., by one or more substituents).
Bicyclic and tricyclic ring systems containing one or more heteroatoms and both aromatic and non-aromatic rings wherein the point of attachment from the ring system to the rest of the molecule is through a non-aromatic ring are considered to be heterocyclyl groups. Bicyclic or tricyclic ring systems where an aryl or a heteroaryl is fused to a cycloalkyl or heterocyclyl and the point of attachment from the ring system to the rest of the molecule is through an aromatic ring are considered to be aryl or heteroaryl groups.
The term "heterocyclylalkyl", as used herein, refers to an alkyl group substituted with a heterocycle group.
The terms "hetaralkyl" and "heteroaralkyl", as used herein, refers to an alkyl group substituted with a heteroaryl group. The ring heteroatoms of the compounds provided herein include N-O, S(O), and S(0)2.
Aryl, heteroaryl, cycloalkyl, and heterocyclyl groups, either alone or a part of a group (e.g., the aryl portion of an aralkyl group), are optionally substituted at one or more substitutable atoms with, unless specified otherwise, substituents independently selected from: halo, -C≡N, Ci-C4 alkyl, =0, -ORb, -ORb', -SRb, -SRb', -(Ci-C4 alkyl)-N(Rb)(Rb), -(Ci-C4 alkyl)-N(Rb)(Rb'), -N(Rb)(Rb), -N(Rb)(Rb ), -0-(C1-C4 alkyl)-N(Rb)(Rb),
-0-(C1-C4 alkyl)-N(Rb)(Rb'), -(C C4 alkyl)-0-(Ci-C4 alkyl) -N(Rb)(Rb), -(C C4 alkyl)-0-(Ci-C4 alkyl)-N(Rb)(Rb'), -C(0)-N(Rb)(Rb), -(d-C4 alkyl)-C(0)-N(Rb)(Rb), -(C1-C4 alkyl)-C(0)-N(Rb)(Rb'), -ORb', Rb', -C(0)(Ci-C4 alkyl), -C(0)Rb', - C(0)N(Rb')(Rb), -N(Rb)C(0)(Rb), -N(Rb)C(0)(Rb'), -N(Rb)S02(Rb), -S02N(Rb)(Rb), - N(Rb)S02(Rb'), and -S02N(Rb)(Rb'), wherein any alkyl substituent is optionally further substituted with one or more of -OH, -0-(C1-C4 alkyl), halo, -NH2, -NH(CrC4 alkyl), or -N(d-C4 alkyl)2;
each Rb is independently selected from hydrogen, and -CrC4 alkyl; or two Rbs are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered heterocyclyl optionally comprising one additional heteroatom selected from N, S, and O; and
each Rb is independently selected from C3-C7 carbocylyl, phenyl, heteroaryl, and heterocyclyl, wherein one or more substitutable positions on said phenyl, cycloalkyl, heteroaryl or heterocycle substituent is optionally further substituted with one or more of -(C C4 alkyl), -(C C4 fluoroalkyl), -OH, -0-(Ci-C4 alkyl), -0-(Ci-C4 fluoroalkyl), halo, -NH2, -NH(C C4 alkyl), or -N(C C4 alkyl)2.
Heterocyclyl groups, either alone or as part of a group, are optionally substituted on one or more any substitutable nitrogen atom with oxo (=0), -Ci-C4 alkyl, or fluoro-substituted C C4 alkyl.
The term "substituted" refers to the replacement of a hydrogen atom by another group.
The term "selective" is meant at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, or 10- fold greater inhibition of glutaminase than other targets.
The term "inhibitor" as used herein means an agent that measurably slows, stops, decreases or inactivates the enzymatic activity of glutaminase to decrease to a level that is less than the glutaminase normal levels of activity. Inhibitors of glutaminase may be peptides or nucleic acids (e.g., glutamate). An agent can be evaluated to determine if it is an inhibitor by measuring either directly or indirectly the activity of glutaminase when subjected to the agent. The activity of the agent can be measured, for example, against a control substance. In some instances, the activity measured of the agent is for inhibition of glutaminase. "Acquire" or "acquiring" as the terms are used herein, refer to obtaining possession of a physical entity, or a value, e.g., a numerical value, by "directly acquiring" or "indirectly acquiring" the physical entity or value. "Directly acquiring" means performing a process (e.g., performing a synthetic or analytical method) to obtain the physical entity or value. "Indirectly acquiring" refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value). Directly acquiring a physical entity includes performing a process that includes a physical change in a physical substance, e.g., a starting material. Exemplary changes include making a physical entity from two or more starting materials, shearing or fragmenting a substance, separating or purifying a substance, combining two or more separate entities into a mixture, performing a chemical reaction that includes breaking or forming a covalent or non-covalent bond. Directly acquiring a value includes performing a process that includes a physical change in a sample or another substance, e.g., performing an analytical process which includes a physical change in a substance, e.g., a sample, analyte, or reagent (sometimes referred to herein as "physical analysis"), performing an analytical method, e.g., a method which includes one or more of the following: separating or purifying a substance, e.g., an analyte, or a fragment or other derivative thereof, from another substance; combining an analyte, or fragment or other derivative thereof, with another substance, e.g., a buffer, solvent, or reactant; or changing the structure of an analyte, or a fragment or other derivative thereof, e.g., by breaking or forming a covalent or non-covalent bond, between a first and a second atom of the analyte; or by changing the structure of a reagent, or a fragment or other derivative thereof, e.g., by breaking or forming a covalent or non-covalent bond, between a first and a second atom of the reagent.
"Acquiring a sample" as the term is used herein, refers to obtaining possession of a sample, e.g., a tissue sample or nucleic acid sample, by "directly acquiring" or
"indirectly acquiring" the sample. "Directly acquiring a sample" means performing a process (e.g., performing a physical method such as a surgery or extraction) to obtain the sample. "Indirectly acquiring a sample" refers to receiving the sample from another party or source (e.g., a third party laboratory that directly acquired the sample). Directly acquiring a sample includes performing a process that includes a physical change in a physical substance, e.g., a starting material, such as a tissue, e.g., a tissue in a human patient or a tissue that has was previously isolated from a patient. Exemplary changes include making a physical entity from a starting material, dissecting or scraping a tissue; separating or purifying a substance (e.g., a sample tissue or a nucleic acid sample);
combining two or more separate entities into a mixture; performing a chemical reaction that includes breaking or forming a covalent or non-covalent bond. Directly acquiring a sample includes performing a process that includes a physical change in a sample or another substance, e.g., as described above.
As used herein a "low" of E-cadherin expression compared to a reference standard refers a low, decreased, or absent level of E-cadherin expression compared to the level of E-cadherin expression in an epithelial cell as characterized by methods known in the art, e.g., on any one of the following references: (Yauch et ah , (2005) Clin Cancer Res 11 :24; Savagner et ah , (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et ah , (2002) Nature Reviews Cancer 2(6):442).
As used herein, a "high" level of vimentin compared to a reference standard refers to a high or increased level of vimentin expression compared to the level of expression of vimentin in an epithelial cell as characterized by methods known in the art, e.g., on any one of the following references: (Yauch et ah , (2005) Clin Cancer Res 11 :24; Savagner et ah , (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et ah , (2002) Nature Reviews Cancer 2(6):442).
As used herein, a "low" or "decreased", level of pyruvate carboxylase expression compared to a reference standard refers to a low, decreased, or absent level of E-cadherin expression compared to the level of E-cadherin expression in an epithelial cell as characterized by methods known in the art, e.g., on any one of the following references: (Yauch et al , (2005) Clin Cancer Res 11 :24; Savagner et al , (2010) Ann Oncol.
21(suppl 7): vii89; Thiery et al , (2002) Nature Reviews Cancer 2(6):442).
As used herein, "cancer" and "tumor" are synonymous terms. The term "cancer" or "tumor" refer to the presence of cells possessing characteristics typical of cancer- causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. Cancer cells are often in the form of a tumor, but such cells may exist alone within an animal, or may be a non-tumorigenic cancer cell, such as a leukemia cell. The cells can possess characteristics typical of a mesenchymal cell, such as characterized on any one of the following references: (Yauch et al , (2005) Clin Cancer Res 11 :24; Savagner et al. , (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al , (2002) Nature Reviews Cancer 2(6):442).
The abbreviations Me, Et, Ph, Tf, Nf, Ts, Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, p-toluenesulfonyl and
methanesulfonyl, respectively. A more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the Journal of Organic Chemistry; this list is typically presented in a table entitled
Standard List of Abbreviations. The abbreviations contained in said list, and all abbreviations utilized by organic chemists of ordinary skill in the art are hereby incorporated by reference.
Methods of Evaluating Compounds
Glutaminase activity can be monitored by detecting production of either of the products of the reaction, glutamate or ammonia. In some embodiments, glutamate production is measured because ammonia is a product of any of a number of biological reactions.
Glutamate production can be measured by any of a number of standard methods known in the art, e.g., chemical and chromatographic detection methods and coupled enzyme assays that utilize NADH and glutamate dehydrogenase. Extracellular glutamate concentrations can also be measured in vivo, using microdialysis methods known in the art. One suitable method for measuring glutamate is a microtiter-based two-step assay in which glutamate formed in the initial step is quantitatively deaminated by glutamate dehydrogenase to yield an equivalent amount of NADH (Godfrey et al., 1977; Kvamme et al., 1985), which can then be detected spectrophotometrically.
Methods of Treatment
In one embodiment, provided is a method for treating or preventing a disease, condition or disorder as described herein (e.g., treating) comprising administering a compound, a pharmaceutically acceptable salt of a compound or pharmaceutical composition comprising a compound described herein (e.g., a compound of formula (I) or in Table 1).
The compounds and compositions described herein can be administered to cells in culture, e.g. in vitro or ex vivo, or to a subject, e.g., in vivo, to treat, prevent, and/or diagnose a variety of disorders, including those described herein below.
As used herein, the term "treat" or "treatment" is defined as the application or administration of a compound, alone or in combination with, a second compound to a subject, e.g., a patient, or application or administration of the compound to an isolated tissue or cell, e.g., cell line, from a subject, e.g., a patient, who has a disorder (e.g., a disorder as described herein), a symptom of a disorder, or a predisposition toward a disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder, one or more symptoms of the disorder or the
predisposition toward the disorder (e.g., to prevent at least one symptom of the disorder or to delay onset of at least one symptom of the disorder).
As used herein, an amount of a compound effective to treat a disorder, or a "therapeutically effective amount" refers to an amount of the compound which is effective, upon single or multiple dose administration to a subject, in treating a cell, or in curing, alleviating, relieving or improving a subject with a disorder beyond that expected in the absence of such treatment. As used herein, an amount of a compound effective to prevent a disorder, or a "a prophylactically effective amount" of the compound refers to an amount effective, upon single- or multiple-dose administration to the subject, in preventing or delaying the occurrence of the onset or recurrence of a disorder or a symptom of the disorder.
The term "patient" and "subject" are synonymous, and as used herein, refer to an animal, typically a human (i.e., a male or female of any age group, e.g., a pediatric patient or adult patient or other mammal, such as primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys, that will be or has been the object of treatment, observation, and/or experiment. When the term is used in conjunction with administration of a compound or drug, then the patient has been the object of treatment, observation, and/or administration of the compound or drug.
Cancers
The methods described herein can be used with any cancer, for example those described by the National Cancer Institute. A cancer can be evaluated to determine whether it is using a method described herein. Exemplary cancers can include but are not limited to, lung cancer, e.g. , non-small cell lung cancer; breast cancer, e.g., triple negative breast cancer; or hepatocellular carcninoma, osteosarcoma, lipomas, chondrosarcoma, or mesothelioma. In some embodiments, the cancer is selected from colon cancer, renal cell carcinoma, acute myeloid leukemia (AML), melanoma, and multiple myeloma.
The cancer can be a primary tumor, i.e., located at the anatomical site of tumor growth initiation. The cancer can also be metastatic, i.e., appearing at least a second anatomical site other than the anatomical site of tumor growth initiation. The cancer can be a recurrent cancer, i.e., cancer that returns following treatment, and after a period of time in which the cancer was undetectable. The recurrent cancer can be anatomically located locally to the original tumor, e.g. , anatomically near the original tumor; regionally to the original tumor, e.g. , in a lymph node located near the original tumor; or distantly to the original tumor, e.g., anatomically in a region remote from the original tumor.
Cancer Combination therapies
In some embodiments, a compound described herein is administered together with one or more additional cancer treatments. Exemplary cancer treatments include, for example: chemotherapy, targeted therapies such as antibody therapies, immunotherapy, and hormonal therapy. Examples of each of these treatments are provided below.
Chemotherapy
In some embodiments, a compound described herein is administered with one or morechemo therapies. Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. "Chemotherapy" usually refers to cytotoxic drugs which affect rapidly dividing cells in general, in contrast with targeted therapy. Chemotherapy drugs interfere with cell division in various possible ways, e.g., with the duplication of DNA or the separation of newly formed chromosomes. Most forms of chemotherapy target all rapidly dividing cells and are not specific for cancer cells, although some degree of specificity may come from the inability of many cancer cells to repair DNA damage, while normal cells generally can.
Examples of chemotherapeutic agents used in cancer therapy include, for example, antimetabolites (e.g., folic acid, purine, and pyrimidine derivatives) and alkylating agents (e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poison, cytotoxic agents, toposimerase inhibitors and others). Exemplary agents include Aclarubicin, Actinomycin, Alitretinon,
Altretamine, Aminopterin, Aminolevulinic acid, Amrubicin, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase, Atrasentan, Belotecan, Bexarotene, endamustine, Bleomycin, Bortezomib, Busulfan, Camptothecin, Capecitabine, Carboplatin,
Carboquone, Carmofur, Carmustine, Celecoxib, Chlorambucil, Chlormethine, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Demecolcine, Docetaxel, Doxorubicin, Efaproxiral, Elesclomol, Elsamitrucin, Enocitabine, Epirubicin, Estramustine, Etoglucid, Etoposide, Floxuridine, Fludarabine, Fluorouracil (5FU), Fotemustine, Gemcitabine, Gliadel implants, Hydroxycarbamide, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Irofulven, Ixabepilone, Larotaxel, Leucovorin, Liposomal doxorubicin, Liposomal daunorubicin, Lonidamine, Lomustine, Lucanthone, Mannosulfan, Masoprocol,
Melphalan, Mercaptopurine, Mesna, Methotrexate, Methyl aminolevulinate,
Mitobronitol, Mitoguazone, Mitotane, Mitomycin, Mitoxantrone, Nedaplatin, Nimustine, Oblimersen, Omacetaxine, Ortataxel, Oxaliplatin, Paclitaxel, Pegaspargase, Pemetrexed, Pentostatin, Pirarubicin, Pixantrone, Plicamycin, Porfimer sodium, Prednimustine, Procarbazine, Raltitrexed, Ranimustine, Rubitecan, Sapacitabine, Semustine, Sitimagene ceradenovec, Satraplatin, Streptozocin, Talaporfin, Tegafur-uracil, Temoporfin,
Temozolomide, Teniposide, Tesetaxel, Testolactone, Tetranitrate, Thiotepa, Tiazofurin, Tioguanine, Tipifarnib, Topotecan, Trabectedin, Triaziquone, Triethylenemelamine, Triplatin, Tretinoin, Treosulfan, Trofosfamide, Uramustine, Valrubicin, Verteporfin, Vinblastine, Vincristine, Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zorubicin, and other cytostatic or cytotoxic agents described herein.
Because some drugs work better together than alone, two or more drugs are often given at the same time. Often, two or more chemotherapy agents are used as combination chemotherapy. In some embodiments, the chemotherapy agents (including combination chemotherapy) can be used in combination with a compound described herein.
Targeted therapy
In some embodiments, a compound described herein is administered with one or more targeted therapies. Targeted therapy constitutes the use of agents specific for the deregulated proteins of cancer cells. Small molecule targeted therapy drugs are generally inhibitors of enzymatic domains on mutated, overexpressed, or otherwise critical proteins within the cancer cell. Prominent examples are the tyrosine kinase inhibitors such as Axitinib, Bosutinib, Cediranib, dasatinib, erlotinib, imatinib, gefitinib, lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, and Vandetanib, and also cyclin-dependent kinase inhibitors such as Alvocidib and Seliciclib. Monoclonal antibody therapy is another strategy in which the therapeutic agent is an antibody which specifically binds to a protein on the surface of the cancer cells. Examples include the anti-HER2/neu antibody trastuzumab (HERCEPTIN®) typically used in breast cancer, and the anti-CD20 antibody rituximab and Tositumomab typically used in a variety of B- cell malignancies. Other exemplary anbibodies include Cetuximab, Panitumumab, Trastuzumab, Alemtuzumab, Bevacizumab, Edrecolomab, and Gemtuzumab. Exemplary fusion proteins include Aflibercept and Denileukin diftitox. In some embodiments, the targeted therapy can be used in combination with a compound described herein.
Exemplary additional therapeutic agents can also include epidermal growth factor receptor (EGFR) inhibitors, e.g., cetuximab, panitumumab, gefitinib, erlotinib, nimotuzamab, matuzamab, zalutumumab, or lapatinib. Resistance to EGFR inhibitors can occur as a result of the transition of a cell to a mesenchymal phenotype or a mesenchymal phenotype, and tumors with EGFR mutations and mesenchymal phenotype can be less sensitive to EGFR inhibitors (see for example, Sequist et al., (2011) Sci Transl Med. 3:75. Buck et al, (2007) Mol Cancer Ther. 6: 532; Thomson et al, (2008) Clin Exp Metastasis 25: 843).
Exemplary additional therapeutic agents can also include glutathione depleting agents, e.g., L-buthionine-(S,R)-sulfoximine (BSO).
Exemplary additional therapeutic agents can also include Phosphoinositide 3- kinase (PI3K) inhibitors, e.g., Perifosine, Idelalisib, BKM120, PX-866, IPI- 145, NVP- BEZ235, GDC0941, and BAY 80-6946.
Exemplary additional therapeutic agents can also include Heat Shock Protein 90 (HSP90) inhibitors, e.g., geldanamycin, radicicol, 17-N-Allylamino-17- demethoxygeldanamycin (17AAG). ganetespib, 4-(4-(2,3-Dihydro-l,4-benzodioxin-6- yl)-5-methyl-lH-pyrazol-3-yl)-6-ethylresorcinol, AUY922 (NVP-AUY922), BIIB021, STA9090, AT13387, NVP-BEP800, and SNX-2112 (PF-04928473). Targeted therapy can also involve small peptides as "homing devices" which can bind to cell surface receptors or affected extracellular matrix surrounding the tumor. Radionuclides which are attached to these peptides (e.g., RGDs) eventually kill the cancer cell if the nuclide decays in the vicinity of the cell. An example of such therapy includes BEXXAR®.
Immunotherapy
In some embodiments, a compound described herein is administered with one or more immunotherapies. Cancer immunotherapy refers to a diverse set of therapeutic strategies designed to induce the patient's own immune system to fight the tumor.
Contemporary methods for generating an immune response against tumors include intravesicular BCG immunotherapy for superficial bladder cancer, and use of interferons and other cytokines to induce an immune response in renal cell carcinoma and melanoma patients.
Allogeneic hematopoietic stem cell transplantation can be considered a form of immunotherapy, since the donor's immune cells will often attack the tumor in a graft- versus-tumor effect. In some embodiments, the immunotherapy agents can be used in combination with a compound described herein.
Hormonal therapy
In some embodiments, a compound described herein is administered with one or more hormonal therapies. The growth of some cancers can be inhibited by providing or blocking certain hormones. Common examples of hormone-sensitive tumors include certain types of breast and prostate cancers. Removing or blocking estrogen or testosterone is often an important additional treatment. In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial. In some embodiments, the hormonal therapy agents can be used in combination with a compound described herein.
Nutrient restricted diets In some embodiments, a compound described herein is administered in conjunction with one or more nutrient restricted diets. Since cancer cells rely on glucose to generate cellular energy, lowering glucose blood levels through carbohydrate and protein restriction may inhibit the growth of some cancers. In certain cancers, nutrient restricted diets such as caloric restriction, fasting, and ketogenic diets may be
therapeutically beneficial. In some embodiments, such nutrient restricted diets can be used in combination with a compound described herein.
Neuronal Disorders
A compound or composition described herein can be used to treat or prevent neuronal cell death as a result of an injury to neuronal tissue, e.g., nervous tissue exposed to an ischemic or hypoxic event, to trauma or to a chronic neurodegenerative disorder. A "neuronal disorder" is a neurological disease or disorder that is associated with glutamate excitotoxicity, e.g., cerebral ischemia or hypoxia resulting from an neurological event such as a stroke or ischemic event. Treatment with the compound may be in an amount effective to provide a neuroprotective effect, e.g., to prevent neuronal cell death.
Compositions and routes of administration
The compositions delineated herein include the compounds delineated herein (e.g., a compound described herein), as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein.
The term "pharmaceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that may be administered to a subject, together with a compound provided herewith, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions provided herewith include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-cc-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
The pharmaceutical compositions provided herewith may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions provided herewith may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3- butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or
carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
The pharmaceutical compositions provided herewith may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. The pharmaceutical compositions provided herewith may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound provided herewith with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
Topical administration of the pharmaceutical compositions provided herewith is useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds provided herewith include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions provided herewith may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included.
The pharmaceutical compositions provided herewith may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. When the compositions provided herewith comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds provided herewith. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds provided herewith in a single composition.
The compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound
composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions provided herewith will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.
Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination provided herewith may be administered, if necessary.
Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
Patient selection and monitoring
The compounds described herein can inhibit glutaminase. Accordingly, a patient and/or subject can be selected for treatment using a compound described herein by first evaluating the patient and/or subject to determine whether the subject is in need of inhibition of glutaminase, and if the subject is determined to be in need of glutaminase inhibition, then administering to the subject a compound described herein.
A subject can be evaluated as being in need of glutaminase inhibition using methods known in the art, e.g., by measuring the presence and/or activity of glutaminase in the patient. In some embodiments, the activity and/or level of glutaminase is evaluated in the cancer.
A patient receiving a compound described herein can be monitored, for example, for improvement in the condition and/or adverse effects. Improvement of a patient's condition can be evaluated, for example, by monitoring the growth, absence of growth, or regression of the cancer (e.g., a tumor). In some embodiments, the patient is evaluated using a radiological assay or evaluation of hemolytic parameters.
A patient and/or subject can be selected for treatment using a compound described hereby by optionally, acquiring a patient sample; evaluating the sample to determine whether the sample is characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, and/or iii) a low or decreased level of pyruvate carboxylase expression compared to a reference standard; and if the patient is determined to have a low level of E-cadherin expression compared to a reference standard, or a high level of vimentin expression compared to a reference standard, then the patient is administered a compound described herein.
In some embodiments, the level of E-cadherin expression is compared to a reference standard, wherein the reference standard is the level of E-cadherin expression in an epithelial cell as characterized on any one of the following references: (Yauch et al., (2005) Clin Cancer Res 11:24; Savagner et al, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442). In some embodiments, the level of E-cadherin expression is low, decreased, or absent compared to the reference standard. In some embodiments, the level of E-cadherin expression is measured by the evaluation of the level of RNA that encodes E-cadherin. In some embodiments, the level of E- cadherin expression is evaluated by the level of E-cadherin protein expression. In some embodiments the level of E-cadherin expression is at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90% less than the reference standard. In some embodiments the level of E- cadherin expression is at least a 1.5, 2, 5, 10, 15, 20, 25, 50, 75, 100 fold decrease in expression compared to the reference standard.
In some embodiments, the level of vimentin expression is compared to a reference standard, wherein the reference standard is the level of vimentin expression in an epithelial cell as characterized on any one of the following references: (Yauch et al, (2005) Clin Cancer Res 11:24; Savagner et al, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442). In some embodiments, the level of vimentin expression is measured by the evaluation of the level of RNA that encodes vimentin. In some embodiments, the level of vimentin expression is evaluated by the level of vimentin protein expression. In some embodiments the level of vimentin expression is at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90% greater than the reference standard. In some embodiments the level of vimentin expression is at least a 1.5, 2, 5, 10, 15, 20, 25, 50, 75, 100 fold increase in expression compared to the reference standard.
In some embodiments, the level of pyruvate carboxylase expression is low or decreased compared to a reference standard, wherein the reference standard is the level of pyruvate carboxylase expression in an epithelial cell as characterized on any one of the following references: (Yauch et ah, (2005) Clin Cancer Res 11:24; Savagner et ah, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442). In some embodiments, the level of pyruvate carboxylase expression is high or increased compared to the reference standard. In some embodiments, the level of pyruvate carboxylase expression is measured by the evaluation of the level of RNA that encodes pyruvate carboxylase. In some embodiments, the level of vimentin expression is evaluated by the level of pyruvate carboxylase protein expression. In some embodiments the level of pyruvate carboxylase expression is at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90% greater than the reference standard. In some embodiments the level of pyruvate carboxylase expression is at least a 1.5, 2, 5, 10, 15, 20, 25, 50, 75, 100 fold increase in expression compared to the reference standard.
Patient Sample
The terms "patient sample", "subject sample", and "sample" are used
interchangeably herein. The patient sample can be a tissue, or bodily fluid, or bodily product. Tissue samples can include fixed, paraffin embedded, fresh, or frozen samples. For example, the tissue sample can include a biopsy, cheek swab. Exemplary tissues include lung, breast, brain, nervous tissue, kidney, ovary, thyroid, pancreas, colon, prostate, lymph node, skin, hair follicles and nails. Exemplary samples include samples derived from solid tumors. Exemplary bodily fluids include blood, plasma, urine, lymph, tears, sweat, saliva, semen, and cerebrospinal fluid. Exemplary bodily products include exhaled breath.
The tissue, fluid or product can be removed from the patient and analyzed. The evaluation can include one or more of: performing the analysis of the tissue, fluid or product; requesting analysis of the tissue fluid or product; requesting results from analysis of the tissue, fluid or product; or receiving the results from analysis of the tissue, fluid or product.
The sample tissue, fluid, or product can be analyzed for the expression level of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase. The sample tissue, fluid, or product can be analyzed for the expression level of a protein described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase. The sample tissue, fluid or product can further be analyzed for the level of gene expression of a gene or plurality of genes of a preselected signaling pathway or phenotypic pathway, e.g., the epithelial to mesenchymal transition pathway, E-cadherin pathway, vimentin pathway, or the pyruvate carboxylase pathway. The sample tissue, fluid or product can further be analyzed for the level of protein expression of a protein or plurality of proteins of a preselected signaling pathway or phenotypic pathway, e.g., the epithelial to mesenchymal transition pathway, E-cadherin pathway, vimentin pathway, or the pyruvate carboxylase pathway.
Methods of evaluating samples
The expression level of a gene described herein, e.g., E-cadherin, vimentin, and pyruvate carboxylase, can be assessed using any of a wide variety of well known methods for detecting expression of a transcribed molecule, gene, protein, mRNA, genomic DNA, or cDNA. Gene expression can be measured or monitored by measure of a gene transcript, e.g., mRNA, by a measure of the quantity of a translated protein, or by a measure of gene product activity; any of which can be measured using standard techniques known to one of skill in the art. Non-limiting examples of such methods include nucleic acid hybridization methods, nucleic acid reverse transcription methods, nucleic acid amplification methods, immunological methods for detection of proteins, protein purification methods, protein function or activity assays.
E-cadherin
The E-cadherin gene is located on human chromosome 16. E-cadherin is a classical cadherin of the cadherin superfamily. The encoded E-cadherin protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail.
Mutations in this gene have been correlated with cancer, including gastric, breast, colorectal, thyroid and ovarian cancers. Loss of function of E-cadherin is contemplated to contribute to cancer progression by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. Identified E-cadherin transcript variants arise from mutation at consensus splice sites.
Vimentin
The vimentin gene is located on human chromosome 10 and encodes a member of the intermediate filament family of proteins. Intermediate filaments, along with microtubules and actin microfilaments, make up the cellular cytoskeleton, which helps maintain cell shape and integrity of the cytoplasm, as well as stabilizing cyto skeletal interactions. Vimentin also functions in mediating immune responses, control of the transport of low-density lipoprotein derived cholesterol from lysosomes to the sites of esterification, and as an organizer of a number of critical proteins involved in attachment, migration, and cell signaling.
Pyruvate Carboxylase (PC)
The PC gene is located on human chromosomes 11 and encodes the protein pyruvate carboxylase, which catalyzes the carboxylation of pyruvate to oxaloacetate. The active enzyme is a homotetramer arranged in a tetrahedron which is located exclusively in the mitochondrial matrix. Pyruvate carboxylase is involved in multiple cellular processes including gluconeogenesis, lipogenesis, insulin secretion and synthesis of the neurotransmitter glutamate. Mutations in this gene have been associated with pyruvate carboxylase deficiency. Alternatively spliced transcript variants with different 5' UTRs, but encoding the same protein, have been identified. Nucleic Acid Molecules
The methods described herein can pertain to the evaluation of a sample for the expression of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase; based on isolated nucleic acids which correspond to the gene described herein, e.g., the mRNA level of E-cadherin; the mRNA level of vimentin; the mRNA level of pyruvate carboxylase. As used herein, the term "nucleic acid" or "nucleic acid molecule" is intended to include DNA molecules {e.g., cDNA or genomic DNA) and RNA molecules {e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single- stranded or double- stranded.
An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. An "isolated" nucleic acid molecule can be free of sequences (such as protein-encoding sequences) which naturally flank the nucleic acid {i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. An "isolated" nucleic acid molecule, such mRNA, can be substantially free of other cellular material cellular material or other contaminating proteins from the cell or tissue source from which the nucleic acid is derived.
A nucleic acid molecule described herein can be isolated using standard molecular biology techniques and the sequence information available in database records known to those of skill in the art. Using all or a portion of such nucleic acid sequences, nucleic acid molecules described herein can be isolated using standard hybridization and cloning techniques {e.g., as described in Sambrook et ah, ed., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
A nucleic acid molecule described herein can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid molecules so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
An isolated nucleic acid molecule can comprise a nucleic acid molecule which has a nucleotide sequence complementary to the nucleotide sequence of a nucleic acid corresponding to gene described herein, or to the nucleotide sequence of a nucleic acid encoding a protein which corresponds to the gene described herein. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.
A nucleic acid molecule described herein can comprise only a portion of a nucleic acid sequence. Such nucleic acid molecules can be used, for example, as a probe or primer. The probe/primer can be one or more substantially purified oligonucleotides. Probes based on the sequence of a nucleic acid molecules described herein can be used to detect transcripts or genomic sequences corresponding to the genes described herein. The probe can contain comprise a label group, e.g. , a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a patient, e.g., detecting mRNA levels.
Methods for Detection of Gene Expression
Methods of detecting and/or quantifying a gene transcript, e.g., mRNA or cDNA made therefrom, can include but are not limited to Southern Blot analysis, Northern Blot analysis, polymerase chain reaction (PCR) analyses and probe arrays. Methods of detecting and/or quantifying a gene transcript, e.g. , mRNA or cDNA made therefrom, can include but are not limited to hybridization based methods, e.g., hybridization with a probe that is specific for the gene transcript, e.g., mRNA or cDNA made therefrom. The level of a gene transcript, e.g., mRNA or cDNA made therefrom, can be assayed by applying the sample, or the mRNA or cDNA made therefrom, or amplified from; to a nucleic acid microarray, or chip array.
The level of a gene transcript, e.g., mRNA or cDNA made therefrom, can be assayed by a polymerase chain reaction (PCR) based method, e.g., quantitative PCR, quantitative real time PCR, real time PCR, reverse transcription PCR, real time reverse transcription PCR. The level of a gene transcript, e.g., mRNA or cDNA made therefrom, can be assayed by a sequencing based method, e.g., quantitative RNA sequencing.
The level of a gene transcript, e.g., mRNA, can be determined by in situ or by in vitro methods known in the art. For in vitro methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from a sample, e.g., from cells of a sample (see, e.g., Ausubel et ah, ed., Current
Protocols in Molecular Biology, John Wiley & Sons, New York 1987-1999).
Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155). For in situ methods, mRNA does not need to be isolated from the cells prior to detection. In such methods, a cell or tissue sample can be prepared/processed using known histological methods. The sample can then be immobilized on a support, and then contacted with a probe that can hybridize to mRNA that encodes the gene transcript of interest.
Determinations can be based on absolute expression level; normalized expression level, or relative expression level; of a gene transcript, e.g., mRNA. Expression levels can be normalized by correcting the absolute expression level of a gene transcript by comparing its expression level to the expression level of another gene which is stably expressed, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as histone H3 gene or the actin gene. This normalization allows the comparison of the expression level in one sample to another sample, e.g., a first sample taken from a patient to a second sample taken from the same patient, e.g., from another tissue or at a different time point; or between samples from different sources, e.g., a patient sample from one patient to a patient sample from another patient.
The expression level can be provided as a relative expression level. The relative expression level can be determined by comparing the absolute level of expression of the gene transcript, e.g., mRNA, to a reference standard. The reference standard can include the level of expression of the gene transcript of interest in a genotypically or
phenotypically defined sample. The reference standard can be the level of expression of the gene transcript of interest, e.g., E-cadherin, vimentin, pyruvate carboxylase, in a cell genotypically or phenotypically characterized as an epithelial cell. An epithelial cell can be characterized as in any one of the following references: (Yauch et ah, (2005) Clin Cancer Res 11:24; Savagner et ah, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et ah, (2002) Nature Reviews Cancer 2(6):442).
The expression level of a gene transcript described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase, can be measured at least at two time-points to determine if a change in the level of expression has occurred. For example, the level of expression can be measured pre- and post-treatment with a compound described herein, or at one or more time-points while treatment with a compound described herein is ongoing. If the expression level is found to be decreased, e.g., decreased expression of E-cadherin compared to a reference standard and/or increased expression of vimentin compared to a reference standard; the subject may be administered treatment with a compound described herein. The reference standard can be the level of expression of the gene transcript of interest in an epithelial cell characterized. An epithelial cell can be characterized by methods known in the art, e.g., as in any one of the following references: (Yauch et ah, (2005) Clin Cancer Res 11:24; Savagner et ah, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442).
Proteins
The methods described herein can pertain to the evaluation of a sample for the expression of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase; based on isolated proteins which correspond to the gene described herein, e.g., the protein level of E-cadherin; the protein level of vimentin; the protein level of pyruvate carboxylase. This can also include the evaluation of biologically active portions, variants, isoforms, or splice variants thereof. The native polypeptide corresponding to the protein of interest can be isolated from the sample by an appropriate purification scheme using standard protein purification techniques known to those of skill in the art.
An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived. The language "substantially free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated. Biologically active portions of a polypeptide can include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein, which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein.
Methods for Detection of Protein Expression
The level of expression of a protein or polypeptide can be detected and quantified by any of a number of means well known to those of skill in the art. Methods of detecting and/or quantifying a protein or polypeptide described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase; can include but are not limited to biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, or various immunoassays such as fluid or gel precipitin reactions, immunodiffusion (single or double), Immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, Western blotting, immunohistochemistry, in situ hybridization, fluorescence-activated cell sorting (FACS) and the like. A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether cells express the protein or polypeptide described herein.
A protein or polypeptide can be detected using an immunoassay. As used herein, immunoassays include assays that utilize an antibody to specifically bind to a protein or polypeptide. An immunoassay can be characterized by the detection of specific binding of a protein or polypeptide to an antibody as opposed to the use of other physical or chemical properties to isolate, target, and quantify the polypeptide. The polypeptide can be detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and
4,837,168). For a review of the general immunoassays, see also Asai (1993) Methods in Cell Biology Volume 37: Antibodies in Cell Biology, Academic Press, Inc. New York; Stites & Terr (1991) Basic and Clinical Immunology 7th Edition. Immunoassays for the detection and/or quantification of a protein or polypeptide can take a wide variety of formats well known to those of skill in the art.
An antibody capable of binding to a protein or polypeptide, e.g., an antibody with a detectable label (either directly or indirectly labeled), corresponding to a protein or polypeptide described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase, can be used to detect the protein or polypeptide. Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof, e.g., Fab or F(ab')2 can be used. The term
"labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling, i.e., physically linking a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The antibody can also be labeled, e.g., a radio-labeled, chromophore- labeled, fluorophore-labeled, or enzyme-labeled antibody. An antibody derivative, e.g., an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair, e.g., biotin-streptavidin, or an antibody fragment, e.g., a single-chain antibody, an isolated antibody hypervariable domain, etc, which binds specifically with a protein described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase, such as the protein encoded by the open reading frame corresponding to the gene transcript of a protein or polypeptide described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase, or such a protein or polypeptide which has undergone all or a portion of its normal post- translational modification, is used.
Proteins from cells can be isolated using techniques that are well known to those of skill in the art. The protein isolation methods employed can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).
The expression level can be provided as a relative expression level. The relative expression level can be determined by comparing the absolute level of expression of the protein, to a reference standard. The reference standard can include the level of expression of the protein of interest in a genotypically or phenotypically defined sample. The reference standard can be the level of expression of the protein of interest, e.g., E- cadherin, vimentin, pyruvate carboxylase, in a cell genotypically or phenotypically characterized as an epithelial cell. An epithelial cell can be characterized by methods known in the art, e.g., as described in on any one of the following references: (Yauch et al, (2005) Clin Cancer Res 11:24; Savagner et al, (2010) Ann Oncol. 21(suppl 7): vii89; Thiery et al, (2002) Nature Reviews Cancer 2(6):442).
The expression level of a protein or polypeptide described herein, e.g., E- cadherin, vimentin, pyruvate carboxylase, can be measured at least at two time-points to determine if a change in the level of expression has occurred. For example, the level of expression can be measured pre- and post-treatment with a compound described herein, or at one or more time-points while treatment with a compound described herein is ongoing. If the expression level is found to be decreased, e.g., decreased expression of E- cadherin compared to a reference standard and/or increased expression of vimentin compared to a reference standard; the subject may be administered treatment with a compound described herein.
Kits
Also described herein are kits comprising a means to assay the level of gene expression of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase. For example, the kit can include an agent capable of interacting with a gene expression product of a gene described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase. The kit can include a plurality of agents capable of interacting with gene expression products of a plurality of genes described herein, e.g., E-cadherin, vimentin, pyruvate carboxylase. The agent can include, but is not limited to, an antibody, a plurality of antibodies, an oligonucleotide, or a plurality of oligonucleotides. The gene expression product can include, but is not limited to, a transcribed molecule, a RNA molecule, a polypeptide, a protein, genomic DNA, or cDNA.
The kit can further optionally include reagents for performing the assays described herein. For example, the kit can include buffers, solvents, stabilizers, preservatives, purification columns, detection reagents, and enzymes, which may be necessary for isolating nucleic acids from a patient sample, amplifying the samples, e.g., by qRT-PCR, and applying the samples to the agent described above; or for isolating proteins from a subject sample, and applying the samples to the agent described above; or reagents for directly applying the subject sample to the agent described above. A kit can also include positive and negative control samples, e.g., control nucleic acid samples (e.g., nucleic acid sample from a non-cancer subject, or a non-tumor tissue sample, or a subject who has not received treatment for cancer, or other test samples for testing at the same time as subject samples. A kit can also include instructional material, which may provide guidance for collecting and processing patient samples, applying the samples to the level of gene expression assay, and for interpreting assay results. The components of the kit can be provided in any form, e.g., liquid, dried, semi- dried, or in lyophilized form, or in a form for storage in a frozen condition. Typically, the components of the kit are provided in a form that is sterile. When reagents are provided in a liquid solution, the liquid solution generally is an aqueous solution, e.g., a sterile aqueous solution. When reagents are provided in a dried form, reconstitution generally is accomplished by the addition of a suitable solvent. The solvent, e.g., sterile buffer, can optionally be provided in the kit.
The kit can include one or more containers for the kit components in a concentration suitable for use in the level of gene expression assays or with instructions for dilution for use in the assay. The kit can contain separate containers, dividers or compartments for the assay components, and the informational material. For example, the positive and negative control samples can be contained in a bottle or vial, the clinically compatible classifier can be sealed in a sterile plastic wrapping, and the informational material can be contained in a plastic sleeve or packet. The kit can include a plurality (e.g., a pack) of individual containers, each containing one or more unit forms (e.g., for use with one assay) of an agent. The containers of the kits can be air tight and/or waterproof. The container can be labeled for use.
The kit can include informational material for performing and interpreting the assay. The kit can also provide guidance as to where to report the results of the assay, e.g., to a treatment center or healthcare provider. The kit can include forms for reporting the results of a gene activity assay described herein, and address and contact information regarding where to send such forms or other related information; or a URL (Uniform Resource Locator) address for reporting the results in an online database or an online application (e.g. , an app). In another embodiment, the informational material can include guidance regarding whether a patient should receive treatment with an anti-cancer stem cell agent, depending on the results of the assay.
The informational material of the kits is not limited in its form. In many cases, the informational material, e.g., instructions, is provided in printed matter, e.g., a printed text, drawing, and/or photograph, e.g., a label or printed sheet. However, the informational material can also be provided in other formats, such as computer readable material, video recording, or audio recording. The informational material of the kit can be contact information, e.g., a physical address, email address, website, or telephone number, where a user of the kit can obtain substantive information about the gene activity assay and/or its use in the methods described herein. The informational material can also be provided in any combination of formats.
A subject sample can be provided to an assay provider, e.g., a service provider (such as a third party facility) or a healthcare provider that evaluates the sample in an assay and provides a read out. For example, an assay provider can receive a sample from a subject, such as a tissue sample, or a plasma, blood or serum sample, and evaluate the sample using an assay described herein, and determines that the subject is a candidate to receive treatment with an inhibitor as described herein. The assay provider can inform a healthcare provider that the subject is a candidate for treatment with an inhibitor as described herein, and the candidate is administered the inhibitor as described herein. The assay provider can provide the results of the evaluation, and optionally, conclusions regarding one or more of diagnosis, prognosis, or appropriate therapy options to, for example, a healthcare provider, or patient, or an insurance company, in any suitable format, such as by mail or electronically, or through an online database. The information collected and provided by the assay provider can be stored in a database.
EXAMPLES
Example A
In this example, the enzymatic activity of glutaminase is measured through a coupled endpoint assay. Glutamine and phosphate are supplied to GAC at a
concentration equal to Km and AC50, respectively, and GAC concentration is adjusted to give a linear reaction for 60 minutes. The glutamate produced is converted to 2-OG by a kinetic excess of glutamate dehydrogenase. This second step is configured for 2X Km for NAD, since excess NAD is inhibitory. However, a kinetic excess of the third coupling enzyme, diaphorase, recycles NAD from NADH to keep the NAD concentration constant during the timecourse of the assay. Diaphorase, also supplied in kinetic excess, oxidizes NADH produced by GDH back to NAD with the concomitant reduction of rezasurin to the highly fluorescent resorufin. Resorufin in measured after the assay is stopped with SDS by Ex544/Em590. A reduction in the signal indicates inhibition of some component of the coupled enzyme system. Prospective hits are counterscreened against GDH/diaphorase alone to remove hits to the coupling enzyme system in a second assay.
1. Materials
BSA Sigma #3294 (protease-free)
diaphorase Worthington Enzyme LS004330. Resuspend at
10 mg/ml in ddH20 and store at -80C.
EDTA Sigma E6758 or equivalent
glutamate dehydrog Sigma G7882
glutamine Sigma G3126 or equivalent
HEPES (pH8.5) Sigma H3375 or equivalent, to pH 8.5 with NaOH
NaCl Sigma S7653 or equivalent
NAD Sigma N7004; note: power will decompose to
inhibitor if stored outside dessicator. Purchase
small lots and prepare stocks in solution and store at -80C. resazunn Sigma 199303
sodium dodecyl sulfate Sigma L4390 or equivalent
sodium phosphate(pH8.5) Prepare from Sigma monobasic (S8282) and
dibasic (S7907) solutions or equivalents; 1M
stock final concentration prepared from 1 M stocks of each of the dibasic and monobasic
solutions.
2. Buffers
2X Buffer (300 mM NaCl, 100 mM HEPES pH 8.5, 0.1% BSA, 0.5 mM EDTA, 100 mM sodium phosphate pH 8.5)
5X Substrate Mix (IX Buffer final concentration, with 13 mM glutamine, 100 μΜ resazurin, 50 μg/ml diaphorase)
1.2X Enzyme Mix (IX Buffer final concentration, with 0.875 μ^πύ GAC, 1.56 mM NAD, 6.25 units/ml GDH)
Stop Mix (6% SDS in dd¾0)
Reaction procedure
1. Add Ιμΐ compound in 100% DMSO
2. Add 40 μΐ of Enzyme Mix and incubate for 60 minute at room temperature
3. Add 10 μΐ of Substrate Mix to start reaction
4. Stop reaction with 25 μΐ of 6% SDS and read Ex544 Em 590
Example B:
In this example, the potential for a compound to inhibit the coupled enzyme assay system of the glutaminase HTS method, which comprises glutamate dehydrogenase and diaphorase, is tested through a coupled endpoint assay. Glutamate is supplied at Km to GDH, which then performs a reductive deamidation to produce 20G. NAD is supplied at 2X Km to the system, and its conversion to NADH is monitored by the activity of diaphorase. Diaphorase, supplied in large kinetic excess to GDH, converts NADH back to NAD to keep NAD levels constant in the reaction while at the same time reducing rezasurin to the highly fluorescent resorufin. Resorufin in measured after the assay is stopped with SDS by Ex544/Em590. A reduction in the signal indicates inhibition of some component of the coupled enzyme system.
3. Materials
BSA Sigma #3294 (protease-free)
diaphorase Worthington Enzyme LS004330. Resuspend at
10 mg/ml in ddH20 and store at -80C.
EDTA Sigma E6758 or equivalent
glutamate dehydrog Sigma G7882
glutamic acid Sigma G1251 or equivalent
HEPES (pH8.5) Sigma H3375 or equivalent, to pH 8.5 with
NaOH
NaCl Sigma S7653 or equivalent
NAD Sigma N7004; note: powder will decompose to inhibitor if stored outside dessicator. Purchase
small lots and prepare stocks in solution and store at -80C. resazunn Sigma 199303
sodium dodecyl sulfate Sigma L4390 or equivalent
4. Buffers
2X Buffer (300 mM NaCl, 100 mM HEPES pH 8.5, 0.1% BSA, 0.5 mM EDTA, 100 mM phosphate pH 8.5)
2X Substrate Mix (IX Buffer final concentration, 40 μΜ resazurin, 1.8 mM glutamate, 20 μg/ml diaphorase)
10X NAD Mix (IX Buffer final concentration, 12.5 mM NAD)
2.5X Enzyme Mix (IX Buffer final concentration, GDH enzyme as determined for appropriate linearity; for example 0.05 units/ml as described here to get 0.02 units/ml final concentration) Reaction procedure
1. Add Ιμΐ compound in 100% DMSO
2. Add 20 μΐ of Enzyme Mix and incubate for 60 minutes at room temperature
3. Add 5 μΐ of NAD Mix
4. Add 25 μΐ of Substrate Mix to start reaction
5. Stop reaction with 25 μΐ of 6% SDS and read Ex544 Em 590
Example 1
5,5'-(thiobis(ethane-2,l-di -thiadiazol-2-amine) (1-2):
A mixture of 3,3'-thiodipropanoic acid (1 equivalent) and thiosemicarbazide (2 equivalents) were taken in POCI3 (10 fold) and stirred at 90 °C for 3 h. The reaction mixture was cooled to room temperature and poured on to ice. The resulting mixture was filtered and then brought to pH 14 using KOH. The mixture was filtered, washed with water and dried to afford the desired product 1-2, whichwas used as such for the next step.
General procedure for the synthesis of compounds (1-3):
Diamine 1-2 (1 equivalent) was taken in DMF and cooled to 0 °C. PYBOP (3 equivalents) was then added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. The corresponding acid (3 equivalents) was added and the reaction mixture was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The mixture was filtered through Buchner funnel, washed with water and dried. The crude product was purified by standard methods to afford the desired products (1-3).
The following compound was synthesized by following the general procedure as described for 1-3:
N,N'-(5,5'-(thiobis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2-diyl))bis(2- cyclohexylacetamide) (
1H NMR (400 MHz, DMSO-d6) δ: 0.90 - 1.30 (m, 12H), 1.55 - 1.82 (m, 10H), 2.36 (t, 4H), 2.96 (t, 4H), 3.25 (t, 4H), 12.38 (brs, 2H); Mass (M++23): 559.30.
Example 2
Scheme 2
General procedure for the carbamate preparation (1-5)
Diamine 1-2 (1 equivalent) was taken in DCM and pyridine (2 equivalents) was added followed by the addition of corresponding chloroformate (3 equivalents) and stirred at room temperature for overnight. Progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the mixture and extracted with DCM. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by standard methods to afford the pure carbamate (1-5).
The following compounds were synthesized by following the general procedure as described for 1-5:
Diphenyl (5,5'-(thiobis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2-diyl))dicarbamate (1)
1H NMR (400 MHz, DMSO-d6) δ: 2.95 (t, 4H), 3.24 (t, 4H), 7.22-7.32 (m, 6H), 7.40-7.50 (m, 4H), 12.62 (s, 2H); Mass (M++23): 551.15.
Dicyclohexyl (5,5'-(thiobis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2-diyl))dicarbamate
(8)
1H NMR (400 MHz, DMSO-d6) δ: 1.22-1.55 (m, 12H), 1.65-1.78 (m, 4H), 1.82- 1.90 (m, 4H), 2.92 (t, 4H), 3.22 (t, 4H), 4.84-4.90 (m, 2H), 11.92 (s, 2H); Mass (M++l): 541.15.
Example 3
Scheme 4
1-2 1-6 l,lX5,5^(thiobis(ethane-2,l-diyl))^
phenylurea) (18)
Diamine 1-2 (1 equivalent) was taken in THF, cooled to -50 °C and LiHMDS (2 equivalents) was added to the mixture and stirred for 30 min. Methyl(phenyl)carbamic chloride (4 equivalents) in THF was then added to the reaction mixture and brought to room temperature and stirred overnight. The progress of the reaction was monitored by TLC. After completion of the reaction, reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by standard methods to afford the desired product 18.
1H NMR (400 MHz, DMSO-d6) δ: 2.85 (t, 4H), 3.15 (t, 4H), 3.28 (s, 6H), 7.22-7.30 (m, 6H), 7.34-7.40 (m, 4H); Mass (M++l): 555.25.
Example 4
Scheme 5
THF/Reflux/4 h * ^
5,5'-(thiobis(ethane-2,l-diyl))bis(N-phenethyl-l,3,4-thiadiazol-2-amine) (9):
N,N'-(5,5'-(thiobis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2-diyl))bis(2- phenylacetamide) 3 (1 equivalent) in THF was added to a stirred suspension of LiALH4 (2.5 equivalents) in THF at 0 °C and refluxed for 4 h. The progress of the reaction was monitored by LCMS. The reaction was quenched by careful addition of saturated NH4C1 solution followed by ethyl acetate and obtained material which was filtered through a pad of celite. The celite layer was further washed with ethyl acetate. The filtrate obtained was evaporated under reduced pressure and purified by standard methods to afford 9.
1H NMR (400 MHz, DMSO-d6+TFA) δ: 2.84 (q, 8H), 3.08 (t, 4H), 3.48 (q, 4H), 7.19-7.36 (m, 10H), 7.66 (m, 2H); Mass (M++23): 519.15.
Example 5
Scheme 7
General procedure for the synthesis of compounds (1-13):
Corresponding sulfide analogue (1 equivalent) was taken in THF, m-CPBA (0.9 equivalents) in THF:H20 (6: 1) was added drop wise at 0 °C and stirred at same
temperature for 10 min. The progress of the reaction was monitored by TLC. After completion of the reaction, reaction mixture was quenched with aq. NaHC03 solution and solvent was evaporated to dryness. Water was added to the residue, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by standard methods to afford the desired products (1-13). The following compounds were synthesized by following the general procedure as described for 1-13:
N,N'-(5,5^(sulfinylbis(ethane- acetamide) (7):
1H NMR (400 MHz, DMSO-d6) δ: 3.18 (t, 2H), 3.20-3.40 (m, 6H), 3.80 (s, 4H), 7.20-7.38 (m, 10H), 12.62 (brs, 2H); Mass (M++l): 541.20.
N,N'-(5,5^(sulfinylbis(ethane-2,l-diyl))bis(13,4 hiadiazole-5,2-diyl))bis(2-(pyri^ 2-yl)acetamide) (17):
1H NMR (400 MHz, DMSO-d6) δ: 3.18 (t, 4H), 3.30-3.42 (m, 4H), 4.00 (s, 4H), 7.26 (t, 2H), 7.40 (d, 2H), 7.78 (t, 2H), 8.48-8.52 (m, 2H); Mass (M++l): 543.10.
Example 6
Scheme 8
RCH2C02H/PYBOP/DIPEA
DMF/RT/Overnight
1-17
3,3'-sulfonyldipropanoic acid (1-14): O o
HO' ΌΗ
3,3'-thiodipropanoic acid (1 equivalent) was taken in THF and to it oxone (2 equivalents) taken in water was slowly added and stirred at room temperature for 3 h. The progress of the reaction was monitored by TLC. After completion of the reaction, water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness to afford the crude product 1-14.
5,5'-(sulfonylbis(ethane-2,l-diyl))bis(l,3,4-thiadiazol-2-amine) (1-15):
3,3'-sulfonyldipropanoic acid (1 equivalent) and thiosemicarbazide (2
equivalents) were taken in PPA and refluxed for overnight. The reaction mixture was then cooled to room temperature. The pH of the reaction mixture was adjusted to 14 using aq. KOH solution, stirred for 30 min and filtered. The material obtained was triturated with diethyl ether and dried to afford the title compound 1-15.
General procedure for the synthesis of compounds (1-16):
Diamine 1-16 (1 equivalent) was taken in DMF cooled to 0 °C and PYBOP (3 equivalents) was added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. Corresponding acid (3 equivalents) was then added to the reaction mixture and stirred at room temperature for overnight. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The mixture was filtered through Buchner funnel and dried. The crude product was purified by standard methods to obtain the desired compounds (1-16). The following compounds were synthesized by following the general procedure as described for 1-16:
N,N'-(5,5^(sulfonylbis(ethane- phenylacetamide) (4):
1H NMR (400 MHz, DMSO-d6) δ: 3.45 (t, 4H), 3.70 (t, 4H), 3.80 (s, 4H), 7.20 7.38 (m, 10H), 12.75 (s, 2H); Mass (M++l): 557.1.
N,N'-(5,5^(sulfonylbis(ethane-2,l-diyl))bis(13,4 hiadiazole-5,2-diyl))bis(2-(pyrM yl)acetamide) (13):
1H NMR (400 MHz, DMSO-d6) δ: 3.45 (t, 4H), 3.68 (t, 4H), 4.00 (s, 4H), 7.25 (t, 2H), 7.40 (d, 2H), 7.78 (t, 2H), 8.50 (s, 2H) 12.75 (s, 2H); Mass (M++l): 559.15.
N,N'-(5,5^(sulfonylbis(ethane-2,l-diyl))bis(13,4 hiadiazole-5,2-diyl))bis(2-(pyrid yl)acetamide) (14):
1H NMR (400 MHz, DMSO-d6) δ: 3.42 (t, 4H), 3.68 (t, 4H), 3.88 (s, 4H), 7.38 (t, 2H), 7.76 (d, 2H), 8.42-8.55 (m, 4H), 12.78 (brs, 2H); Mass (M++l): 559.1. N,N^(5,5^(2,2^sulfonylbis(ethane-2,l-diyl))bis(13,4 hiadiazole-5,2-diyl))bis(3- phenylpropanamide) (21
1H NMR (400 MHz, DMSO-d6) δ: 2.80 (t, 4H), 2.95 (t, 4H), 3.45 (t, 4H), 3.70 (t, 4H), 7.10 - 7.32 (m, 10H), 12.5 (brs, 2H); Mass (M++l): 585.3.
General procedure for the carbamate preparation (1-17)
5,5'-(sulfonylbis(ethane-2,l-diyl))bis(l,3,4-thiadiazol-2-amine) (1 equivalent) was taken in DCM, and to it was added pyridine (2 equivalents) followed by the addition of corresponding chloroformate (2 equivalents) and stirred at room temperature for overnight. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and extracted with DCM. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated to dryness. The crude product was purified by standard methods to afford the desired compounds (1-17).
The following compounds were synthesized by following the general procedure as described for 1-17:
Diisopropyl (5,5'-(sulfonylbis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2- diyl))dicarbamate (23):
1H NMR (400 MHz, DMSO-d6) δ: 1.25 (d, 12H), 3.42 (t, 4H), 3.65 (t, 4H), 4.88- 4.98 (m, 2H), 12.00 (s, 2H); Mass (M++l): 493.10. Diisobutyl (5,5'-(sulfonylbis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2- diyl))dicarbamate (22):
1H NMR (400 MHz, DMSO-d6) δ: 0.90 (d, 12H), 1.85-1.98 (m, 2H), 3.42 (t, 4H), 3.65 (t, 4H), 3.98 (d, 4H), 12.10 (s, 2H); Mass (M++l): 521.00.
Example 7
General procedure for the synthesis of compounds (1-19):
Appropriate carbamate (1 equivalent) was taken in acetone, and to it oxone (2.5 equivalents) taken in water was added slowly and stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC. After completion of the reaction, acetone was evaporated under reduced pressure. Water was added to the reaction mixture and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and evaporated to dryness. The crude was purified by standard methods to afford the desired products (1-19).
The following compounds were synthesized by following the general procedure as described for 1-19:
Dibenzyl (5,5'-(sulfonylbis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2-diyl))dicarbamate (19):
1H NMR (400 MHz, DMSO-d6) δ: 3.45 (t, 4H), 3.70 (t, 4H), 5.24 (s, 4H), 7.34-7.44 (m, 10H), 12.22 (s, 2H); Mass (M++l): 589.1.
Di-tert-butyl (5,5'-(sulfonylbis(ethane-2,l-diyl))bis(l,3,4-thiadiazole-5,2- diyl))dicarbamate (15):
1H NMR (400 MHz, DMSO-d6) δ: 1.45 (s, 18H), 3.45 (t, 4H), 3.70 (t, 4H), 11.82 (s, 2H); Mass (M++l): 521.15.
Example 8
(pentane-l,5-diyl)bis(l -thiadiazol-2-amine) (1-50) :
The title compound was synthesized from pimelic acid 1-49 following the general procedure described for compound 1-2.
General procedure for the synthesis of compounds (1-51):
Diamine 1-50 (1 equivalent) was taken in DMF and cooled to 0 °C. PYBOP (3 equivalents) was then added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. The corresponding acid (3 equivalents) was added and the reaction mixture and was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The reaction mixture was worked up and purified by standard methods to afford the desired products (1-51).
The following compounds were synthesized by following the general procedure as described for 1-51:
N,N'-(5,5'-(pentane-l,5-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-phenylacetamide) (2):
1H NMR (400 MHz, DMSO-d6) δ: 1.40 (t, 2H), 1.70 (t, 4H), 2.94 (t, 4H), 3.80 (s, 4H), 7.22-7.40 (m, 10H), 12.64 (s, 2H); Mass (M++l): 507.25.
N,N'-(5,5'-(pentane-l,5-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(pyridin-3- yl)acetamide) (10):
1H NMR (400 MHz, DMSO-d6) δ: 1.36 (t, 2H), 1.70 (m, 4H), 2.96 (t, 4H), 3.92 (s, 4H), 7.50 (t, 2H), 7.90 (d, 2H), 8.50-8.60 (m, 4H), 12.70 (s, 2H); Mass (M++23): 531.25.
N,N'-(5,5'-(pentane-l,5-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(pyridin-2- yl)acetamide) (11):
1H NMR (400 MHz, DMSO-d6) δ: 1.43 (t, 2H), 1.72 (m, 4H), 2.99 (t, 4H), 4.0 (s, 4H), 7.26 (t, 2H), 7.40 (d, 2H), 7.80 (t, 2H), 8.50 (d, 2H), 12.65 (s, 2H); Mass (M++23): 531.10.
N,N'-(5,5'-(pentane-l,5-diyl)bis(l,3,4-thiad^^
(20):
1H NMR (400 MHz, DMSO-d6) δ: 1.40 (t, 2H), 1.74 (t, 4H), 2.80 (t, 4H), 2.88 - 3.0 (m, 8H), 7.15 - 7.34 (m, 10H), 12.40 (brs, 2H); Mass (M++l): 535.05.
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(lH-pyrrolo[3,2- b]pyridin-3-yl)acetamide) (127):
1H NMR (500 MHz, DMSO-d6) δ: 1.75 (m, 4H), 3.00 (m, 4H), 3.98 (s, 4H), 7.10- 7.13 (m, 2H), 7.60 (d, 2H), 7.76-7.77 (m, 2H), 8.30-8.32 (m, 2H), 11.22 (s, 2H), 11.82 (s, 2H); Mass (M++l): 573.2 N,N'-(5,5^(butane-l,4-diyl)bis(13,4-thiadiazole-5,2-diyl))bis(2-(lH-indazol-3- yl)acetamide) (126
1H NMR (500 MHz, DMSO-d6) δ: 12.88 (s, 2H), 7.74-7.76 (d, 2H), 7.48-7.49 (d, 2H), 7.32-7.35 (t, 2H), 7.07-7.09 (t, 2H), 4.14 (s, 4H), 2.98 (s, 4H), 1.73 (s, 4H); Mass (M+l): 573.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(lH-pyrrolo[2,3- c]pyridin-3-yl)acetamide) (125):
1H NMR (500 MHz, DMSO-d6) δ: 12.51-12.61 (m, 2H), 11.45-11.48 (d, 2H),
8.68- 8.72 (d, 2H), 8.09-8.12 (d, 2H), 7.53-7.56 (t, 4H), 3.91 (s, 4H), 2.98-3.02 (t, 4H),
1.69- 1.74 (d, 4H). Mass (M+l): 573.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(lH-pyrrolo[3,2- c]pyridin-3-yl)ace mide) (124):
1H NMR (500 MHz, DMSO-d6) δ: 12.66 (s, 2H), 11.41 (s, 2H), 8.86 (s, 2H), 8.15-8.16 (d, 2H), 7.35-7.37 (t, 4H), 3.96 (s, 4H), 2.99 (s, 4H), 1.74 (s, 4H). Mass (M+1): 573.2
N,N'-(5,5^(butane-l,4-diyl)bis(13,4 hiadiazole-5,2-diyl))bis(2-(lH-indol-4- yl)acetamide) (123):
1H NMR (500 MHz, DMSO-d6) δ: 1.73 (m, 4H), 2.98 (m, 4H), 4.00 (s, 4H), 6.54 (s, 2H), 6.94 (d, 2H), 7.04 (t, 2H), 7.30-7.33 (m, 4H), 11.13 (s, 2H), 12.55 (s, 2H); Mass (M++l): 571.3
N,N'-(5,5^(butane-l,4-diyl)bis(13,4 hiadiazole-5,2-diyl))bis(2-(l-methyl-lH-inda 3-yl)acetamide) (122
1H NMR (500 MHz, DMSO-d6) δ: 1.74 (m, 4H), 3.00 (m, 4H), 4.00 (s, 6H), 4.15 (s, 4H), 7.12 (t, 2H), 7.40 (t, 2H), 7.59 (d, 2H), 7.76 (d, 2H); Mass (M++l): 601.3
N,N'-(5,5^(butane-l,4-diyl)bis(13,4 hiadiazole-5,2-diyl))bis(2-(l-methyl-lH-indo 3-yl)acetamide) (130):
1H NMR (500 MHz, DMSO-d6) δ: 1.72 (t, 4H), 2.98 (t, 4H), 3.75 (s, 6H), 3.88 (s, 4H), 7.02 (t, 2H), 7.14 (t, 2H), 7.26 (s, 2H), 7.39 (d, 2H), 7.57 (d, 2H), 12.61 (s, 2H); Mass (M++l): 599.3
Example 9
Scheme 17
Ethyl 5-(5-amino-l,3,4-thiadiazol-2-yl)pentanoate (1-70): A mixture of 6-ethoxy-6-oxohexanoic acid (1.0 equivalent) and thiosemicarbazide (1.0 equivalents) were taken in POCI3 (3.3 equivalents) and stirred at 80 °C for 3 h. The reaction mixture was cooled to room temperature and poured on to ice. The resulting mixture was filtered and then brought to pH 8 using KOH. The resulting material was washed with water and dried to afford the desired product (1-70). This material was used as such for the next step.
General procedure for the synthesis of compounds (1-71):
To a solution of ethyl 5-(5-amino-l,3,4-thiadiazol-2-yl)pentanoate (1 equivalent) and TEA (3 equivalents) in DCM was then added the corresponding chloride (1.2 equivalents) and stirred at room temperature overnight. The resulting mixture was concentrated in vacuo, quenched with water, filtered, washed with water and dried to afford the desired products (1-71).
General procedure for the synthesis of compounds (1-72):
To a solution of compounds (1-71) (1 equivalent) in MeOH/THF was then added LiOH (2 equivalents, 4N) and stirred at 40°C for 1 hour. The resulting mixture was concentrated in vacuo, adjusted pH to 3-4, filtered and dried to afford the desired products (1-72).
General procedure for the synthesis of compounds (1-73):
A mixture of compounds (1-72) (1.0 equivalent) and thiosemicarbazide (1.0 equivalents) were taken in POCl3 (3.3 equivalents) and stirred at 80 °C for 3 h. The reaction mixture was cooled to room temperature and poured on to ice. The resulting mixture was filtered and then brought to pH 8 using KOH. The resulting mixture was washed with water and dried to afford the desired products (1-73), which were used as such for the next step.
General procedure for the synthesis of compounds (1-74):
A mixture of compound (1-73) (1 equivalent), the corresponding acid (1.2 equivalents), HATU (1.5 equivalents) and DIPEA (2.0 equivalents) was stirred at room temperature overnight. The resulting mixture was purified by standard procedures to afford the desired products.
The following compounds were synthesized by following the general procedure as described for 1-74:
N-(5-(4-(5-acetamido-l,3,4-thiadiazol-2-yl)butyl)-l,3,4-thiadiazol-2-yl)-2-methyl-lH- benzo[d]imidazole-5-carboxamide (128):
1H NMR (500 MHz, DMSO-d6) δ: 1.81(s, 4H), 2.15(s, 3H), 2.54 (s, 3H), 3.04-3.06(m, 4H), 7.52-7.61 (m, IH), 7.90-7.94(t, IH), 8.24-8.37 (d, IH), 12.39 (s, IH),; 12.56-12.64 (d, IH), 12.80 (s, IH); Mass (M++H): 457.1
N-(5-(4-(5-acetamido-l,3,4-thiadiazol-2-yl)butyl)-l,3,4-thiadiazol-2-yl)-2-(5- methoxy-lH-indol-3-yl)acetamide (129):
1H NMR (500 MHz, DMSO-d6) δ: 1.74 (s, 4H), 2.15 (s, 3H), 2.98 (t, 4H), 3.74 (s, 3H), 3.84 (s, 2H) , 6.71-6.74 (m, IH), 7.08 (d, IH) 7.23-7.25 (d, 2H), 10.82 (s, IH); Mass (M++H): 486.1
N-(5-(4-(5-acetamido-l,3,4-thiadiazol-2-yl)butyl)-l,3,4-thiadiazol-2-yl)-2-(3,4- dimethoxyphenyl)acetamide (118):
1H NMR (500 MHz, DMSO-d6) δ: 1.73-1.76 (m, 4H), 2.15 (s, 3H), 3.00 (d, 4H), 3.72 (t, 8H), 6.82-6.94 (m, 3H), 12.39 (s, IH), 12.60 (s, IH); Mass (M++H): 477.2 N-(5-(4-(5-acetamido-l,3,4-thiadiazol-2-yl)butyl)-l,3,4-thiadiazol-2-yl)-2- phenylacetamide (131):
1H NMR (500 MHz, DMSO-d6) δ: 1.75 (t, 4H), 2.15 (s, 3H), 3.07 (t, 4H), 3.79 (s, 2H), 7.32-7.33 (m, 5H), 12.5 (s, 2H); Mass (M++H): 417.1
Example 10
Scheme 18
RCH2C02H/PYBOP/
DIPEA
DMF/RT/Overnig t
1-61
Octanedioic acid (1-59):
10% Palladium on carbon (10% wt) was added to a solution of oct-4-ynedioic acid 1-56 in ethanol. The mixture was degassed with argon and then stirred under an atmosphere of H2 for 14 h. The mixture was filtered through celite and concentrated to afford octanedioic acid. 5,5'-(hexane-l,6-diyl)bis(l, -thiadiazol-2-amine) (1-60):
The title compound was synthesized from octanedioic acid 1-59 and
thiosemicarbazide by following the general procedure as described for compound 1-2.
Compounds 1-61 were synthesized by following the general procedure as described for 1-3.
N,N'-(5,5'-(hexane-l, -diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-phenylacetamide) (12):
The title compound was synthesized from 5,5'-(hexane-l,6-diyl)bis(l,3,4- thiadiazol-2-amine) 1-60 by following the general procedure as described for compound 1-61.
1H NMR (400 MHz, DMSO-d6) δ: 1.36 (t, 4H), 1.64 (t, 4H), 2.94 (t, 4H), 3.89 (s, 4H), 7.20-7.36 (m, 10H), 12.62 (s, 2H); Mass (M++23): 543.10.
N,N'-(5,5'-(hexane-l,6-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(pyridin-2- yl)acetamide) (16):
The title compound was synthesized from 5,5'-(hexane-l,6-diyl)bis(l,3,4- thiadiazol-2-amine) 1-60 by following the general procedure as described for compound 1-61.
1H NMR (400 MHz, DMSO-d6) δ: 1.38 (t, 4H), 1.70 (t, 4H), 2.95 (t, 4H), 4.0 (s, 4H), 7.30 (t, 2H), 7.41 (d, 2H), 7.78 (t, 2H), 8.50 (d, 2H), 12.68 (s, 2H); Mass (M++23): 545.20.
Example 11
Scheme 19
Λ
EtoA^^s ^AOEt U
°CI
I-80 1-81
4-((carboxymethyl)thio)butanoic acid (1-81):
Ethyl 4-((2-ethoxy-2-oxoethyl)thio)butanoate 1-80 was taken in 50% aq. HC1 and refluxed for 1 h. The progress of the reaction was monitored by TLC. After completion of the reaction, reaction mixture was brought to room temperature and concentrated under reduced pressure. The resulting material was triturated with diethyl ether, filtered and dried to afford the desired product 1-81.
1H NMR (400 MHz, DMSO-d6) δ: 1.9-2.0 (m, 2H), 2.4-2.5 (t, 2H), 2.8-2.9 (t, 2H), 3.2-3.3 (t, 2H), 11.0 (br s, 2H). 5-(3-(((5-amino-13,4-thiadiazol-2-yl)methyl)thio)propyl)-l,3,4-thiadiazol-2-amin^ (1-82):
The title compound was synthesized from 4-((carboxymethyl)thio)butanoic acid
1- 81 by following the general procedure as described for 1-2.
1H NMR (400 MHz, DMSO-d6) δ: 1.9-2.0 (m, 2H), 2.5-2.6 (t, 2H), 2.8-2.9 (t, 2H), 3.9 (s, 2H), 7.0 (br s, 2H), 7.1 (br s, 2H).
2- Phenyl-N-(5-(3-(((5-(2-phenylacetamido)-l,3,4-thiadiazol-2- yl)methyl)thio)propyl)-l -thiadiazol-2-yl)acetamide (6):
The title compound was synthesized from 5-(3-(((5-amino-l,3,4-thiadiazol-2- yl)methyl) thio)propyl)-l,3,4-thiadiazol-2-amine 1-82 by following the general procedure as described for 1-3.
1H NMR (400 MHz, DMSO-d6) δ: 1.95 (t, 2H), 2.58 (t, 2H), 3.0 (t, 2H), 3.80 (s, 4H), 4.12 (s, 2H), 7.20 - 7.40 (m, 10H), 12.70 (d, 2H); Mass (M++l) 524.85
Example 12
Scheme 21
1-95
26
5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazol-2-amine) (1-95):
A mixture of glutaric acid (1 equivalent) and thiosemicarbazide (2 equivalents) were taken in POCl3 (10 fold) and stirred at 90 °C for 3 h. The reaction mixture was cooled to room temperature and poured on to ice. The resulting mixture was filtered and then brought to pH 14 using KOH. The resulting material was filtered, washed with water and dried to afford the desired product 1-95. This material was used as such for the next step.
N,N'-(5,5^(propane-l,3-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(pyridin-3- yl)acetamide) (26):
Diamine 1-95 (1 equivalent) was taken in DMF and cooled to 0 °C. HATU (2.5 equivalents) was then added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. The corresponding acid (2.5 equivalents) was added and the reaction mixture was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The resulting mixture was purified by standard methods to afford the desired product (26).
1H NMR (500 MHz, DMSO-d6) δ: 2.094 - 2.152 (m, 2H), 3.030 - 3.059 (t, 4H), 3.865 (s, 4H), 7.348-7.736 (m, 2H), 8.468-8.512 (m, 2H), 12.719 (brs, 2H); Mass (M++l): 481.2
Example 13
Scheme 22
5 (E)-5,5'-(but-2-ene-l,4-diyl)b -thiadiazol-2-amine) (1-96):
A mixture of (E)-hex-3-enedioic acid (1 equivalent) and thiosemicarbazide (2 equivalents) were taken in POCl3 (10 fold) and stirred at 90 °C for 3 h. The reaction mixture was cooled to room temperature and poured on to ice. The resulting mixture was filtered and then brought to pH 14 using KOH. The reaction mixture was filtered, washed with water and dried to afford the desired product 1-96. This material was used as such for the next step.
(E)-N,N'-(5,5^(but-2-ene-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(pyridin-3- yl)acetamide) (27):
Diamine 1-96 (1 equivalent) was taken in DMF and cooled to 0 °C. HATU (2.5 equivalents) was then added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. The corresponding acid (2.5 equivalents) was added and the reaction mixture was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The reaction mixture was worked up and purified by standard methods to afford the desired product (27).
1H NMR (500 MHz, DMSO-d6) δ: 3.744 - 3.753 (d, 4H), 3.855 (s, 4H), 5.851- 5.856 (t, 2H), 7.350-7.375 (m, 2H), 7.719-7.734 (m, 2H), 8.473-8.509(m,4H), 12.664 (brs, 2H); Mass (M++l): 493.1
N,N'-(5,5^(butane-l,4-diyl)bis(13,4 hiadiazole-5,2-diyl))bis(2-(pyridin-3- yl)acetamide) (28):
Compound (27) (1 equivalent) was taken in MeOH. Filled the system with hydrogen and added Pd/C (0.1 equivalents) was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, The crude product was purified by standard methods to afford the desired product (28).
1H NMR (500 MHz, DMSO-d6) δ: 1.70 - 1.80 (m, 4H), 2.97 - 3.03 (m, 4H), 3.86 (s, 4H), 7.352-7.736 (m, 2H), 8.474-8.514 (m, 2H), 12.664 (brs, 2H); Mass (M++l): 495.2 Example 14
Scheme 23
Method B: RC02R'
I-97 CH3ONa/DMF/1 h 1-98
MW, 100°C
5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazol-2-amine) (1-97):
A mixture of adipic acid (1 equivalent) and thiosemicarbazide (2 equivalents) were taken in POCI3 (10 fold) and stirred at 90°C for 3 h. The reaction mixture was cooled to room temperature and poured on to ice. The resulting mixture was filtered and then brought to pH 14 using KOH. The mixture was filtered, washed with water and dried to afford the desired product 1-97, which was used as such for the next step.
General procedure for the synthesis of compounds (1-98):
Method A: Diamine 1-97 (1 equivalent) was taken in DMF and cooled to 0 °C. HATU (3 equivalents) was then added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. The corresponding acid (3 equivalents) was added and the reaction mixture was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The mixture was worked up and purified by standard methods to afford the desired products (1-98).
Method B: The mixture of Diamine 1-97 (1 equivalent), RCOOR' (4 equivalent), CH30Na (4 equivalent) in DMF in the sealed vial which was irradiated in the micromave reactor on a Biotage Smith Synthesis at 100°C for lh. The reaction was monitored by LCMS. After completion of the reaction, the crude product was purified by standard methods to afford the desired products (1-98).
The following compounds were synthesized by following the general procedure as described for 1-98:
N,N'-(5,5'-(pentane-l,5-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-phenylacetamide) (37):
1H NMR (500 MHz, DMSO-d6) δ: 1.75 (t, 4H), 3.00 (t, 4H), 3.80 (s, 4H), 7.25- 7.28 (m, 2H), 7.30-7.34 (m, 8H), 12.64 (s, 2H); Mass (M++l): 493.1
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(4- hydroxyphenyl)acetamide) (38):
H
1H NMR (500 MHz, DMSO-d6) δ: 1.74 (t, 4H), 2.97 (t, 4H), 3.62 (s, 4H), 6.68 (d, 4H), 7.08 (d, 4H); Mass (M++l): 525.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(5-oxo-5- phenylpentanamide) (40):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (t, 4H), 1.92-1.98 (m, 4H), 2.54-2.57 (m, 4H), 3.02 (t, 4H), 3.10 (t, 4H), 7.52 (t, 4H), 7.63 (t, 2H), 7.96(d, 4H), 12.40 (s, 2H); Mass (M++l): 605.3
N,N'-(5,5^(butane-l,4-diyl)bis(13,4 hiadiazole-5,2-diyl))bis(2-(3-methylisox yl)acetamide) (42):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (t, 4H), 2.22(s, 6H), 3.03 (t, 4H), 4.07 (s, 4H), 6.30 (s, 2H), 12.77 (s, 2H); Mass (M++l): 503.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(6-methoxy-3-oxo- 2,3-dihydro-lH-inden-l-yl)acetamide) (43):
1H NMR (500 MHz, DMSO-d6) δ: 1.78 (t, 4H), 2.37(d, IH), 2.40(d, IH), 2.69(d, IH), 2.72(d, IH), 2.82(d, IH), 2.86(d, IH), 3.03 (t, 4H), 3.12(d, IH), 3.15(d, IH), 3.74- 3.78 (m, 2H), 3.84 (s, 6H), 6.99(d, IH), 7.00(d, IH), 7.18(d, 2H), 7.56(s, IH), 7.58(s, IH), 12.50 (s, 2H); Mass (M++l): 661.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(2- hydroxyphenyl)propanamide) (45):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (t, 4H), 2.71 (t, 4H), 2.84 (t, 4H), 3.01 (t, 4H), 6.69 (t, 2H), 6.77 (d, 2H), 7.00 (t, 2H), 7.04 (d, 2H); Mass (M++l): 553.3
Di-tert-butyl 2,2'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2- diyl))bis(azanediyl)bis(2-oxoethane-2,l-diyl)bis(methylcarbamate) (46):
1H NMR (500 MHz, DMSO-d6) δ: 1.29 (s, 9H), 1.41 (s, 9H), 1.78 (t, 4H), 2.86 (s, 3H), 2.88 (s, 3H), 3.03 (t, 4H), 4.09 (s, 2H), 4.12 (s, 2H), 12.51 (s, 2H); Mass (M++l): 599.3
N,N'-(5,5^(butane-l,4-diyl)bis(13,4-thiadiazole-5,2-diyl))bis(2-(pyridin-2- yl)acetamide) (47):
1H NMR (500 MHz, DMSO-d6) δ: 1.76 (t, 4H), 3.00 (t, 4H), 3.99 (s, 4H), 7.27 (d, IH), 7.28 (d, IH), 7.38 (s, IH), 7.40 (s, IH), 7.76 (t, 2H), 8.48 (d, 2H); Mass (M++l): 495.1
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(3-(furan-2- yl)propanamide) (4
1H NMR (500 MHz, DMSO-d6) δ: 1.76 (t, 4H), 2.79 (t, 4H), 2.94 (t, 4H), 3.01 (t, 4H), 6.10 (d, 2H), 6.34 (s, 2H), 7.51 (s, 2H), 12.46 (s, 2H); Mass (M++l): 501.2
N,N'-(5,5^(butane-l,4-diyl)bis(13,4 hiadiazole-5,2-diyl))bis(2-(4-(l-oxoisoindolm yl)phenyl)propanamide) (50):
1H NMR (500 MHz, DMSO-d6) δ: 1.45-1.45 (d,6H), 1.73 (s,4H),2.99 (s,4H),4.01-4.02 (d,2H) 5.00 (s,4H), 7.42-7.43 (d,4H), 7.53-7.56 (m,2H), 7.65-7.68 (t,4H), 7.86-7.87 (d,4H),12.61(s,2H); Mass (M++l): 783.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(naphthalen-l- yl)acetamide) (51)
1H NMR (500 MHz, DMSO-d6) δ: 1.72 (t, 4H), 2.98 (t, 4H), 4.30 (s, 4H), 7.48- 7.54 (m, 8H), 7.86 (d, 2H), 7.94 (d, 2H), 8.05 (d, 2H), 12.82 (s, 2H); Mass (M++l): 593.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(4- chlorophenyl)propanamide) (52):
I
1H NMR (500 MHz, DMSO-d6) δ: 1.43 (s, 3H), 1.45 (s, 3H), 1.74 (t, 4H), 3.00 (t, 4H), 3.99-4.04 (m, 2H), 7.38-7.42 (m, 8H), 12.64 (s, 2H); Mass (M++l): 589.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(3-(3- methoxyphenyl)propanamide) (53):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (t, 4H), 2.77 (t, 4H), 2.89 (t, 4H), 3.01 (t, 4H), 3.72 (s, 6H), 6.74-6.80 (m, 6H), 7.19 (t, 2 H), 12.41 (s, 2H); Mass (M++l): 581.3
N,N'-(5,5^(butane-l,4-diyl)bis(13,4 hiadiazole-5,2-diyl))bis(3-(pyridin-3- yl)propanamide) (54):
1H NMR (500 MHz, DMSO-d6) δ: 1.76 (s,4H),2.79-2.82 (t,4H),2.93- 3.01(m,8H),7.30-7.32 (m,2H),7.65-7.66(d,2H),8.40-8.46 (t,4H),12.43 (s,2H); Mass (M++l): 523.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(benzo[d][l,3]dioxol- 5-yl)acetamide) (55
1H NMR (500 MHz, DMSO-d6) 5: 1.74 (s,4H),3.00 (s,4H),3.69 (s,4H),5.98 (s,4H),6.76-6.89 (m,6H),12.58 (s,2H); Mass (M++l): 581.7 N,N'-(5,5^(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(benzo[d]isoxazol-3- yl)acetamide) (60):
1H NMR (500 MHz, DMSO-d6) 5: 1.75 (s,4H),3.01 (s,4H),4.34 (s,4H),7.39-7.42 (t,2H),7.65-7.68 (t,2H),7.51-7.76 (d,2H),7.87-7.89(d,2H), 12.94 (d,2H); Mass (M++l): 575.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(5-methoxy-lH- indol-3-yl)acetamide) (61):
1H NMR (500 MHz, DMSO-d6) δ: 1.73-1.75 (d,4H),2.97 (s,4H),3.72-3.73 (d,6H),3.82 (d,4H),6.71-6.73 (m,2H), 7.08 (s,2H),7.23-7.24 (d,4H),10.80(s,2H),12.66 (s,2H); Mass (M++l): 631.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-methyl-4-oxo-4- phenylbutanamide) (62):
1H NMR (500 MHz, DMSO-d6) δ: 1.21 (s, 3H), 1.22 (s, 3H), 1.76 (t, 4H), 3.01 (t, 4H), 3.20-3.24 (m, 4H), 3.52-3.58 (m, 2 H), 7.53 (t, 4H), 7.65 (t, 2H), 7.98 (d, 4H), 12.54 (s, 2H); Mass (M++l): 605.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(3,4- dimethoxyphenyl)acetamide) (63):
1H NMR (500 MHz, DMSO-d6) δ: 1.74 (t, 4H), 2.98 (t, 4H), 3.69 (s, 4H), 3.72 (s, 6H), 3.74 (s, 6H), 6.82 (d, IH), 6.83 (d, IH), 6.88 (s, IH), 6.90 (s, IH), 6.93 (d, 2 H), 12.59 (s, 2H); Mass (M++l): 613.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))dicyclopent-3- enecarboxamide (64):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (t, 4H), 2.52-2.57 (m, 6H), 2.61-2.66 (m, 4H), 3.00 (t, 4H), 5.67 (s, 4H), 12.43 (s, 2H); Mass (M++l): 445.2
Diethyl 4,4'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(azanediyl)bis(4- oxobutanoate) (66)
1H NMR (500 MHz, DMSO-d6) 5: 1.14-1.17 (t,6H),1.76 (s,4H),2.61-2.64
(t,4H),2.71-2.73 (t,4H),3.01 (s,4H),4.02-4.07 (m,4H),12.46 (s,2H); Mass (M++l): 513.7 N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(lH-tetrazol-5- yl)acetamide) (71):
1H NMR (500 MHz, DMSO-d6) 5: 1.77 (s,4H),3.02 (s,4H),3.97 (s,4H); Mass (M++l): 477.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(6-oxoheptanamide) (72):
1H NMR (500 MHz, DMSO-d6) 5: 1.43-1.49 (m, 4H), 1.52-1.57 (m, 4H), 1.76 (t, 4H), 2.07 (s, 6H), 2.45 (t, 8H), 3.01 (t, 4H), 12.36 (s, 2H); Mass (M++l): 509.3 N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(2- methoxyphenyl)acetamide) (132):
1H NMR (500 MHz, DMSO-d6) 5: 1.77 (s,4H),3.03 (s,4H),3.79 (s,6H),4.86 (s,4H),6.86-7.02 (m,8H),12.59 (s,2H); Mass (M++l): 585.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(4-(4- methoxyphenyl)butanamide) (75):
1H NMR (500 MHz, DMSO-d6) δ: 1.76 (s,4H) 1.84-1.87(t,4H),2.43-2.46
(t,4H),2.51-2.54 (m,4H), 3.00-3.01 (d,4H),3.71 (s,6H),6.82-6.84(d,4H),7.10-7.11 (d,4H), 12.35 (s,2H); Mass (M++l): 609.7
Diethyl 5,5'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(azanediyl)bis(5- oxopentanoate) (76):
1H NMR (500 MHz, DMSO-d6) 5: 1.16-1.18 (d,6H),1.76 (s,4H), 1.80- 1.86 (m,4H),2.32-2.35 (t,4H),2.48 (s,4H),3.01 (s,4H),4.02-4.06 (m,4H),13.39 (s,2H); Mass (M++l): 541.7
N,N'-(5,5^(butane-l,4-diyl)bis^
yl)acetamide) (78):
1H NMR (500 MHz, DMSO-d6) 5: 1.74 (s,4H),3.01 (s,4H),3.89 (s,4H),7.49-7.50 (d,2H),7.79-7.81 (m,2H),8.34 (d,2H),12.70(s,2H); Mass (M++l):584.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(4- cyclohexylbutanamide) (80):
1H NMR (500 MHz, DMSO-d6) 5:0.8-0.9 (d,4H),1.15-1.22 (m,12H),1.57-1.65 (m,14H),1.76 (s,4H),2.40-2.42 (d,4H),3.01-3.02 (d,4H),12.33 (s,2H); Mass (M++l):581.7
(3E3'E)-N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(4-phenylbut- 3-enamide) (81):
1H NMR (500 MHz, DMSO-d6) δ: 1.76 (m, 4H), 3.01 (m, 4H), 3.42 (m, 4H),6.37 (td, 2H), 6.55 (d, 2H), 7.24 (m, 2H), 7.32 (m, 4H), 7.42 (m, 4H), 12.51 (brs, 2H); Mass (M++l): 545.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4 hiadiazole-5,2-diyl))bis(4^henylbutanamide) (82):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (brs, 4H), 1.90 (m, 4H), 2.47 (t, 4H), 2.60 (t, 4H), 3.01 (brs, 4H), 7.16-7.29 (m, 10H), 12.35 (brs, 2H); Mass (M++l): 549.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(3,4- difluorophenyl)acetamide) (83):
1H NMR (500 MHz, DMSO-d6) δ: 1.74 (brs, 4H), 3.00 (brs, 4H), 3.82 (s, 4H), 7.15 (m, 2H), 7.39 (m, 4H), 12.67 (s, 2H); Mass (M++l): 565.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))di-l-naphthamide (85):
1H NMR (500 MHz, DMSO-d6) δ: 1.89 (brs, 4H), 3.14 (brs, 4H), 7.60 (m, 6H), 7.90 (m, 2H), 8.04 (m, 2H), 8.15 (m, 2H), 8.23 (m, 2H), 13.09 (brs, 2H); Mass (M++l): 565.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(2- chlorophenyl)acetamide) (86):
1H NMR (500 MHz, DMSO-d6) δ: 1.76 (brs, 4H), 3.01 (brs, 4H), 3.99 (s, 4H), 7.33-7.45 (m, 8H), 12.71 (brs, 2H); Mass (M++l): 561.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(lH-indol-3- yl)acetamide) (87):
1H NMR (500 MHz, DMSO-d6) 5: 1.73 (s,4H),2.98 (s,4H),3.88 (s,4H),6.97-7.00 (t,2H),7.06-7.09 (t,2H),7.28 (s,2H),7.35-7.36 (d,2H),7.55-7.56 (d,2H), 10.96 (s,2H),12.58 (s,2H); Mass (M++l):571.7 N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-methyl-2- phenylpropanamide)
1H NMR (500 MHz, DMSO-d6) δ: 1.60 (s, 12H), 1.77 (brs, 4H), 3.01 (brs, 4H), 7.25-7.37 (m, 10H), 11.97 (brs, 2H); Mass (M++l): 549.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(2,5- dioxoimidazolidin-4-yl)acetamide) (89) :
1H NMR (500 MHz, DMSO-d6) δ: 1.76 (brs, 4H), 2.77-2.81 (ABq, 2H), 2.90-2.94 (ABq, 2H), 3.01 (brs, 4H), 4.35 (t, 2H), 7.93 (s, 2H), 10.66 (brs, 2H), 12.53 (brs, 2H); Mass (M++l): 537.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))dicyclohexanecarboxamide (90):
1H NMR (500 MHz, DMSO-d6) δ: 1.16-1.28 (m, 6H), 1.35-1.42 (m, 4H), 1.64 (brd, 2H), 1.72-1.82 (m, 12H), 2.54 (m, 2H), 3.00 (brs, 4H), 12.30 (brs, 2H); Mass (M++l): 477.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(3-(2- chlorophenyl)propanamide) (91):
1H NMR (500 MHz, DMSO-d6) 5: 1.76 (s,4H),2.76-2.79 (t,4H),3.01-3.04
(t,8H),7.24-7.29 (m,2H),7.34-7.35 (m,2H), 12.42 (s,2H); Mass (M++l):589.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(3-oxo-l,3- dihydroisobenzofuran-l-yl)acetamide) (93) :
1H NMR (500 MHz, DMSO-d6) δ: 12.61 (s, 2H), 7.74-7.87 (m, 4H), 7.73-7.74 (d, 2H),7.61-7.64 (t, 2H), 6.02-6.04 (m, 2H), 3.05 (s, 4H), 2.91-2.96 (m, 2H), 1.79-1.80 (d, 4H). Mass (M+l): 605.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))diacetamide (94):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (t, 4H), 2.16 (s, 6H), 3.01 (t, 4H), 12.39 (s, 2H); Mass (M++l): 341.1
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2- diyl))dicyclopentanecarboxamide (95) :
1H NMR (500 MHz, DMSO-d6) 5: 1.59 (m,4H), 1.59- 1.72 (m,8H),1.76
(s,4H),l.85-1.90 (m,4H),2.51-2.96 (m,2H),3.01 (s,4H),12.38 (s,2H); Mass (M++l): 449.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(3-(3,4,5- trimethoxyphenyl)propanamide) (101):
1H NMR (500 MHz, DMSO-d6) δ: 1.77 (m, 4H), 2.76 (t, 4H), 2.86 (t, 4H), 3.01 (m, 4H), 3.61 (s, 6H), 3.72 (s, 12H), 6.53 (s, 4H), 12.40 (brs, 2H); Mass (M++l):701.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))dicyclobutanecarboxamide (102):
1H NMR (500 MHz, DMSO-d6) 5: 1.81-1.94 (m,6H), 1.96- 1.98 (t,2H),2.10-2.25 (m,6H),3.01 (s,4H),3.33-3.40 (m,2H),12.26 (s,2H); Mass (M++l):421.7
N,N'-(2,2^(5,5^(butane-l,4-diyl)bis(l,3,4 hiadiazole-5,2-diyl))bis(azanediy oxoethane-2,l-diyl))dibenzamide (103) :
1H NMR (500 MHz, DMSO-d6) δ:.59 (s, 2H), 8.94-8.96 (t, 2H), 7.88-7.90 (t, 4H), 7.48-7.58 (m, 6H), 4.18-4.19 (d, 4H), 3.03 (s, 4H), 1.77 (s, 4H). Mass (M+1): 579.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(3-(2,3- dimethoxyphenyl)propanamide) (106) :
1H NMR (500 MHz, DMSO-d6) δ: 12.41 (s, 2H), 6.97-6.98 (m, 2H), 6.89-6.90 (m, 2H), 6.76-6.78 (m, 2H), 3.79 (s, 6H), 3.71 (s, 6H), 3.00-3.01 (d, 4H), 2.87-2.90 (t, 4H), 2.70-2.73 (t, 4H), 1.76 (s, 4H). Mass (M+1): 641.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(4- (dimethylamino)phenyl)acetamide) (107) :
1H NMR (500 MHz, DMSO-d6) δ: 12.55 (s, 2H), 7.12-7.13 (d, 4H), 6.66-6.68 (d, 4H), 3.63 (s, 4H), 2.98-2.99 (d, 2H), 2.85 (s, 12H), 1.73 (s, 4H). Mass (M+1): 579.3 N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(3- phenoxypropanamide) (111):
1H NMR (500 MHz, DMSO-d6) δ: 12.57 (s, 2H), 7.26-7.29 (m, 4H), 6.92-6.95 (m, 6H), 4.26-4.28 (t, 4H), 3.01-3.02 (d, 4H), 2.93-2.96 (t, 4H), 1.77 (s, 4H). Mass (M+1): 553.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(4- phenylbutanamide) (112):
1H NMR (500 MHz, DMSO-d6) 5: 1.75 (s,4H),2.82-2.85 (t,4H),3.00 (s,4H),3.39- 3.41 (t,4H),7.53-7.56 (t,4H),7.64 (m,2H),7.98-8.00 (t,4H), 12.50 (s,2H); Mass
(M++l):577.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(4- chlorophenyl)acetamide) (113):
1H NMR (500 MHz, DMSO-d6) 5: 1.74 (s,2H),3.00(s,4H),3.81 (s,4H),7.33-7.40 (m,8H), 12.66 (s,2H); Mass (M++l):562.7
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4 hiadiazole-5,2-diyl))bis(3-methylbutanamid^ (115):
1H NMR (500 MHz, DMSO-d6) δ: 0.92 (d, 12H), 1.77 (m, 4H), 2.08 (m, 4H), 2.34 (d, 4H), 3.02 (m, 4H), 12.38 (s, 2H); Mass (M++l): 425.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-o-tolylacetamide) (114):.
1H NMR (500 MHz, DMSO-d6) δ: 12.66 (s, 2H), 7.14-7.24 (m, 8H), 3.83 (s, 4H), 2.99-3.00 (t, 4H), 2.25 (s, 6H), 1.74 (s, 4H). Mass (M+l): 521.3
N,N'-(5,5^(butane-l,4-diyl)bis(l,3,4 hiadiazole-5,2-diyl))bis(2-(2-methyl-lH-ind^ 3-yl)acetamide) (116):
1H NMR (500 MHz, DMSO-d6) δ: 12.59 (s, 2H), 10.87 (s, 2H), 7.46-7.48 (d, 2H), 7.22-7.24 (d, 2H), 6.90-6.99 (m, 4H), 3.82 (s, 4H), 2.97 (s, 4H), 2.37 (s, 6H), 1.72 (s, 4H). Mass (M+l): 599.2
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(4- (benzyloxy)phenyl)acetamide) (117):
1H NMR (500 MHz, DMSO-d6) δ: 12.64 (s, 2H), 7.31-7.45 (m, 10H), 7.21-7.25 (t, 2H), 6.88-6.99 (m, 6H), 5.08 (s, 4H), 3.75 (s, 4H), 3.00 (s, 4H), 1.75 (s, 4H). Mass (M+l): 705.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-(2,4- dimethoxyphenyl)acetamide) (119):
1H NMR (500 MHz, DMSO-d6) δ: 1.75 (brs, 4H), 3.00 (brs, 4H), 3.68 (s, 4H), 3.71 (s, 6H), 3.75 (s, 6H), 6.48 (dd, 2H), 6.54 (d, 2H), 7.10 (d, 2H), 12.49 (brs, 2H); Mass (M++l): 613.3 N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4 hiadiazole-5,2-diyl))bis(2-m-tolylacetamide)
(120):
1H NMR (500 MHz, DMSO-d6) δ: 1.74 (m, 4H), 2.29 (s, 6H), 3.00 (m, 4H), 3.74 (s, 4H), 7.06-7.13 (m, 6H), 7.21 (m, 2H), 12.65 (brs, 2H); Mass (M++l): 521.3
N,N'-(5,5'-(butane-l,4-diyl)bis(l,3,4-thiadiazole-5,2-diyl))bis(2-cyclohexylacetamide) (121):
1H NMR (500 MHz, DMSO-d6) δ: 0.95 (m, 4H), 1.10-1.25 (m, 6H), 1.58-1.65 (m, 10H), 1.76 (m, 6H), 2.33 (d, 4H), 3.00 (m, 4H), 12.36 (brs, 2H); Mass (M++l): 505.3
Example 15
Scheme 24 ,.NH2
O O ° O H2N AK
N
Oxone H
HO OH H,N -NH, HO-^^S-^-^OH THF,MeOH,H20 POC /90 °C/3 h -
1-14 1-15
HAT TUU//DD II PPEEAA//DDMMF/ ^
RT/overnight
1-16
3,3'-sulfonyldipropanoic acid (1-14): O o
o I I
HO' s ΌΗ
I I
O
A mixture of 3,3'-thiodipropanoic acid (1 equivalent) and Oxone (2.93
equivalents) were taken in THF, MeOH, H20 (1: 1 : 1) and stirred at rt for 8 h. The reaction mixture was brought to pH 5 using HC1, then extracted with EtOAc. The organic layer was concentrated in vacuo to afford the desired product 1-14, which was used as such for the next step.
5,5'-(2,2'-sulfonylbis(ethane-2,l-diyl))bis(l,3,4-thiadiazol-2-amine) (1-15):
A mixture of 3,3'-sulfonyldipropanoic acid (1 equivalent) and thiosemicarbazide (2 equivalents) were taken in POCl3 (10 fold) and stirred at 90 °C for 3 h. The reaction mixture was cooled to room temperature and poured on to ice. The resulting mixture was filtered and then brought to pH 14 using KOH. The mixture was filtered, washed with water and dried to afford the desired product 1-15, which was used as such for the next step.
General procedure for the synthesis of compounds (1-16):
Diamine 1-15 (1 equivalent) was taken in DMF and cooled to 0 °C. HATU (3 equivalents) was then added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. The corresponding acid (3 equivalents) was added and the reaction mixture was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The mixture was filtered through Buchner funnel, washed with water and dried. The crude product was purified by standard procedures to afford the desired products 1-16. The following compounds were synthesized by following the general procedure as described for 1-16:
N,N'-(5,5^(2,2^sulfonylbis(ethane-2^
dimethoxyphenyl)acetamide) (30):
1H NMR (400 MHz, DMSO-d6) δ: 3.51 - 3.53 (m, 4H), 3.67 - 3.74 (m, 20H), 6.83-6.94 (m, 6H), 12.64 (brs, 2H); Mass (M++H): 677.2
N,N'-(5,5^(2,2^sulfonylbis(ethane^
methoxyphenyl)acetamide) (31):
1H NMR (400 MHz, DMSO-d6) δ: 3.42 (m, 18H), 6.87-6.88 (d, 4H), 7.21-7.23 (d, 4H); Mass (M++H): 617.1
N,N'-(5,5^(2,2^sulfonylbis(ethane-2,l-diyl))bis(13,4-thiadiazole-5,2-diyl))bis(2- (tetrahydro-2H-pyran-2-yl)acetamide) (33) :
1H NMR (400 MHz, DMSO-d6) δ: 1.36 (m, 2H), 1.46 (m, 6H), 1.60 (m, 2H), 1.76 (m, 2H), 2.60 (m, 4H), 3.29 (m, 2H), 3.46 (m, 4H), 3.71 (m, 6H), 3.82 (m, 2H), 9.29 (brs, 2H); Mass (M++H): 573.2
Example 16 Scheme 25
N,N'-(5,5^(2,2^thiobis(ethane-2,l-diyl))bis(13,4 hiadiazole-5,2-diyl))bis(2-me lH-benzo[d]imidazole-6-carboxamide) (34) :
Diamine 1-2 (1 equivalent) was taken in DMF and cooled to 0 °C. HATU (3 equivalents) was then added followed by the addition of DIPEA (3 equivalents) and stirred for 10 min. The corresponding acid (3 equivalents) was added and the reaction mixture was stirred for overnight at room temperature. The progress of the reaction was monitored by LCMS. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The mixture was filtered through Buchner funnel, washed with water and dried. The crude product was purified by standard methods to afford the desired product 34.
1H NMR (400 MHz, DMSO-d6) δ: 2.51 - 2.54 (d, 6H), 3.01 - 3.04 (t, 4H), 3.32 - 3.34 (t, 4H), 7.52-7.58 (d, 2H), 7.91-7.92 (d, 2H), 8.25-8.37 (d, 2H), 12.56 (brs, 4H); Mass (M++H): 605.2
Example 17
General procedure for the preparation of compound I-144a-b:
To a stirred solution of methyl 2-(4-hydroxyphenyl)acetate 1-142 (2.4 mmol) in THF (6 ml) was added triphenylphosphine (3.6 mmol) followed by appropriate Boc-amino alcohol I-143a-b (3.6 mmol), DEAD (3.6 mmol) in 3 ml THF over a period of 30 minutes and the reaction mixture was stirred at room temperature for 3 h. After completion of the reaction solvent was removed under reduced pressure and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product which was purified by standard methods to afford the desired product. I-144a (n=l): 1H NMR (400 MHz, TFA) δ: 1.4 (s, 9H), 3.4 (t, 2H), 3.5 (s, (s, 3H), 4.0 (t, 2H), 5.0 (br s, 1H), 6.8 (d, 2H), 7.2 (d, 2H).
General procedure for the preparation of compound I-145a-b:
To a stirred suspension of methyl ester I-144a-b (2.1 mmol) in THF and water (1: 1, 20 ml) was added Lithium hydroxide (4.2 mmol) and the reaction mixture was stirred at room temperature 4 h. After completion of the reaction solvent was removed under reduced pressure and acidified with aqueous citric acid. The solution was extracted into ethyl acetate, washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was used as such for the next step.
I-145a (n=l): 1H NMR (400 MHz, TFA) δ: 1.4 (s, 9H), 3.4 (t, 2H), 3.5 (s, 2H), 4.0 (s, 2H), 5.0 (br s, 1H), 6.8 (d, 2H), 7.2 (d, 2H).
N-(5-(2-((2-(5-amino-l,3,4 hiadiazol-2-yl)ethyl)sulfonyl)ethyl)-13,4-thiadiazol- 2-yl)-2-phenylacetamide -146):
To a stirred solution of N-(5-(2-((2-(5-amino-l,3,4-thiadiazol-2-yl)ethyl)thio)ethyl)- l,3,4-thiadiazol-2-yl)-2-phenylacetamide 1-139 (1.2 mmol) in acetone and water (2: 1, 4.5 ml) was added oxone (1.8 mmol) and the reaction mixture was stirred at room temperature for 3 h. After completion of the reaction solvent was removed under reduced pressure and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product which was purified by standard methods to afford the desired product.
ESMS Calculated for Ci6H18N603S3 : 438.54, Observed: 438.10 (M+).
General procedure for the preparation of compound I-147a-b:
HBoc
To a stirred solution of N-(5-(2-((2-(5-amino-l,3,4-thiadiazol-2- yl)ethyl)sulfonyl)ethyl)-l,3,4-thiadiazol-2-yl)-2-phenylacetamide 1-146 (1 equivalent) in DMF at 0 °C was added appropriate amine I-145a-b (1 equivalent), DIPEA (1.5 equivalents) followed by the addition of HATU (1.5 equivalents) and stirred for 10 min. The reaction mixture was stirred for 3 h at room temperature. The progress of the reaction was monitored by TLC. After completion of the reaction, water was added to the reaction mixture and stirred for 10 min. The mixture was filtered through Buchner funnel, washed with water and dried. The crude product was purified by standard methods to afford the desired products I-147a-b.
I-147a: 1H NMR (400 MHz, DMSO-d6) δ: 1.4 (s, 9H), 3.2-3.4 (m, 4H), 3.4-3.5 (m, 4H), 3.6-3.7 (m, 6H), 3.8 (s, 2H), 3.9 (t, 2H), 7.0 (d, 2H), 7.2 (d, 2H), 7.3-7.4 (m, 5H).
General procedure for the preparation of compound I-148a-b:
To a stirred solution of I-147a-b (0.27 mmol) in dichloromethane (15 ml) at 0 °C was added Trifluoroacetic acid (0.6 ml) and stirred for 3 h at room temperature. After completion of the reaction, mixture was concentrated under reduced pressure and neutralized with ammonia, filtered and, washed with MeOH and dried to afford the desired product.
2-(4-(2-aminoethoxy)phenyl)-N-(5-(2-((2-(5-(2-phenylacetamido)-l,3,4-thiadiazol-2- yl)ethyl)sulfonyl)ethyl)- -thiadiazol-2-yl)acetamide (29):
1H NMR (400 MHz, TFA) δ: 3.8 (m, 2H), 3.82-4.0 (m, 8H), 4.1-4.2 (m, 4H), 4.4 (m, 2H), 7.0 (d, 2H), 7.32-7.52 (m, 8H); Mass (M++l): 616.3
2-(4-(3-aminopropoxy)phenyl)-N-(5-(2-((2-(5-(2-phenylacetamido)-l,3,4-thiadiazol- 2-yl)ethyl)sulfonyl)ethyl)- -thiadiazol-2-yl)acetamide (36):
1H NMR (400 MHz, TFA) δ: 2.3 (s, 2H), 3.59 (s, 2H), 3.8-3.9 (m, 8H), 3.9-4.0 (m, 6H), 4.23 (m, 2H), 6.9-7.0 (m, 4H), 7.2-7.4 (m, 5H), 11.45 (br s, 2H); Mass (M++l): 630.4 Having thus described several aspects of several embodiments, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.

Claims

CLAIMS What is claimed is:
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein
X is a bond, -S-, -S(O)-, -S02-, -CH=CH-, -NH-, or -C(0)-;
each W, Y and Z is independently -S-, -CH=, -CH=CH-, -CH=CR1-, - CR^CR1-, -0-, -N=, or -NH-, provided that (1) for each ring at least one of W, Y and Z is not -CH= and (2) when one of W is -S- and the Y in the same ring is N, then the Z in the same ring is not -CH=;
each R1 and R2 is independently d_6 alkylene-R4, -N(R3)-R4, -N(R3)-C(0)-R4, -C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4, -N(R3)-C(0)-N(R3)-R4, -0-C(0)-N(R3)-R4, - N(R3)-C(0)-Ci_6 alkylene-C(0)-R4, -N(R3)-C(0)-Ci_6 alkylene-N(R3)-C(0)-R4 or - N(R3a)-C(0)-CH2-N(R3)-C(0)-R4;
each R3 is independently hydrogen, Ci_6 alkyl or aryl;
each R4 is independently Ci_6 alkyl, Ci_6 alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl, heterocyclyl, cycloalkyl or cycloalkylalkyl, each of which is substituted with 0-3 occurrences of R5, or two adjacent R5 moieties, taken together with the atoms to which they are attached form a heterocyclyl, heteroaryl, cycloalkyl or aryl;
each R5 is independently oxo (=0), Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 alkoxy, cyano, halo, -OH, -SH, -OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2, -0-C(0)-Ci_6 alkyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)alkyl, aryl, aryloxy, - C(0)-aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclylalkyl or heterocyclyl, wherein each aryl, heteroaryl or heterocyclyl is further substituted with 0-3 occurrences of R7; each R6 is independently hydrogen, fluoro, OH or Ci_6 alkyl; each R7 is independently hydrogen, Ci_6 alkyl, -OH, -SH, cyano, halo, -CF3, - OCF3, -S02-Ci_6 alkyl, -N02, -N(R7)-C(0)-Ci_6 alkyl, -N(R6)2 or Ci_6 alkoxy;
m is 1 , 2 or 3 ;
n is 1, 2 or 3 ; provided that when X is bond, the sum of m and n is from 3 to 6 and when X is -S-, -S(O)-, -S02-, -CH=CH-, or -C(O)-, the sum of m and n is from 2 to 4;
o is 1, 2 or 3 ; and
p is 1, 2 or 3 ;
with the proviso that: (1) when X is -S-, m and n are both 2, each R6 is H, then (i) R1 and R2 are not both -NHC(0)-R4, wherein R4 is Ci_6 alkyl, a monocyclic ring, monocyclic aralkyl, monocyclic heterocyclylalkyl, monocyclic heteroaralkyl and each member of R4 is substituted with 0-3 occurrences of R5; and (ii) R1 and R2 are not both -NHC(0)0-methyl, -NHC(0)0-ethyl, -NHC(0)-6-pyrimidine-2,4(lH,3H)- dionyl, -N(ethyl)C(0)-benzyl, or -NHC(0)NH-phenyl wherein said phenyl of the - NHC(0)NH -phenyl moiety is optionally substituted with 1 or 2 groups selected from methyl, nitro, and halo;
(2) when X is -S-, m and n are both 1 , each R6 is H, then (i) R1 and R2 are not both -NH-phenyl or -NH-4-methoxy-phenyl or -NHC(0)-benzyl;
(3) when X is a bond, the sum of m and n is 3, each R6 is H, then R1 and R2 are not both-NHC(0)-R4, wherein R4 is monocyclic aryl or monocyclic aralkyl or methyl, and each member of R4 is optionally substituted with 0-3 occurrences of R5;
(4) when X is a bond, m and n are both 2, each R6 is H, then R1 and R2 are not both -NHC(0)-furanyl, -NHC(0)-phenyl, -NHC(0)-o-methoxy-phenyl, -NHC(0)-Ci_ 6 alkyl, -NH-benzyl, -NHC(0)-NH-phenyl, -NHC(0)-NH-benzyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is substituted with 0-3 occurrences of R5;
(5) when X is a bond, the sum of m and n is 5, each R6 is H, then R1 and R2 are not both -NHC(0)-Ci_6 alkyl, -NHC(0)-cyclohexyl, or -NH-phenyl wherein said phenyl of the -NH-phenyl moiety is optionally substituted with methyl; and (6) when X is a bond, m and n are both 3, each R6 is H, then R1 and R2 are not both NH-phenyl;
(7) when X is a bond, m and n are both 2, and one of W, Y or Z is -CH=CH- or -CH=CR1 -, then R1 and R2 are not both -NHC(0)C(R*)2-phenyl wherein the phenyl is unsubstituted or substituted with 0-3 occurrences of R5 and R* is H, -OH, - Ci_2 alkyl-OH, -Ci-2 alkyl-OCH3, or -CH3;
(8) when X is a bond, m and n are both 2, one of W, Y or Z is -CH=CH- or - CH=CR1 -, and one of R1 and R2 is -NHC(0)CH2-RA, wherein RA is hydrogen, -NH2, heteroaryl, or a fused ring, wherein the heteroaryl is unsubstituted or substituted with 0-3 occurrences of R5; -NHC(0)NH-benzyl; or -NHC02-benzyl; then the other of R1 and R2 is not -NHC(0)C(R*)2-phenyl, wherein the phenyl is unsubstituted or substituted with 0-3 occurrences of R5, and R* is H, -OH, -Ci-2 alkyl-OH, -Ci-2 alkyl- OCH3, or methyl;
2. The compound of claim 1, wherein X is -S-, -S(O)-, -S02-, a bond, - C(O)- or -CH=CH-.
3. The compound of claim 1, wherein X is-S(O)-, -S02-, -C(O)- or - CH=CH-.
4. The compound of claim 1 , wherein each R1 and R2 is independently - N(R3)-R4, -C(0)-N(R3)-R4, -N(R3)-C(0)-0-R4 or -N(R3)-C(0)-N(R3)-R4.
5. The compound of claim 4, wherein X is -S- and m and n are both 2.
6. The compound of claim 1 , wherein at least one of W, Y and Z is - CH=CH-, -CH=CR1- or -CR^CR1-.
7. The compound of claim 1, wherein each W is -S-, each Y is -N= and each Z is -N=.
8. The compound of claim 1, wherein each W is -CH=, each Z is -O- and each Y is -N=.
9. The compound of claim 1, wherein o is 1 and p is 1.
10. The compound of claim 1, wherein R1 and R2 are each -N(R3)-C(0)- O-R4, wherein R3 is hydrogen.
11. The compound of claim 10, wherein R1 and R2 are the same.
12. The compound of claim 1, wherein the compound is a compound of Formula (II):
The compound of claim 12, wherein R1 and R2 are the same.
14. The compound of claim 1, wherein the compound is a compound of Formula (III):
15. The compound of claim 1, wherein the compound of Formula (I) is selected from Compounds 1-132 of Table 1.
16. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
17. A method of treating cancer, the method comprising administering a compound of claim 1 or a composition of claim 16 to a subject in need thereof.
18. The method of claim 17, wherein the cancer is selected from a cancer characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, or iii) a low or decreased level of pyruvate carboxylase expression.
19. The method of claim 17, wherein the cancer is lung cancer, non-small cell lung cancer, breast cancer, hepatocellular carcninoma, osteosarcoma, lipomas, chondrosarcoma or mesothelioma.
EP13808311.8A 2012-11-21 2013-11-21 Glutaminase inhibitors and methods of use Active EP2922832B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729321P 2012-11-21 2012-11-21
PCT/US2013/071212 WO2014081925A1 (en) 2012-11-21 2013-11-21 Glutamase inhibitors and method of use

Publications (2)

Publication Number Publication Date
EP2922832A1 true EP2922832A1 (en) 2015-09-30
EP2922832B1 EP2922832B1 (en) 2019-10-09

Family

ID=49780330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13808311.8A Active EP2922832B1 (en) 2012-11-21 2013-11-21 Glutaminase inhibitors and methods of use

Country Status (15)

Country Link
US (3) US10011574B2 (en)
EP (1) EP2922832B1 (en)
JP (1) JP6333280B2 (en)
KR (1) KR20150085078A (en)
CN (1) CN105263915B (en)
AU (2) AU2013347933C1 (en)
BR (1) BR112015011756A2 (en)
CA (1) CA2892089A1 (en)
EA (1) EA029531B1 (en)
ES (1) ES2761951T3 (en)
HK (1) HK1213889A1 (en)
IL (1) IL238959A (en)
MX (1) MX369691B (en)
SG (1) SG11201504022RA (en)
WO (1) WO2014081925A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2640918C2 (en) 2010-11-01 2018-01-12 Псивида Юэс, Инк. Biodegradable devices based on silicon for therapeutic agents delivery
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EP3954686A1 (en) 2012-11-16 2022-02-16 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20220013017A (en) 2014-01-06 2022-02-04 리젠 파마슈티컬스 소시에떼 아노님 Novel glutaminase inhibitors
EA201691896A1 (en) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. CONNECTIONS AND METHODS OF THEIR APPLICATION
CR20160497A (en) 2014-04-30 2016-12-20 Pfizer DERIVATIVES OF DIHETEROCICLO LINKED TO CYCLALKYL
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
JP6798890B2 (en) 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ， インコーポレイテッド Combination therapy with glutaminase inhibitors
PL3164394T3 (en) 2014-07-03 2020-09-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating diseases
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
JP2017523211A (en) 2014-08-04 2017-08-17 ドレクセル ユニバーシティ Novel compounds and methods of using them to treat or ameliorate IL-1R mediated diseases or disorders
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EA037152B1 (en) * 2015-03-30 2021-02-11 Калитера Байосайенсиз, Инк. Method of treating cancer
AU2016246521B2 (en) 2015-04-06 2020-07-09 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
CN107921044B (en) 2015-06-30 2022-01-21 德州大学系统董事会 GLS1 inhibitors for the treatment of disease
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
CA3009355A1 (en) 2015-12-22 2017-06-29 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
CN110139649A (en) 2016-08-25 2019-08-16 卡利泰拉生物科技公司 With the combination treatment of glutamine enzyme inhibitor
EP3503893A4 (en) 2016-08-25 2020-04-29 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN107137401A (en) * 2017-03-28 2017-09-08 刘纪君 A kind of pharmaceutical composition for treating post-natal depression
WO2019079632A1 (en) 2017-10-18 2019-04-25 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
CN114805346A (en) * 2021-07-08 2022-07-29 成都硕德药业有限公司 Heterocyclic derivative, preparation method and application thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) * 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
CA2155759A1 (en) 1993-03-29 1994-10-13 Bernd Janssen 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
ES2237919T4 (en) 1998-06-18 2007-05-01 Bristol-Myers Squibb Company AMINOTIAZOL INHIBITORS REPLACED WITH CARBON OF CYCLINE DEPENDENT KINASES.
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
DE60200248T2 (en) 2002-08-01 2005-01-27 Mtm Laboratories Ag Procedure for solution-based diagnosis
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
WO2006101925A2 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
CA2702462A1 (en) 2007-11-19 2009-05-28 Genentech, Inc. Compositions and methods for inhibiting tumor progression
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP3021120A1 (en) 2009-02-20 2016-05-18 Michael P. Lisanti Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
US20120142028A1 (en) 2009-04-17 2012-06-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20130109592A1 (en) 2010-06-23 2013-05-02 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (en) 2011-03-04 2012-10-31 Novartis Ag NEW QUINASE INHIBITORS
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN104220090A (en) * 2011-09-20 2014-12-17 淡马锡生命科学实验室有限公司 Enterovirus 71 specific antibodies and uses thereof
CA2856386C (en) 2011-11-21 2022-05-31 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
CA2867456A1 (en) 2012-03-15 2013-09-19 The Research Foundation For The State University Of New York Combination therapies including inhibitors of the extracellular domain of e-cadherin
CA2892089A1 (en) * 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
KR20220013017A (en) 2014-01-06 2022-02-04 리젠 파마슈티컬스 소시에떼 아노님 Novel glutaminase inhibitors
EA201691896A1 (en) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. CONNECTIONS AND METHODS OF THEIR APPLICATION

Also Published As

Publication number Publication date
EP2922832B1 (en) 2019-10-09
US10414740B2 (en) 2019-09-17
IL238959A (en) 2017-12-31
AU2013347933A2 (en) 2015-07-09
US20140142146A1 (en) 2014-05-22
BR112015011756A2 (en) 2017-07-11
JP2016500107A (en) 2016-01-07
US10011574B2 (en) 2018-07-03
JP6333280B2 (en) 2018-05-30
ES2761951T3 (en) 2020-05-21
US20180370930A1 (en) 2018-12-27
HK1213889A1 (en) 2016-07-15
SG11201504022RA (en) 2015-06-29
AU2018204692A1 (en) 2018-07-19
EA029531B1 (en) 2018-04-30
AU2013347933A1 (en) 2015-06-11
MX2015006478A (en) 2015-12-03
AU2013347933C1 (en) 2018-10-04
WO2014081925A1 (en) 2014-05-30
AU2013347933B2 (en) 2018-03-29
MX369691B (en) 2019-11-19
EA201590997A1 (en) 2015-11-30
CN105263915A (en) 2016-01-20
IL238959A0 (en) 2015-07-30
KR20150085078A (en) 2015-07-22
US9303002B2 (en) 2016-04-05
CN105263915B (en) 2019-04-12
CA2892089A1 (en) 2014-05-30
US20150299152A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
US10414740B2 (en) Glutaminase inhibitors and method of use
US10689375B2 (en) Compounds and their methods of use
US9029531B2 (en) Compounds and their methods of use
JP2020019807A (en) Compounds and their methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150622

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGIOS PHARMACEUTICALS, INC.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213889

Country of ref document: HK

17Q First examination report despatched

Effective date: 20160617

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEMIEUX, RENE, M.

Inventor name: YAN, SHUNQI

Inventor name: SALITURO, FRANCESCO, G.

Inventor name: TRAVINS, JEREMY

Inventor name: POPOVICI-MULLER, JANETA

Inventor name: SAUNDERS, JEFFREY, O.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190417

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAUNDERS, JEFFREY, O.

Inventor name: POPOVICI-MULLER, JANETA

Inventor name: SALITURO, FRANCESCO, G.

Inventor name: LEMIEUX, RENE, M.

Inventor name: TRAVINS, JEREMY

Inventor name: YAN, SHUNQI

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013061538

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1188646

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191009

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1188646

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200109

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200210

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200110

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200109

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2761951

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013061538

Country of ref document: DE

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191121

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200209

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

26N No opposition filed

Effective date: 20200710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131121

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20211129

Year of fee payment: 9

Ref country code: FR

Payment date: 20211124

Year of fee payment: 9

Ref country code: ES

Payment date: 20211201

Year of fee payment: 9

Ref country code: DE

Payment date: 20211126

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20211122

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602013061538

Country of ref document: DE

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER PART, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1213889

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191009

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013061538

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221121

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221121

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221122